[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"\"}":3,"_public_publisher_byId_c9dcdf0d-1f44-46cc-93b6-4b34cd3868a8":656,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"totalCitation\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:c9dcdf0d-1f44-46cc-93b6-4b34cd3868a8,\"}":774},{"meta":4,"data":6},{"total":5},"117",[7,60,176,207,299,413,445,480,543,572],{"id":8,"createTime":9,"updateTime":10,"relativeEntities":11,"slug":12,"properties":13,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":29,"subjectFields":30,"manageAffiliations":31,"indexDatabases":32,"url":33,"thumbnailPath":34,"statistic":35,"gsStatistic":26,"type":26,"analyzePriority":26},"5a09599f-54d1-44c3-8f16-3847ac552024","2023-08-17T04:28:50.832+00:00","2025-10-13T23:58:52.517+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Truy%E1%BB%81n-nhi%E1%BB%85m-Vi%E1%BB%87t-Nam",{"country":14,"issn":16,"introduce":18,"title":21},{"VOID":15},"VN",{"VOID":17},"08667829",{"EN":19,"VI":20},"{\"ops\":[{\"insert\":\"Vietnam Journal of Infectious Diseases is a social - professional forum of the Vietnam Society for Infectious Diseases, whose responsibility is to introduce the researches, the scientific advances in Vietnam and from the world; to contribute to the improvement of knowledges for health care staffs about clinic, treatment, guideline, prevention, epidemiology for infectious diseases, HIV\u002FAIDS and community health care; to provide, exchange and publish scientific information to the public accurately and promptly.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Vietnam Journal of Infectious Diseases publishes in the whole country; serves the professional work for researchers, clinical staffs, administrators, undergraduate and postgraduate students who are working and studying in the infections, tropical diseases and HIV\u002FAIDS from central to local levels, also organizations and individuals in the world who are interested in infectious and tropical diseases and prevention for HIV\u002FAIDS.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Editor in Chief:\"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"insert\":\"Prof. Dr. Nguyen Van Kinh. - Chairman of Editorial Board\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"Prof. Dr. Nguyen Van Mui.\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Headquarter:\"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Address:\"},{\"insert\":\" Level 6, National Hospital for Tropical Diseases, No. 78 Giai Phong Street, Dong Da District, Hanoi city, Vietnam.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Tel:\"},{\"insert\":\" \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:02435765464\"},\"insert\":\"02435765464\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913552672\"},\"insert\":\"0913552672\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913228072\"},\"insert\":\"0913228072\"},{\"insert\":\".\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Email\"},{\"insert\":\": \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Findex\u002Fadmin\u002Fcontexts\u002Fmailto:tungphamvan52@gmail.com\"},\"insert\":\"tungphamvan52@gmail.com\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Fmailto:tapchitruyennhiem@gmail.com\"},\"insert\":\"tapchitruyennhiem@gmail.com\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Bank account:\"},{\"insert\":\" 0021000275119, Vietcombank Hanoi Branch. Transaction office No. 7, 402 Tran Khat Chan, Hai Ba Trung District, Hanoi city, Vietnam.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}","{\"ops\":[{\"insert\":\"Tạp chí Truyền nhiễm Việt Nam là cơ quan ngôn luận của Hội Truyền nhiễm Việt Nam, chịu sự lãnh đạo, chỉ đạo trực tiếp của Thường vụ Ban Chấp hành Hội Truyền nhiễm Việt Nam; sự kiểm tra, giám sát về nghiệp vụ báo chí của các cơ quan chức năng quản lý báo chí thuộc Bộ Thông tin và Truyền thông và Ban Tuyên giáo Trung ương Đảng.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Tạp chí có trách nhiệm giới thiệu các công trình nghiên cứu khoa học, những tiến bộ khoa học trên thế giới và trong nước, góp phần nâng cao kiến thức khoa học cho cán bộ y tế về lâm sàng, điều trị, hướng dẫn, dự phòng, dịch tễ học các bệnh truyền nhiễm, HIV\u002FAIDS và chăm sóc sức khỏe cộng đồng; cung cấp, trao đổi, phổ biến các thông tin khoa học tới công chúng chính xác và kịp thời.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Tạp chí xuất bản 03 tháng\u002F01 kỳ và được phát hành qua Bưu điện và tự phát hành trong phạm vi toàn quốc.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Lãnh đạo Tạp chí: \"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"insert\":\"Tổng Biên tập: ThS.BSCKII Nguyễn Trung Cấp\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"Phó Tổng Biên tập:\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"            TS.BSCKII Phạm Ngọc Thạch\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Trụ sở tòa soạn:\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Địa chỉ: Tầng 6, Bệnh viện Bệnh Nhiệt đới Trung ương, 78 đường Giải Phóng, phường Phương Mai, quận Đống Đa, thành phố Hà Nội.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Điện thoại:\"},{\"insert\":\" \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:02435765464\"},\"insert\":\"02435765464\"},{\"insert\":\" - \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913228072\"},\"insert\":\"0913228072\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Email\"},{\"insert\":\": \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Findex\u002Fadmin\u002Fcontexts\u002Fmailto:tungphamvan52@gmail.com\"},\"insert\":\"tungphamvan52@gmail.com\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Fmailto:tapchitruyennhiem@gmail.com\"},\"insert\":\"tapchitruyennhiem@gmail.com\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Tài khoản:\"},{\"insert\":\" Số 0021000275119 Ngân hàng Ngoại thương Việt Nam, chi nhánh Hà Nội (Vietcombank Hà Nội). Phòng giao dịch số 7, 402 Trần Khát Chân, quận Hai Bà Trưng, Thành phố Hà Nội.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}",{"EN":22,"VI":23},"Vietnam Journal of Infectious Diseases","Tạp chí Truyền nhiễm Việt Nam","PUBLISHER","VERIFIED",null,"Admin update database","PENDING",51,[],[],[],"https:\u002F\u002Ftruyennhiemvietnam.vn\u002Findex.php\u002Fvjid","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F5a09599f-54d1-44c3-8f16-3847ac552024\u002Fadb0e52bf25e0de580fd4289519cb8bf.jpg",{"impactFactor":36,"impactFactorByYear":37,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":41,"totalPublicationByYear":42,"totalCitation":48,"totalCitationByYear":49,"totalCitationPerPublication":54,"totalCitationPerPublicationByYear":55,"hindexLast5Year":59,"hindex":59},0,{"2022":38,"2023":39,"2024":40},0.01,0.03,0.13,315,{"2020":43,"2021":44,"2022":45,"2023":46,"2024":47},63,58,57,65,72,43,{"2020":50,"2021":51,"2022":52,"2023":53},8,15,9,11,0.14,{"2020":40,"2021":56,"2022":57,"2023":58},0.26,0.16,0.17,3,{"id":61,"createTime":62,"updateTime":63,"relativeEntities":64,"slug":65,"properties":66,"entityType":24,"verifyStatus":25,"verifyTime":78,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":79,"subjectFields":80,"manageAffiliations":81,"indexDatabases":136,"url":137,"thumbnailPath":26,"statistic":138,"gsStatistic":155,"type":175,"analyzePriority":26},"25b6bd10-676c-40c0-8dc3-356d1679a284","2023-05-19T02:22:33.430+00:00","2026-06-18T23:33:57.141+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Y-D%C6%B0%E1%BB%A3c-h%E1%BB%8Dc-C%E1%BA%A7n-Th%C6%A1",{"country":67,"issn":68,"introduce":70,"title":73,"gsId":76},{"VOID":15},{"VOID":69},"23541210",{"EN":71,"VI":72},"\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">04\u002F10\u002F2015 Ministry of Information and Communications allowed Can Tho journal of medicine and pharmacy to operate (102 \u002FGP-BTTTT)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">07\u002F16\u002F2015 Can Tho journal of medicine and pharmacy is internationally recognized: ISSN 2354-1210\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">In 2016, The journal has been included in the list of medical science journals by The State Council for professorship which is awarded a work score of 0-0.5 points for a published article.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Can Tho Journal of Medicine and Pharmacy welcome original works that haven’t been submitted or published in other medical journals. Posts must contain content related to one of the journal’s categories.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The content published\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The journal is divided into 3 categories:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Scientific research article: are valuable scientific works, which have been researched and accepted.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Overview of medicine, biology and pharmacy: serving the objective of continuing training in the fields of medicine, biology and pharmacy; to systematize classical and modern knowledge.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Update information on new knowledge about medicine, biology, pharmacy in the country and in the world.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Scope\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Publication and introduction of scientific research in the fields:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Medicine (internal medicine, surgery, pediatrics, obstetrics and gynecology, odonto-stomatology, laboratory, oncology, traditional medicine, nursing).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Biology (genetics, biotechnology).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Pharmacology (pharmaceutics, drug quality analysis-control, synthetic pharmaceutical chemistry, biochemistry, pharmacognosy, botany, clinical pharmacy).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- To enhance the quality of undergraduate, postgraduate education, scientifically researching and meet the necessary treatment in hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Introducing the updated domestic and oversea information about science technology to promote scientific research and exchanging technology in local, other universities.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Exchanging pharmaceutical and medical information for social health developing in the Mekong Delta and Vietnam.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The object\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Postgraduate students, student of Can Tho University of Medicine and Pharmacy, scientists from schools, research institutes, hospitals, health centers, pharmaceutical companies of the Mekong Delta; other provinces and regions in Vietnam and other country.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Address\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Headquarters of Can Tho Journal of Medicine and Pharmacy, located Scientific Research and International Cooperation Office: 179 Nguyen Van Cu Street, An Khanh Ward, Ninh Kieu District, Can Tho City, Vietnam.\u003C\u002Fspan>\u003C\u002Fp>","\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Ngày 16\u002F7\u002F2015, Tạp chí Y Dược học Cần Thơ được cấp chỉ số quốc tế: ISSN 2354-1210.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Từ tháng 4\u002F2016, Tạp chí đã được Hội đồng Giáo sư ngành Y đưa vào danh sách các tạp chí khoa học Y học được tính điểm công trình 0-0,5 điểm cho một bài báo đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Năm 2020 Tạp chí Y Dược học Cần Thơ đã được phê duyệt vào danh mục của các Hội đồng Giáo sư ngành Dược học được tính điểm công trình 0-0,5 điểm cho một bài báo đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ ra 12 số\u002Fnăm, 180-200 trang\u002Fsố.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Từ tháng 12\u002F2022 Tạp chí Y Dược học Cần Thơ là thành viên của hệ thống Crossref và từ tháng 01\u002F2023 tạp chí thực hiện bình duyệt online kín 2 chiều nhằm tăng tính minh bạch, tin cậy của các công trình nghiên cứu khoa học và đảm bảo tốt nhất chất lượng khoa học của bài viết.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tôn chỉ, mục đích và phạm vi của tạp chí\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tôn chỉ và mục đích hoạt động của tạp chí: xuất bản nhằm mục đích phổ biến kết quả từ các đề tài nghiên cứu khoa học; giao lưu trao đổi khoa học, chia sẻ kinh nghiệm, học tập, đồng thời cập nhật thông tin khoa học mới trong các lĩnh vực y, sinh, dược học trong và ngoài nước.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Phạm vi của tạp chí: Tạp chí xuất bản được chia thành 3 chuyên mục: (i) Bài báo nghiên cứu khoa học là kết quả công trình nghiên cứu khoa học có giá trị đã được triển khai nghiên cứu, (ii) Bài tổng quan y, sinh, dược học: phục vụ mục tiêu đào tạo liên tục trong lĩnh vực y, sinh, dược học; nhằm hệ thống hóa những kiến thức kinh điển và hiện đại; (iii) Thông tin cập nhật kiến thức mới về y, sinh, dược học trong nước và trên thế giới.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Chính sách truy cập mở\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ áp dụng chính sách truy cập mở đối với các bài báo đã xuất bản đến với độc giả, nhằm mở rộng cơ hội tiếp cận các kết quả nghiên cứu chất lượng cao và tăng cường trao đổi kiến thức. Tạp chí đăng tải trực tuyến (miễn phí) toàn văn các bài báo được công bố trên website của Tạp chí (https:\u002F\u002Ftapchi.ctump.edu.vn).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đạo đức xuất bản\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ cam kết tuân thủ đạo đức xuất bản phù hợp với các hướng dẫn và tiêu chuẩn của the Committee on Publication Ethics (COPE), tuân thủ các nguyên tắc của COPE’s Core Practices, Best Practices Guidelines for Journal Editors và Guidelines on Good Publication Practices.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Bản thảo bài báo chỉ được chấp nhận khi được tác giả chịu trách nhiệm chính cam kết các nội dung sau: Các nội dung của bản thảo chưa được đăng tải toàn bộ hoặc một phần ở các tạp chí khác; Tất cả các tác giả đều có đóng góp một cách đáng kể vào quá trình nghiên cứu hoặc chuẩn bị bản thảo và cùng chịu trách nhiệm về các nội dung của bản thảo; Tuân thủ các biện pháp đảm bảo đạo đức nghiên cứu (ví dụ thỏa thuận đồng ý tham gia nghiên cứu).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Cam kết bảo mật\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí cam kết thực hiện và tuân thủ các quy định của luật và các văn bản hướng dẫn liên quan đến bảo mật thông tin cá nhân trên không gian mạng. Các thông tin mà người dùng (tác giả, độc giả, biên tập viên, người phản biện) nhập vào các biểu mẫu trên Hệ thống Quản lý xuất bản trực tuyến của tạp chí chỉ được sử dụng vào các mục đích đã được tuyên bố rõ ràng và sẽ không được cung cấp cho bất kỳ bên thứ ba nào khác, hay dùng vào bất kỳ mục đích nào khác.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Phí gửi bài\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Lệ phí gửi đăng bài: 1.000.000đ\u002Fbài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Lệ phí gửi đăng nhanh: 1.500.000đ\u002Fbài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đối với tác giả là cán bộ viên chức thuộc Trường Đại học Y Dược Cần Thơ thì được hỗ trợ 50% lệ phí gửi đăng bài.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đối với sinh viên thực hiện đề tài nghiên cứu khoa học cấp trường được hỗ trợ 100% lệ phí đăng bài ( Tác giả gửi đính kèm “ Quyết định về việc giao tổ chức thực hiện đề tài nghiên cứu khoa học cấp Trường của sinh viên”).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Hình thức nộp lệ phí:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Tiền mặt:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Nộp trực tiếp tại Phòng Tài chính - Kế toán, Trường Đại học Y Dược Cần Thơ, số 179 Nguyễn Văn Cừ, P. An Khánh, Q. Ninh Kiều, thành phố Cần Thơ.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Chuyển khoản:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tên Tài khoản: Trường ĐHYD Cần Thơ, Số TK: 0111000115668, tại ngân hàng Vietcombank chi nhánh Cần Thơ.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Thời gian: Áp dụng từ ngày 01\u002F02\u002F2023.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">* Phí gửi bài không được hoàn trả khi bài viết bị từ chối hoặc tác giả xin rút bài viết.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Quy trình phản biện bài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ thực hiện quy trình phản biện kín hai chiều nghiêm ngặt. Danh tính của những người phản biện không được tiết lộ cho các tác giả và ngược lại. Quy trình thẩm định bài báo đăng gồm các bước sau:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tiếp nhận bản thảo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tác giả liên hệ gửi bản thảo đến Tạp chí qua hệ thống trực tuyến tại website: https:\u002F\u002Ftapchi.ctump.edu.vn. Hướng dẫn về cách đăng ký, gửi bài và chuẩn bị bản thảo được cung cấp trên website của Tạp chí.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Sàng lọc sơ bộ\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Sau khi Tòa soạn nhận được bài báo của tác giả, Ban Thư ký sẽ tiến hành kiểm tra sơ bộ bài báo (các yêu cầu về nội dung và hình thức). Những bài báo không đúng quy cách hoặc có nội dung không phù hợp hoặc vi phạm bản quyền sẽ bị từ chối (Ban Thư ký thông báo phản hồi đến tác giả trong vòng 1 tuần). Những bài báo đủ điều kiện, được Ban Thư ký tòa soạn chuyển đến Ban Biên tập có cùng chuyên môn với nội dung bài báo để đề xuất người phản biện. Thời gian kể từ khi Ban Biên tập nhận bài báo đến khi đề xuất người phản biện bài báo chậm nhất là 5 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Vòng phản biện\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Ban Thư ký gửi bài và yêu cầu phản biện đến 02 phản biện độc lập.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Các phản biện gởi nhận xét cho Ban Thư ký. Thời gian từ khi gửi bài cho phản biện đến khi nhận ý kiến của phản biện tối đa là 20 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Xử ký kết quả phản biện\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Nếu ý kiến đồng ý cho đăng và không cần chỉnh sửa, Ban Thư ký tiếp tục đăng bài theo qui trình.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Nếu ý kiến đồng ý đăng và cần chỉnh sửa, Ban Thư ký sẽ thông tin đến tác giả chỉnh sửa theo yêu cầu của người phản biện. Thời gian chỉnh sửa và gửi lại kéo dài không quá 2 tuần, từ khi tác giả bài báo nhận được thông tin (Quá trình này có thể lặp lại tối đa 2 lần\u002F1 bài báo). Khi có sự thống nhất, đồng ý của người phản biện; bài báo được tiếp tục đăng theo qui trình.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">3. Những bài báo có chất lượng không đạt yêu cầu, cả 2 phản biện không đồng ý cho đăng sẽ bị Tòa soạn từ chối đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Xuất bản\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Ban Thư ký tổng hợp các bản thảo đã được tác giả hoàn thiện sau thẩm định trình Ban Biên tập xem xét, Tổng Biên tập phê duyệt, quyết định bài đăng theo các tiêu chí: sự phù hợp nội dung với tôn chỉ và mục đích, thể loại bài viết (ưu tiên các bài có bài có nghiên cứu chuyên sâu, hàm lượng khoa học cao), đóng góp mới bài báo, bài báo được ưu tiên đăng trong số gần nhất của Tạp chí theo thứ tự: tính thời sự, chất lượng bài báo và thời gian gửi bài.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Ban Biên tập và Ban Thư ký biên tập bản thảo, chế bản, đọc rà soát lỗi. Thời gian hoàn thành từ 10-15 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">3. Ban Thư ký có trách nhiệm thông báo cho tác giả bài báo (bằng e-mail) về tình hình phê duyệt bài báo, thời gian, số kỳ, tập xuất bản bài báo theo qui định.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">4. Danh sách bài báo theo số Tạp chí được in ấn và phát hành trong năm định kỳ được công bố chính thức trên website: https:\u002F\u002Ftapchi.ctump.edu.vn\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>",{"EN":74,"VI":75},"Cantho Journal of Medicine and Pharmacy","Tạp chí Y Dược học Cần Thơ",{"VOID":77},"wcQ1uqwAAAAJ","2023-05-30T08:17:21.868+00:00",32,[],[82],{"id":83,"createTime":84,"updateTime":85,"relativeEntities":86,"slug":87,"properties":88,"entityType":98,"verifyStatus":25,"verifyTime":99,"verifyNote":26,"syncStatus":28,"languages":100,"translateLanguages":26,"viewCount":103,"url":104,"parentIds":105,"statistic":106},"6413896b-eca9-442b-a73f-182a58a0ce40","2023-06-12T14:59:13.446+00:00","2026-06-19T02:29:32.871+00:00",[],"Tr%C6%B0%E1%BB%9Dng-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Y-D%C6%B0%E1%BB%A3c-C%E1%BA%A7n-Th%C6%A1",{"country":89,"title":90,"address":93,"abbreviation":96},{"VOID":15},{"EN":91,"VI":92},"Can Tho University of Medicine and Pharmacy","Trường Đại học Y Dược Cần Thơ",{"VI":94,"EN":95},"Số 179, đường Nguyễn Văn Cừ, phường An Khánh, quận Ninh Kiều, thành phố Cần Thơ, Việt Nam","No 179, Nguyen Van Cu street, An Khanh ward, Ninh Kieu district, Can Tho city, Vietnam",{"VOID":97},"ctump","AFFILIATION","2023-08-01T14:07:27.977+00:00",[101,102],"VI","EN",12,"http:\u002F\u002Fwww.ctump.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":107,"i10Index":111,"i10IndexLast5Year":59,"totalPublication":112,"totalPublicationByYear":113,"totalCitation":122,"totalCitationByYear":123,"totalCitationPerPublication":128,"totalCitationPerPublicationByYear":129,"hindexLast5Year":135,"hindex":135},{"2022":108,"2023":109,"2024":110,"2025":38},0.1,0.05,0.07,4,1489,{"2013":114,"2014":115,"2015":115,"2016":111,"2017":115,"2018":59,"2019":114,"2020":116,"2021":117,"2022":118,"2023":119,"2024":120,"2025":121,"2026":111},2,1,10,84,281,680,260,156,313,{"2013":59,"2014":114,"2018":124,"2021":125,"2022":126,"2023":127},17,36,123,132,0.21,{"2013":130,"2014":114,"2018":131,"2021":132,"2022":133,"2023":134},1.5,5.67,0.43,0.44,0.19,6,[],"https:\u002F\u002Ftapchi.ctump.edu.vn\u002Findex.php\u002Fctump",{"impactFactor":36,"impactFactorByYear":139,"i10Index":114,"i10IndexLast5Year":114,"totalPublication":140,"totalPublicationByYear":141,"totalCitation":147,"totalCitationByYear":148,"totalCitationPerPublication":151,"totalCitationPerPublicationByYear":152,"hindexLast5Year":135,"hindex":135},{"2022":38,"2023":36,"2024":39,"2025":38},1956,{"0":114,"2019":114,"2020":50,"2021":142,"2022":143,"2023":144,"2024":145,"2025":146},76,403,789,305,371,524,{"0":114,"2019":135,"2021":124,"2022":149,"2023":150,"2024":111,"2025":114},287,206,0.27,{"0":115,"2019":59,"2021":153,"2022":154,"2023":56,"2024":38,"2025":38},0.22,0.71,{"impactFactor":26,"impactFactorByYear":26,"i10Index":114,"i10IndexLast5Year":114,"totalPublication":156,"totalPublicationByYear":157,"totalCitation":163,"totalCitationByYear":164,"totalCitationPerPublication":169,"totalCitationPerPublicationByYear":170,"hindexLast5Year":135,"hindex":135},461,{"0":158,"2019":114,"2021":159,"2022":160,"2023":161,"2024":158,"2025":162},7,37,296,107,5,419,{"2021":59,"2022":59,"2023":165,"2024":166,"2025":167,"2026":168},71,126,171,41,0.91,{"2021":171,"2022":38,"2023":172,"2024":173,"2025":174},0.08,0.66,18,34.2,"JOURNAL",{"id":177,"createTime":178,"updateTime":179,"relativeEntities":180,"slug":181,"properties":182,"entityType":24,"verifyStatus":25,"verifyTime":193,"verifyNote":26,"syncStatus":28,"languages":194,"translateLanguages":26,"viewCount":36,"subjectFields":195,"manageAffiliations":196,"indexDatabases":197,"url":198,"thumbnailPath":26,"statistic":26,"gsStatistic":199,"type":175,"analyzePriority":26},"f8d0bf97-8d89-482e-b58c-2fc481a0b79b","2025-10-27T06:27:08.591+00:00","2026-06-18T23:33:41.667+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Khoa-h%E1%BB%8Dc-v%C3%A0-C%C3%B4ng-ngh%E1%BB%87-nhi%E1%BB%87t-%C4%91%E1%BB%9Bi",{"country":183,"introduce":184,"gsId":186,"title":188,"issn":191},{"VOID":15},{"EN":185},"\u003Cp style=\"text-align:justify;\">     Journal of Tropical Science and Engineering (JTSE) is a multidisciplinary scientific journal, licensed to operate as a print journal in 2012 and an electronic journal in 2024 (License No.1479\u002FGP-BTTTT dated August 20, 2012 and No.91\u002FGP-BTTTT dated April 9, 2024 issued by the Ministry of Information and Communications of Vietnam). The JTSE is headquartered in Hanoi.\u003C\u002Fp>\u003Cp style=\"text-align:justify;\">        The JTSE is published every 3 months (4 issues\u002Fyear), publishing research results and overview articles in 3 groups of fields: Tropical Ecology and Environment; Chemistry and Material Sciences; Biomedicine and Pharmacy. In 2022, the JTSE registered the international identifier Digital Object Identifier (DOI): 10.58334\u002Fvrtc.jtst and assigned DOI codes to all articles of the journal. The members of the Editorial Board of the JTSE are prestigious scientists and leading scientists from Vietnam and many countries in the world. The JTSE has been recognized by the Vietnam State Council for Professorship to score scientific articles in Chemistry, Medicine and Biology with scores ranging from 0-0.75 points.\u003C\u002Fp>\u003Cp style=\"text-align:justify;\">      Currently, the JTSE is building and perfecting a set of criteria and making efforts to join the List of prestigious  international journals with a roadmap to enter Scopus and SCIE in the coming time.\u003C\u002Fp>",{"VOID":187},"MS2_GJQAAAAJ",{"VI":189,"EN":190},"Tạp chí Khoa học và Công nghệ nhiệt đới","Journal of Tropical Science and Engineering",{"VOID":192},"08667535","2025-10-27T06:27:25.058+00:00",[101,102],[],[],[],"https:\u002F\u002Ftapchikhcnnd.com.vn",{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":200,"totalPublicationByYear":201,"totalCitation":161,"totalCitationByYear":203,"totalCitationPerPublication":153,"totalCitationPerPublicationByYear":205,"hindexLast5Year":114,"hindex":114},481,{"0":115,"2020":115,"2021":115,"2022":114,"2024":115,"2025":202,"2026":115},474,{"2017":114,"2018":115,"2019":111,"2020":162,"2021":162,"2022":116,"2023":50,"2024":162,"2025":204,"2026":52},52,{"2020":162,"2021":162,"2022":162,"2024":162,"2025":206,"2026":52},0.11,{"id":208,"createTime":209,"updateTime":210,"relativeEntities":211,"slug":212,"properties":213,"entityType":24,"verifyStatus":25,"verifyTime":221,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":222,"subjectFields":223,"manageAffiliations":224,"indexDatabases":225,"url":226,"thumbnailPath":26,"statistic":227,"gsStatistic":276,"type":175,"analyzePriority":26},"a3d1e82a-57e2-40f9-940e-f5fa8b9ef64a","2023-06-01T07:11:26.039+00:00","2026-06-18T23:33:28.573+00:00",[],"VNU-Journal-of-Science-Earth-and-Environmental-Sciences",{"issn":214,"title":216,"country":218,"gsId":219},{"VOID":215},"26159279",{"EN":217},"VNU Journal of Science: Earth and Environmental Sciences",{"VOID":15},{"VOID":220},"UmXD8vEAAAAJ","2023-06-01T07:17:59.210+00:00",27,[],[],[],"https:\u002F\u002Fjs.vnu.edu.vn\u002FEES",{"impactFactor":36,"impactFactorByYear":228,"i10Index":234,"i10IndexLast5Year":36,"totalPublication":235,"totalPublicationByYear":236,"totalCitation":246,"totalCitationByYear":247,"totalCitationPerPublication":261,"totalCitationPerPublicationByYear":262,"hindexLast5Year":103,"hindex":103},{"2010":229,"2012":40,"2013":230,"2014":230,"2015":231,"2016":54,"2017":171,"2018":109,"2019":110,"2020":57,"2021":232,"2022":233,"2023":151,"2024":58},0.02,0.04,0.09,0.31,0.4,19,656,{"2008":237,"2009":238,"2010":239,"2011":238,"2012":240,"2013":241,"2014":239,"2015":242,"2016":243,"2017":244,"2018":245,"2019":165,"2020":125,"2021":168,"2022":125,"2023":222,"2024":111},23,24,22,28,25,20,146,29,78,1038,{"2008":248,"2009":249,"2010":250,"2011":251,"2012":252,"2013":253,"2014":254,"2015":255,"2016":256,"2017":257,"2018":161,"2019":258,"2020":259,"2021":29,"2022":260},119,64,66,86,38,73,59,31,129,39,97,53,26,1.58,{"2008":263,"2009":264,"2010":59,"2011":265,"2012":266,"2013":267,"2014":268,"2015":269,"2016":270,"2017":271,"2018":272,"2019":272,"2020":273,"2021":274,"2022":275},5.17,2.67,3.58,1.36,2.92,2.68,1.55,0.88,1.34,1.37,1.47,1.24,0.72,{"impactFactor":26,"impactFactorByYear":26,"i10Index":173,"i10IndexLast5Year":135,"totalPublication":277,"totalPublicationByYear":278,"totalCitation":279,"totalCitationByYear":280,"totalCitationPerPublication":288,"totalCitationPerPublicationByYear":289,"hindexLast5Year":158,"hindex":298},113,{"2007":114,"2008":103,"2009":173,"2010":116,"2011":51,"2012":239,"2013":103,"2014":162,"2015":53,"2016":135},616,{"2009":162,"2010":114,"2011":52,"2012":124,"2013":222,"2014":255,"2015":48,"2016":44,"2017":281,"2018":282,"2019":259,"2020":283,"2021":284,"2022":285,"2023":286,"2024":257,"2025":287,"2026":59},54,60,49,47,34,44,33,5.45,{"2009":290,"2010":291,"2011":292,"2012":293,"2013":294,"2014":295,"2015":296,"2016":297},0.28,0.2,0.6,0.77,2.25,6.2,3.91,9.67,14,{"id":300,"createTime":301,"updateTime":302,"relativeEntities":303,"slug":304,"properties":305,"entityType":24,"verifyStatus":25,"verifyTime":316,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":234,"subjectFields":317,"manageAffiliations":318,"indexDatabases":388,"url":389,"thumbnailPath":390,"statistic":391,"gsStatistic":409,"type":175,"analyzePriority":26},"a7166325-6c9e-4db3-8a59-7c879701a372","2023-07-31T04:28:49.231+00:00","2026-06-18T23:33:22.428+00:00",[],"VNU-Journal-of-Science-Policy-and-Management-Studies",{"country":306,"issn":307,"eissn":309,"title":311,"gsId":314},{"VOID":15},{"VOID":308},"26159295",{"VOID":310},"25881116",{"EN":312,"VI":313},"VNU Journal of Science: Policy and Management Studies","Tạp chí Nghiên cứu Chính sách và Quản lý",{"VOID":315},"xKW2E_cAAAAJ","2023-08-01T03:23:46.688+00:00",[],[319],{"id":320,"createTime":321,"updateTime":322,"relativeEntities":323,"slug":324,"properties":325,"entityType":98,"verifyStatus":25,"verifyTime":335,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":336,"url":337,"parentIds":338,"statistic":339},"12466116-8f60-4b01-8faf-2411483a0977","2023-05-30T09:37:38.472+00:00","2026-06-19T02:14:28.352+00:00",[],"Vietnam-National-University",{"country":326,"title":327,"abbreviation":330,"address":332},{"VOID":15},{"EN":328,"VI":329},"Vietnam National University, Hanoi","Đại học Quốc gia Hà Nội",{"VOID":331},"VNU",{"VI":333,"EN":334},"Số 144 Xuân Thủy, Phường Dịch Vọng Hậu, Quận Cầu Giấy, Hà Nội, Việt Nam","No. 144 Xuan Thuy Street, Dich Vong Hau Ward, Cau Giay District, Hanoi, Vietnam","2023-08-02T13:58:17.029+00:00",16,"http:\u002F\u002Fwww.vnu.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":340,"i10Index":285,"i10IndexLast5Year":162,"totalPublication":344,"totalPublicationByYear":345,"totalCitation":354,"totalCitationByYear":355,"totalCitationPerPublication":368,"totalCitationPerPublicationByYear":369,"hindexLast5Year":336,"hindex":336},{"2014":109,"2015":231,"2016":231,"2017":206,"2018":341,"2019":110,"2020":342,"2021":343,"2022":171,"2023":231,"2024":110,"2025":39},0.06,0.18,0.35,1247,{"2003":115,"2004":115,"2005":114,"2006":59,"2007":111,"2008":162,"2009":59,"2010":50,"2011":124,"2012":336,"2013":260,"2014":244,"2015":250,"2016":281,"2017":346,"2018":347,"2019":348,"2020":349,"2021":350,"2022":351,"2023":352,"2024":353,"2025":255,"2026":50},94,88,83,67,176,185,187,93,1644,{"2004":111,"2005":115,"2006":52,"2007":298,"2008":356,"2009":298,"2010":286,"2011":357,"2012":244,"2013":358,"2014":359,"2015":360,"2016":361,"2017":362,"2018":363,"2019":364,"2020":365,"2021":366,"2022":367,"2023":367,"2024":162},13,81,48,70,151,115,109,259,174,181,121,101,1.32,{"2004":111,"2005":370,"2006":59,"2007":371,"2008":372,"2009":373,"2010":374,"2011":375,"2012":376,"2013":377,"2014":378,"2015":379,"2016":380,"2017":381,"2018":382,"2019":383,"2020":384,"2021":385,"2022":386,"2023":387,"2024":109},0.5,3.5,2.6,4.67,5.5,4.76,1.81,1.85,2.41,2.29,2.13,1.16,2.94,2.1,2.7,0.69,0.55,0.54,[],"https:\u002F\u002Fjs.vnu.edu.vn\u002FPaM","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002Fa7166325-6c9e-4db3-8a59-7c879701a372\u002Fecfe83f4bcc60c7023ae04d8900fe0ac.jpg",{"impactFactor":36,"impactFactorByYear":392,"i10Index":111,"i10IndexLast5Year":36,"totalPublication":394,"totalPublicationByYear":395,"totalCitation":399,"totalCitationByYear":400,"totalCitationPerPublication":293,"totalCitationPerPublicationByYear":403,"hindexLast5Year":158,"hindex":158},{"2018":109,"2019":171,"2020":393,"2021":108,"2022":54,"2023":206,"2024":54},0.23,320,{"2015":50,"2016":239,"2017":286,"2018":396,"2019":397,"2020":159,"2021":398,"2022":168,"2023":79,"2024":255},30,35,40,247,{"2015":115,"2016":242,"2017":401,"2018":222,"2019":402,"2020":79,"2021":239,"2022":50,"2023":116},77,50,{"2015":404,"2016":169,"2017":405,"2018":406,"2019":407,"2020":408,"2021":386,"2022":291,"2023":232},0.12,1.75,0.9,1.43,0.86,{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":103,"totalPublicationByYear":410,"totalCitation":234,"totalCitationByYear":411,"totalCitationPerPublication":261,"totalCitationPerPublicationByYear":412,"hindexLast5Year":114,"hindex":59},{"2015":114,"2016":116},{"2016":115,"2017":114,"2018":114,"2019":59,"2020":114,"2021":59,"2022":114,"2023":114,"2024":115,"2026":115},{"2016":108},{"id":414,"createTime":415,"updateTime":416,"relativeEntities":417,"slug":418,"properties":419,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":238,"subjectFields":428,"manageAffiliations":429,"indexDatabases":430,"url":431,"thumbnailPath":26,"statistic":432,"gsStatistic":438,"type":175,"analyzePriority":26},"16e65a3f-d274-47dd-8691-56d76eb58c3d","2023-05-30T09:10:06.062+00:00","2026-06-18T23:33:17.679+00:00",[],"Vietnam-Journal-of-Otorhinolaryngology-Head-and-Neck-Surgery",{"country":420,"issn":421,"title":423,"gsId":426},{"VOID":15},{"VOID":422},"18593704",{"EN":424,"VI":425},"Vietnam Journal of Otorhinolaryngology - Head and Neck Surgery","Tạp chí Tai Mũi Họng Việt Nam",{"VOID":427},"L78B_eIAAAAJ",[],[],[],"https:\u002F\u002Ftapchitaimuihong.vn\u002Findex.php\u002Ftmh",{"impactFactor":36,"impactFactorByYear":433,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":434,"totalPublicationByYear":435,"totalCitation":111,"totalCitationByYear":436,"totalCitationPerPublication":230,"totalCitationPerPublicationByYear":437,"hindexLast5Year":115,"hindex":115},{"2024":229},95,{"2022":52,"2023":286,"2024":255,"2025":53},{"2023":111},{"2023":231},{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":240,"totalPublicationByYear":439,"totalCitation":234,"totalCitationByYear":440,"totalCitationPerPublication":441,"totalCitationPerPublicationByYear":442,"hindexLast5Year":114,"hindex":114},{"2023":53,"2024":116,"2025":135,"2026":115},{"2024":59,"2025":298,"2026":114},0.68,{"2024":443,"2025":444,"2026":114},0.3,2.33,{"id":446,"createTime":447,"updateTime":448,"relativeEntities":449,"slug":450,"properties":451,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":396,"subjectFields":460,"manageAffiliations":461,"indexDatabases":462,"url":463,"thumbnailPath":464,"statistic":465,"gsStatistic":472,"type":175,"analyzePriority":26},"25988add-c322-4eda-afda-63b1559bb824","2023-04-07T03:49:55.817+00:00","2026-06-18T23:32:23.776+00:00",[],"T%E1%BA%A1p%20ch%C3%AD%20Y%20-%20D%C6%B0%E1%BB%A3c%20h%E1%BB%8Dc%20qu%C3%A2n%20s%E1%BB%B1",{"country":452,"issn":453,"title":455,"gsId":458},{"VOID":15},{"VOID":454},"18590748",{"EN":456,"VI":457},"Journal of Military Pharmaco-medicine","Tạp chí Y - Dược học quân sự",{"VOID":459},"_pmQ8IEAAAAJ",[],[],[],"https:\u002F\u002Fjmpm.vn\u002Findex.php\u002Fjmpm","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F25988add-c322-4eda-afda-63b1559bb824\u002F09c6bc42157cf5ece95edc971ccddb52.jpg",{"impactFactor":36,"impactFactorByYear":466,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":467,"totalPublicationByYear":468,"totalCitation":135,"totalCitationByYear":470,"totalCitationPerPublication":38,"totalCitationPerPublicationByYear":471,"hindexLast5Year":115,"hindex":115},{"2023":229,"2024":38},475,{"2022":168,"2023":365,"2024":469,"2025":124},236,{"2022":114,"2023":111},{"2022":109,"2023":229},{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":277,"totalPublicationByYear":473,"totalCitation":401,"totalCitationByYear":474,"totalCitationPerPublication":441,"totalCitationPerPublicationByYear":475,"hindexLast5Year":59,"hindex":59},{"2015":115,"2018":114,"2019":115,"2020":115,"2021":59,"2022":103,"2023":159,"2024":287,"2025":237},{"2020":115,"2021":115,"2022":115,"2023":52,"2024":237,"2025":79,"2026":116},{"2020":115,"2021":476,"2022":171,"2023":477,"2024":478,"2025":479},0.33,0.24,0.7,1.39,{"id":481,"createTime":482,"updateTime":483,"relativeEntities":484,"slug":485,"properties":486,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":496,"translateLanguages":26,"viewCount":45,"subjectFields":497,"manageAffiliations":498,"indexDatabases":525,"url":526,"thumbnailPath":527,"statistic":528,"gsStatistic":26,"type":26,"analyzePriority":26},"2b8d7b12-2d20-4777-be98-077f44f03c69","2023-09-07T07:40:58.286+00:00","2025-07-13T21:21:00.542+00:00",[],"VNU-Journal-of-Social-Sciences-and-Humanities",{"country":487,"issn":488,"introduce":490,"title":493},{"VOID":15},{"VOID":489},"23541172",{"EN":491,"VI":492},"{\"ops\":[{\"insert\":\"VNU Journal of Social Sciences and Humanities (ISSN 2354-1172) is a double-blind peer-reviewed journal published by University of Social Sciences and Humanities, Vietnam National University, Hanoi, Vietnam, under the publication permit no. 155\u002FGP-BTTTT, issued on 11\"},{\"attributes\":{\"script\":\"super\"},\"insert\":\"th \"},{\"insert\":\"May, 2015 by Ministry of Information and Communications. The journal publishes four Vietnamese issues and two English issues per year.\\nCurrently, there are 35 reputable professors in the editorial board. The main objectives of the journal include: providing an intellectual platform for Vietnamese and international scholars; promoting interdisciplinary studies in social sciences and humanities; becoming the leading journal in social sciences and humanities in Vietnam; being indexed by worldwide databases and having academic recognition internationally in the near future.\\nThe journal is currently indexed by Google Scholar, WorldCat, Open Archives, Cosmos Impact Factor, Advanced Sciences Index, Scientific Indexing Services, CrossRef, EBSCO Information Services and Vietnam National University’s digital archive.\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Journal of Social Sciences and Humanities-Vietnam\"},{\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"ISSN 2354-1172, email: tapchikhxhnv@gmail.com, tckhxhnv@vnu.edu.vn\"},{\"insert\":\"\\n\"}]}","{\"ops\":[{\"insert\":\"Được thành lập ngày 31\u002F8\u002F2015 (giấy phép hoạt động số 155\u002FGP-BVHTT ngày 11 tháng 5 năm 2015 của Bộ Thông tin và Truyền thông, mã số tiêu chuẩn quốc tế ISSN 2354-1172), Tạp chí Khoa học Xã hội và Nhân văn (Journal of Social Sciences and Humanities) là ấn phẩm khoa học chính thức, duy nhất của Trường Đại học Khoa học Xã hội và Nhân văn, ĐHQG Hà Nội, phát triển và kế thừa Chuyên san Khoa học Xã hội và Nhân văn, Tạp chí Khoa học, ĐHQG Hà Nội.\\nTạp chí xuất bản định kỳ (04 số tiếng Việt\u002Fnăm và 02 số tiếng Anh\u002Fnăm), có nhiệm vụ \"},{\"attributes\":{\"italic\":true},\"insert\":\"công bố, giới thiệu các công trình nghiên cứu khoa học khoa học xã hội và nhân văn của các tác giả là các nhà khoa học trong và ngoài nước, phục vụ giảng dạy, học tập và nghiên cứu khoa học\"},{\"insert\":\". Hội đồng biên tập của Tạp chí hiện bao gồm 33 nhà khoa học có uy tín trong nước và quốc tế. Tạp chí tập trung và ưu tiên đăng tải những bài báo theo định hướng của tinh thần cởi mở, sáng tạo, nhanh chóng vươn lên để tiếp cận và sánh ngang với các tạp chí có uy tín hàng đầu của khu vực và trên thế giới. Nội dung chính của Tạp chí bao gồm các Bài nghiên cứu (khoảng 6000 đến 15000 từ), các bài điểm sách, thông tin khoa học (khoảng 300 đến 1500 từ) được trình bày theo đúng cấu trúc và chuẩn mực của một tạp chí khoa học.\\nCác bài viết của Tạp chí hiện đang được trích dẫn bởi Google Scholar, WorldCat, Open Archives, Cosmos Impact Factor, Advanced Sciences Index, Scientific Indexing Services, CrossRef, EBSCO Information Services.\\nMọi thông tin xin liên hệ: \"},{\"attributes\":{\"italic\":true},\"insert\":\"Phòng Tạp chí, 701 - E, Trường Đại học Khoa học Xã hội và Nhân văn, 336 Nguyễn Trãi, Thanh Xuân, Hà Nội. ĐT: 024.35581984; email: tckhxhnv@vnu.edu.vn \"},{\"insert\":\"hoặc \"},{\"attributes\":{\"italic\":true},\"insert\":\"tapchikhxhnv@gmail.com \"},{\"insert\":\"\\n\"}]}",{"EN":494,"VI":495},"VNU Journal of Social Sciences and Humanities","Tạp chí Khoa học Xã hội và Nhân văn",[101,102],[],[499],{"id":500,"createTime":501,"updateTime":502,"relativeEntities":503,"slug":504,"properties":505,"entityType":98,"verifyStatus":25,"verifyTime":509,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":222,"url":26,"parentIds":510,"statistic":511},"8b6e349b-0daf-4895-9c3f-85f30f1bfd42","2023-07-31T12:55:58.430+00:00","2026-06-19T02:30:07.899+00:00",[],"Tr%C6%B0%E1%BB%9Dng-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Khoa-h%E1%BB%8Dc-X%C3%A3-h%E1%BB%99i-v%C3%A0-Nh%C3%A2n-v%C4%83n-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-H%C3%A0-N%E1%BB%99i",{"title":506},{"EN":507,"VI":508},"VNU University of Social Sciences and Humanities","Trường Đại học Khoa học Xã hội và Nhân văn, Đại học Quốc gia Hà Nội","2023-08-02T15:28:49.057+00:00",[],{"impactFactor":36,"impactFactorByYear":512,"i10Index":59,"i10IndexLast5Year":115,"totalPublication":514,"totalPublicationByYear":515,"totalCitation":518,"totalCitationByYear":519,"totalCitationPerPublication":520,"totalCitationPerPublicationByYear":521,"hindexLast5Year":162,"hindex":162},{"2016":229,"2017":230,"2018":229,"2021":230,"2022":58,"2023":513,"2024":38},0.15,365,{"2013":115,"2014":158,"2015":125,"2016":252,"2017":44,"2018":516,"2019":286,"2020":396,"2021":259,"2022":517,"2023":396,"2024":115,"2025":59,"2026":115},21,42,169,{"2015":283,"2016":135,"2017":52,"2018":50,"2019":298,"2020":53,"2021":359,"2022":115,"2023":115},0.46,{"2015":266,"2016":57,"2017":57,"2018":522,"2019":523,"2020":524,"2021":368,"2022":229,"2023":39},0.38,0.32,0.37,[],"http:\u002F\u002Fjournal.ussh.vnu.edu.vn\u002Findex.php\u002Fvjossh","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F2b8d7b12-2d20-4777-be98-077f44f03c69\u002F0bd0751202944a4b4165b482e6e623e4.png",{"impactFactor":36,"impactFactorByYear":529,"i10Index":162,"i10IndexLast5Year":115,"totalPublication":530,"totalPublicationByYear":531,"totalCitation":537,"totalCitationByYear":538,"totalCitationPerPublication":343,"totalCitationPerPublicationByYear":540,"hindexLast5Year":135,"hindex":135},{"2016":341,"2017":39,"2018":229,"2019":38,"2020":110,"2021":231,"2022":231,"2023":341,"2024":39},764,{"2015":255,"2016":245,"2017":532,"2018":259,"2019":533,"2020":534,"2021":535,"2022":536,"2023":534,"2024":254,"2025":50},111,106,68,92,89,265,{"2015":539,"2016":241,"2017":168,"2018":51,"2019":349,"2020":260,"2021":244,"2022":298,"2023":114},46,{"2015":541,"2016":523,"2017":524,"2018":290,"2019":542,"2020":522,"2021":523,"2022":57,"2023":39},1.48,0.63,{"id":544,"createTime":545,"updateTime":546,"relativeEntities":547,"slug":548,"properties":549,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":558,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":50,"subjectFields":559,"manageAffiliations":560,"indexDatabases":561,"url":562,"thumbnailPath":563,"statistic":564,"gsStatistic":26,"type":26,"analyzePriority":26},"6ec01bd0-15c0-469a-86ac-41339076ae0a","2023-08-10T07:08:33.153+00:00","2026-01-31T21:19:06.362+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Da-li%E1%BB%85u-h%E1%BB%8Dc-Vi%E1%BB%87t-Nam",{"country":550,"issn":551,"introduce":553,"title":555},{"VOID":15},{"VOID":552},"18594824",{"VI":554},"{\"ops\":[{\"insert\":\"Tạp chí “Da liễu học Việt Nam” (Tiếng Anh: Vietnamese Journal of Dermatology and Venereology) thuộc Hội Da liễu Việt Nam, xuất bản 4 số mỗi năm bằng tiếng Việt hoặc tiếng Anh.\\nTạp chí Da liễu học Việt Nam hoạt động với mục đích, tôn chỉ là phổ biến, trao đổi thông tin trong lĩnh vực chuyên ngành da liễu; đăng tải các công trình nghiên cứu khoa học; chuyển giao công nghệ - kinh tế và khoa học kỹ thuật liên quan đến lĩnh vực da liễu.\\nPhạm vi của tạp chí là tất cả các bài báo khoa học, bài tổng quan, giới thiệu ca lâm sàng, … có liên quan tới chuyên ngành da liễu trong và ngoài nước. Tạp chí công bố các công trình nghiên cứu liên quan đến mô hình bệnh tật, các phương pháp chẩn đoán, điều trị, dự phòng và phục hồi chức năng các bệnh thuộc chuyên ngành da liễu. Ngoài ra, tạp chí còn đăng tải các bài tổng quan, cập nhật thông tin, kiến thức, hướng dẫn chẩn đoán, điều trị trong chuyên ngành da liễu trong nước và quốc tế; đăng tải các bài ca lâm sàng đặc biệt trong chuyên ngành da liễu.\\nTạp chí Da liễu học Việt Nam được biết tới là một tạp chí chuyên ngành có uy tín trong lĩnh vực da liễu. Các bài báo về nghiên cứu khoa học đăng trong Tạp chí được bình duyệt một cách nghiêm ngặt bởi ít nhất 2 chuyên gia. Hội đồng biên tập tạp chí bao gồm các nhà khoa học có uy tín (Giáo sư, Phó Giáo sư, Tiến sĩ, Bác sĩ…) trong chuyên ngành da liễu nhằm đảm bảo chất lượng và tính khách quan, khoa học cho các bài viết đăng trên Tạp chí.\\n\"}]}",{"EN":556,"VI":557},"Vietnamese Journal of Dermatology and Venereology","Tạp chí Da liễu học Việt Nam","Admin Import",[],[],[],"https:\u002F\u002Fvjdv.vn\u002Findex.php\u002Fvjdv","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F6ec01bd0-15c0-469a-86ac-41339076ae0a\u002F3cbc81720e58429dc7b1c4d7ab1935ca.jpg",{"impactFactor":36,"impactFactorByYear":565,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":566,"totalPublicationByYear":567,"totalCitation":116,"totalCitationByYear":570,"totalCitationPerPublication":109,"totalCitationPerPublicationByYear":571,"hindexLast5Year":115,"hindex":115},{"2023":38,"2024":230},182,{"2022":568,"2023":45,"2024":569},69,56,{"2022":52,"2023":115},{"2022":40,"2023":229},{"id":573,"createTime":574,"updateTime":575,"relativeEntities":576,"slug":577,"properties":578,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":587,"translateLanguages":26,"viewCount":283,"subjectFields":588,"manageAffiliations":589,"indexDatabases":647,"url":648,"thumbnailPath":649,"statistic":650,"gsStatistic":26,"type":26,"analyzePriority":26},"19221551-7519-47ff-a892-331d1139c64b","2023-09-12T07:03:05.744+00:00","2026-01-24T20:54:40.144+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Khoa-h%E1%BB%8Dc-S%E1%BB%A9c-kho%E1%BA%BB-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-Th%C3%A0nh-ph%E1%BB%91-H%E1%BB%93-Ch%C3%AD-Minh",{"country":579,"issn":580,"introduce":582,"title":584},{"VOID":15},{"VOID":581},"27349446",{"EN":583},"{\"ops\":[{\"attributes\":{\"bold\":true},\"insert\":\"1. History\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Science and Technology Development Journal\"},{\"insert\":\" (STDJ) (ISSN 2734-9446), Vietnam National University - Ho Chi Minh City (VNU-HCM) was established in 1997. And the first issue was published in January 1998 with ISSN 1859-0128. Since then, STDJ has become the most important scientific forum of scientists from VNU-HCM as well as other universities. The magazine has undergone 20 years of development and has become a bridge for scientific exchanges, as well as enriching reference materials for the faculty, doctoral students, students of VNU-HCM in particular and other universities, institutes...\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Science and Technology Development Journal - Health Sciences (STDJ-HS) is a subjournal of Science and Technology Development Journal since 2020.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\" \"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"2. Focus and Scope\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Publishing articles with contents on healthcare, research projects in the field of health, advanced directions in health education and management. Therefore, STDJ-HS will accept articles from doctors, administrators, teachers, researchers, graduate students and fellows. The authors will be responsible for the accuracy of the data, opinions, opinions and material cited in the article.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Facilitating the exchange of scientific and technological information and act as a bridge between theory and practice in the community of educators, scientists, managers, policy makers and enterprises in and out of the country.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}",{"EN":585,"VI":586},"VNUHCM JOURNAL OF HEALTH SCIENCES","Tạp chí Khoa học Sức khoẻ Đại học Quốc gia Thành phố Hồ Chí Minh",[101,102],[],[590],{"id":591,"createTime":592,"updateTime":593,"relativeEntities":594,"slug":595,"properties":596,"entityType":98,"verifyStatus":25,"verifyTime":606,"verifyNote":26,"syncStatus":28,"languages":607,"translateLanguages":26,"viewCount":608,"url":609,"parentIds":610,"statistic":611},"fc4c2560-868c-4677-acb1-8686bef88727","2023-06-26T04:48:23.774+00:00","2026-06-19T01:46:17.248+00:00",[],"%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-Th%C3%A0nh-ph%E1%BB%91-H%E1%BB%93-Ch%C3%AD-Minh",{"country":597,"title":598,"abbreviation":601,"address":603},{"VOID":15},{"EN":599,"VI":600},"Vietnam National University Ho Chi Minh City","Đại học Quốc gia Thành phố Hồ Chí Minh",{"VOID":602},"VNUHCM",{"VI":604,"EN":605},"khu phố 6, Phường Linh Trung, Thành phố Thủ Đức, Thành phố Hồ Chí Minh, Việt Nam","Quarter 6, Linh Trung Ward, Thu Duc City, Ho Chi Minh City, Vietnam","2023-08-16T14:13:07.134+00:00",[101,102],45,"https:\u002F\u002Fvnuhcm.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":612,"i10Index":285,"i10IndexLast5Year":51,"totalPublication":613,"totalPublicationByYear":614,"totalCitation":624,"totalCitationByYear":625,"totalCitationPerPublication":634,"totalCitationPerPublicationByYear":635,"hindexLast5Year":124,"hindex":124},{"2014":36,"2015":38,"2016":109,"2017":39,"2018":229,"2019":38,"2020":110,"2021":171,"2022":110,"2023":110,"2024":171,"2025":229},3708,{"2005":115,"2006":115,"2007":115,"2008":135,"2009":111,"2010":53,"2011":52,"2012":568,"2013":615,"2014":351,"2015":616,"2016":469,"2017":617,"2018":127,"2019":618,"2020":619,"2021":620,"2022":621,"2023":622,"2024":623,"2025":159,"2026":50},164,266,177,226,603,931,314,246,74,2399,{"2006":115,"2008":50,"2010":162,"2011":242,"2012":222,"2013":43,"2014":626,"2015":627,"2016":628,"2017":629,"2018":258,"2019":630,"2020":631,"2021":632,"2022":633,"2023":353,"2024":115},250,124,157,162,152,385,559,128,0.65,{"2006":115,"2008":636,"2010":637,"2011":638,"2012":639,"2013":522,"2014":640,"2015":641,"2016":642,"2017":643,"2018":644,"2019":642,"2020":645,"2021":292,"2022":646,"2023":522,"2024":38},1.33,0.45,2.22,0.39,1.35,0.47,0.67,0.92,0.73,0.64,0.41,[],"http:\u002F\u002Fstdjhs.scienceandtechnology.com.vn\u002Findex.php\u002Fstdjhs","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F19221551-7519-47ff-a892-331d1139c64b\u002F2e10768b7d1e380c36a25ed0c714dd7e.png",{"impactFactor":36,"impactFactorByYear":651,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":652,"totalPublicationByYear":653,"totalCitation":516,"totalCitationByYear":654,"totalCitationPerPublication":151,"totalCitationPerPublicationByYear":655,"hindexLast5Year":59,"hindex":59},{"2022":57,"2023":108,"2024":39},79,{"2020":116,"2021":240,"2022":239,"2023":52,"2024":162,"2025":162},{"2020":59,"2021":51,"2022":59},{"2020":443,"2021":387,"2022":54},{"code":657,"data":658,"meta":26},"SUCCESS",{"id":659,"createTime":660,"updateTime":661,"relativeEntities":662,"slug":663,"properties":664,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":114,"subjectFields":673,"manageAffiliations":706,"indexDatabases":726,"url":768,"thumbnailPath":26,"statistic":769,"gsStatistic":26,"type":26,"analyzePriority":26},"c9dcdf0d-1f44-46cc-93b6-4b34cd3868a8","2023-05-29T10:55:48.592+00:00","2025-11-21T09:54:15.321+00:00",[],"JHEP-Reports",{"country":665,"issn":667,"introduce":669,"title":671},{"VOID":666},"NL",{"VOID":668},"25895559",{"EN":670},"JHEP Reports is an open access companion title to the highly-respected Journal of Hepatology. It publishes original papers, reviews, and letters to the Editor concerned with basic, translation and clinical research in the field of hepatology. JHEP Reports is an innovative Journal publishing articles on global issues in hepatology, with specific focus on clinical trials, novel diagnostics, precision medicine and therapeutics, cellular and molecular research, metabolism, cancer, microbiome, systems biology, epidemiology, and biotechnology advances and devices.",{"EN":672},"JHEP Reports",[674,682,690,698],{"id":675,"createTime":676,"updateTime":677,"relativeEntities":678,"label":679,"description":681,"parentId":26,"standard":26,"scholarHubFieldId":26},"a520f91c-9c10-4000-96b1-c80ea7776e25","2023-05-29T10:24:12.053+00:00","2023-11-21T07:53:13.948+00:00",[],{"EN":680},"Gastroenterology",{},{"id":683,"createTime":684,"updateTime":685,"relativeEntities":686,"label":687,"description":689,"parentId":26,"standard":26,"scholarHubFieldId":26},"01203b2d-e9ba-432d-a4b0-d0f3ced5dfa6","2023-05-29T10:24:07.274+00:00","2023-11-21T07:04:43.214+00:00",[],{"EN":688},"Hepatology",{},{"id":691,"createTime":692,"updateTime":693,"relativeEntities":694,"label":695,"description":697,"parentId":26,"standard":26,"scholarHubFieldId":26},"6dc081f7-79a9-45f6-8ed3-54ef5518db41","2023-05-29T10:24:14.547+00:00","2023-11-21T07:19:21.114+00:00",[],{"EN":696},"Immunology and Allergy",{},{"id":699,"createTime":700,"updateTime":701,"relativeEntities":702,"label":703,"description":705,"parentId":26,"standard":26,"scholarHubFieldId":26},"77761c13-d9ff-4113-b615-60dad0c16000","2023-05-29T10:24:33.231+00:00","2023-11-21T06:06:57.205+00:00",[],{"EN":704},"Internal Medicine",{},[707,717],{"id":708,"createTime":709,"updateTime":710,"relativeEntities":711,"slug":712,"properties":713,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":52,"url":26,"parentIds":716,"statistic":26},"c204a4fd-ec04-47ff-9c5b-5d693c99cecf","2023-05-29T10:24:07.053+00:00","2024-02-19T16:29:56.082+00:00",[],"Elsevier-BV",{"title":714},{"EN":715},"Elsevier BV",[],{"id":718,"createTime":719,"updateTime":720,"relativeEntities":721,"slug":722,"properties":723,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":53,"url":26,"parentIds":725,"statistic":26},"c749757b-dddf-4e6f-9697-b9c441adc06c","2023-05-29T10:24:07.401+00:00","2025-11-21T10:06:14.206+00:00",[],"Elsevier",{"title":724},{"EN":722},[],[727,746],{"id":728,"indexDatabase":729,"url":743,"indexYears":26,"academicFieldIds":744,"indexDatabaseRanking":26},"21daddc5-e029-427b-8e9d-2d0c7d1e9c43",{"id":730,"createTime":731,"updateTime":732,"relativeEntities":733,"label":734,"description":736,"key":739,"publicationTags":740,"standard":26},"a4921856-b128-4d9f-8f1f-e80813d3bbd4","2023-05-22T09:59:31.026+00:00","2025-11-21T10:07:52.153+00:00",[],{"EN":735,"VI":735},"ISI\u002FSCIE - Science Citation Index Expanded",{"VI":737,"EN":738},"Cơ sở dữ liệu SCIE","SCIE database","scie",[741,742],"SCIE","ISI","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002Fnull",[745],"4b2c1694-c69d-4b20-b2eb-9687848dfb30",{"id":747,"indexDatabase":748,"url":760,"indexYears":761,"academicFieldIds":762,"indexDatabaseRanking":767},"06399bf7-4dc2-49a2-9071-967c7609630f",{"id":749,"createTime":750,"updateTime":751,"relativeEntities":752,"label":753,"description":755,"key":757,"publicationTags":758,"standard":26},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9","2023-05-22T09:57:18.509+00:00","2025-11-21T10:07:52.274+00:00",[],{"EN":754,"VI":754},"Scopus - Elsevier",{"EN":754,"VI":756},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[759],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F21101037196","2019-2025",[763,764,765,766],"34ca0c58-3b99-4064-9bf3-a754a6e2e9a7","d39aa686-8d5d-45f0-81c4-13c21a0f2f39","7e7a8be0-3213-4ad0-b9db-1ab0e7d051c8","e872d6d8-194c-4b83-9ea3-8b78dd28210d","NONE","https:\u002F\u002Fwww.jhep-reports.eu\u002F",{"impactFactor":36,"impactFactorByYear":770,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":245,"totalPublicationByYear":771,"totalCitation":36,"totalCitationByYear":772,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":773,"hindexLast5Year":36,"hindex":36},{},{"2019":158,"2020":111,"2021":124,"2022":298,"2023":287,"2024":59},{},{},{"meta":775,"data":777},{"total":776},"277",[778,1186,1356,1421,1790,2189,2325,2519,2723,3008],{"id":779,"createTime":780,"updateTime":781,"relativeEntities":782,"slug":783,"properties":784,"entityType":791,"verifyStatus":25,"verifyTime":792,"verifyNote":793,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":794,"fullTextUrl":26,"authors":795,"publicationType":994,"publisherRelationship":995,"citationCount":36,"citationInfo":1030,"publishDate":1032,"publishYear":1033,"citationAnalyzeStatus":1034,"lastCitationAnalyze":1035,"indexDatabases":26,"openAccess":26,"references":1036,"isForceReanalyzing":1185},"febd8753-4fea-42f7-8023-f4d038fa48a8","2024-01-08T19:34:19.471+00:00","2026-05-17T21:33:20.718+00:00",[],"Burden-risk-factors-and-outcomes-of-multidrug-resistant-bacterial-colonisation-at-multiple-sites-in-patients-with-cirrhosis",{"title":785,"doi":787,"gsPaper":789},{"EN":786},"Burden, risk factors, and outcomes of multidrug-resistant bacterial colonisation at multiple sites in patients with cirrhosis",{"VOID":788},"10.1016\u002Fj.jhepr.2023.100788",{"VOID":790},"[\"13595713999868138760\"]","PUBLICATION","2024-04-29T02:43:13.208+00:00","Auto Verify","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2589555923001192",[796,812,829,841,853,865,877,889,901,913,930,944,956,968,982],{"id":797,"sortIndex":298,"researcher":26,"roles":798,"affiliations":800,"properties":809},"f24c9b4a-e720-439a-aaf8-da9a7eabd262",[799],"AUTHOR",[801],{"id":26,"sortIndex":36,"affiliation":802,"properties":26},{"id":803,"createTime":804,"updateTime":804,"relativeEntities":805,"slug":26,"properties":806,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"7f2a1ba9-5708-4359-a7a0-8d9747d495a8","2023-12-13T06:55:29.710+00:00",[],{"title":807},{"VI":808},"Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India",{"title":810},{"VI":811},"Virendra Singh",{"id":813,"sortIndex":111,"researcher":26,"roles":814,"affiliations":815,"properties":826},"a0132821-5a43-4986-bd1e-d258a3a096e3",[799],[816],{"id":26,"sortIndex":36,"affiliation":817,"properties":26},{"id":818,"createTime":819,"updateTime":820,"relativeEntities":821,"slug":822,"properties":823,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"190cb45e-05a2-49df-b2fe-b9a0606827b4","2024-01-10T14:59:06.731+00:00","2025-02-09T11:20:27.174+00:00",[],"Department-of-Medical-Microbiology-Postgraduate-Institute-of-Medical-Education-and-Research-Chandigarh-India",{"title":824},{"VI":825},"Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India",{"title":827},{"VI":828},"Manisha Biswal",{"id":830,"sortIndex":52,"researcher":26,"roles":831,"affiliations":832,"properties":838},"104354d7-6749-429f-a3cd-a1f5b82d0570",[799],[833],{"id":26,"sortIndex":36,"affiliation":834,"properties":26},{"id":803,"createTime":804,"updateTime":804,"relativeEntities":835,"slug":26,"properties":836,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":837},{"VI":808},{"title":839},{"VI":840},"Arka De",{"id":842,"sortIndex":50,"researcher":26,"roles":843,"affiliations":844,"properties":850},"62304903-b655-4224-b463-19045afc2f8b",[799],[845],{"id":26,"sortIndex":36,"affiliation":846,"properties":26},{"id":803,"createTime":804,"updateTime":804,"relativeEntities":847,"slug":26,"properties":848,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":849},{"VI":808},{"title":851},{"VI":852},"Sahaj Rathi",{"id":854,"sortIndex":116,"researcher":26,"roles":855,"affiliations":856,"properties":862},"bb487bc7-a518-4b31-bbe0-79c5af4a4ba4",[799],[857],{"id":26,"sortIndex":36,"affiliation":858,"properties":26},{"id":803,"createTime":804,"updateTime":804,"relativeEntities":859,"slug":26,"properties":860,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":861},{"VI":808},{"title":863},{"VI":864},"Madhumita Premkumar",{"id":866,"sortIndex":158,"researcher":26,"roles":867,"affiliations":868,"properties":874},"388e3d12-5cff-4b84-b181-251243bb9dcc",[799],[869],{"id":26,"sortIndex":36,"affiliation":870,"properties":26},{"id":803,"createTime":804,"updateTime":804,"relativeEntities":871,"slug":26,"properties":872,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":873},{"VI":808},{"title":875},{"VI":876},"Parminder Kaur",{"id":878,"sortIndex":356,"researcher":26,"roles":879,"affiliations":880,"properties":886},"9d89dae3-84d4-4d88-881e-06857f8c8ce6",[799],[881],{"id":26,"sortIndex":36,"affiliation":882,"properties":26},{"id":803,"createTime":804,"updateTime":804,"relativeEntities":883,"slug":26,"properties":884,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":885},{"VI":808},{"title":887},{"VI":888},"Ajay Duseja",{"id":890,"sortIndex":103,"researcher":26,"roles":891,"affiliations":892,"properties":898},"3ca472b6-b33d-4450-a80e-2ea8d5355cf7",[799],[893],{"id":26,"sortIndex":36,"affiliation":894,"properties":26},{"id":818,"createTime":819,"updateTime":820,"relativeEntities":895,"slug":822,"properties":896,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":897},{"VI":825},{"title":899},{"VI":900},"Pallab Ray",{"id":902,"sortIndex":135,"researcher":26,"roles":903,"affiliations":904,"properties":910},"313a144f-3d80-4477-9b02-66b2d5270e6f",[799],[905],{"id":26,"sortIndex":36,"affiliation":906,"properties":26},{"id":803,"createTime":804,"updateTime":804,"relativeEntities":907,"slug":26,"properties":908,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":909},{"VI":808},{"title":911},{"VI":912},"Pratibha Garg",{"id":914,"sortIndex":115,"researcher":26,"roles":915,"affiliations":916,"properties":927},"3560b033-9885-4946-8144-ed2efb32c89d",[799],[917],{"id":26,"sortIndex":36,"affiliation":918,"properties":26},{"id":919,"createTime":920,"updateTime":921,"relativeEntities":922,"slug":923,"properties":924,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"218451f6-023c-4cde-86c6-958debcd2d1f","2024-01-16T22:26:34.652+00:00","2025-02-02T12:26:56.228+00:00",[],"Department-of-Internal-Medicine-Postgraduate-Institute-of-Medical-Education-and-Research-Chandigarh-India",{"title":925},{"VI":926},"Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India",{"title":928},{"VI":929},"P. Venkata Divakar Reddy",{"id":931,"sortIndex":59,"researcher":26,"roles":932,"affiliations":933,"properties":939},"53a9fdac-44c0-4ac1-92fe-bd2ca49bc514",[799],[934],{"id":26,"sortIndex":36,"affiliation":935,"properties":26},{"id":818,"createTime":819,"updateTime":820,"relativeEntities":936,"slug":822,"properties":937,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":938},{"VI":825},{"title":940,"gsAuthor":942},{"VI":941},"Archana Angrup",{"VOID":943},"[\"orPNjocAAAAJ\"]",{"id":945,"sortIndex":114,"researcher":26,"roles":946,"affiliations":947,"properties":953},"1d9d431a-1fd9-40d4-a04c-6a9365b2d3ac",[799],[948],{"id":26,"sortIndex":36,"affiliation":949,"properties":26},{"id":818,"createTime":819,"updateTime":820,"relativeEntities":950,"slug":822,"properties":951,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":952},{"VI":825},{"title":954},{"VI":955},"Shashi Vig",{"id":957,"sortIndex":162,"researcher":26,"roles":958,"affiliations":959,"properties":965},"5c9aaa7d-e56d-4178-aaf1-e1680a31b424",[799],[960],{"id":26,"sortIndex":36,"affiliation":961,"properties":26},{"id":803,"createTime":804,"updateTime":804,"relativeEntities":962,"slug":26,"properties":963,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":964},{"VI":808},{"title":966},{"VI":967},"Arun Valsan",{"id":969,"sortIndex":36,"researcher":26,"roles":970,"affiliations":971,"properties":977},"fa044272-59ee-4bd2-9416-971056ccedbe",[799],[972],{"id":26,"sortIndex":36,"affiliation":973,"properties":26},{"id":803,"createTime":804,"updateTime":804,"relativeEntities":974,"slug":26,"properties":975,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":976},{"VI":808},{"title":978,"gsAuthor":980},{"VI":979},"Nipun Verma",{"VOID":981},"[\"zYfHSvoAAAAJ\"]",{"id":983,"sortIndex":53,"researcher":26,"roles":984,"affiliations":985,"properties":991},"f664d840-3088-4745-bd6c-e99ef57b84a2",[799],[986],{"id":26,"sortIndex":36,"affiliation":987,"properties":26},{"id":803,"createTime":804,"updateTime":804,"relativeEntities":988,"slug":26,"properties":989,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":990},{"VI":808},{"title":992},{"VI":993},"Sunil Taneja","ARTICLE",{"url":794,"publisher":996,"properties":1025},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":997,"slug":663,"properties":998,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":114,"subjectFields":1003,"manageAffiliations":1004,"indexDatabases":1005,"url":768,"thumbnailPath":26,"statistic":1020,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"country":999,"issn":1000,"introduce":1001,"title":1002},{"VOID":666},{"VOID":668},{"EN":670},{"EN":672},[],[],[1006,1013],{"id":747,"indexDatabase":1007,"url":760,"indexYears":761,"academicFieldIds":1012,"indexDatabaseRanking":767},{"id":749,"createTime":750,"updateTime":751,"relativeEntities":1008,"label":1009,"description":1010,"key":757,"publicationTags":1011,"standard":26},[],{"EN":754,"VI":754},{"EN":754,"VI":756},[759],[763,764,765,766],{"id":728,"indexDatabase":1014,"url":743,"indexYears":26,"academicFieldIds":1019,"indexDatabaseRanking":26},{"id":730,"createTime":731,"updateTime":732,"relativeEntities":1015,"label":1016,"description":1017,"key":739,"publicationTags":1018,"standard":26},[],{"EN":735,"VI":735},{"VI":737,"EN":738},[741,742],[745],{"impactFactor":36,"impactFactorByYear":1021,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":245,"totalPublicationByYear":1022,"totalCitation":36,"totalCitationByYear":1023,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":1024,"hindexLast5Year":36,"hindex":36},{},{"2019":158,"2020":111,"2021":124,"2022":298,"2023":287,"2024":59},{},{},{"volume":1026,"pages":1028},{"VOID":1027},"5",{"VOID":1029},"100788",{"total":36,"publishYear":36,"statisticByYear":1031},{},"2023-08-01",2023,"DONE_ANALYZE_CITATION","2026-05-17T21:33:20.717+00:00",[1037,1043,1052,1061,1069,1077,1083,1091,1099,1104,1110,1119,1128,1134,1139,1147,1153,1161,1167,1170,1178],{"id":1038,"text":1039,"url":1040,"identifiers":1041},"1e331d9b-70e6-4355-a285-be385acd5a8c","2022, Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis, Lancet, 399, 629, 10.1016\u002FS0140-6736(21)02724-0","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0140673621027240",{"doi":1042},"10.1016\u002Fs0140-6736(21)02724-0",{"id":26,"text":1044,"url":1045,"identifiers":1046},"Laxminarayan, 2016, Antibiotic resistance in India: drivers and opportunities for action, PLoS Med, 13, 10.1371\u002Fjournal.pmed.1001974","https:\u002F\u002Fdoi.org\u002F10.1371\u002Fjournal.pmed.1001974",{"mag":1047,"pmc":1048,"openalex":1049,"pm":1050,"doi":1051},"2290464731","4775002","W2290464731","26934098","10.1371\u002Fjournal.pmed.1001974",{"id":26,"text":1053,"url":1054,"identifiers":1055},"Singh, 2019, The human gut resistome: current concepts & future prospects, Indian J Med Res, 150, 345, 10.4103\u002Fijmr.IJMR_1979_17","https:\u002F\u002Fdoi.org\u002F10.4103\u002Fijmr.ijmr_1979_17",{"mag":1056,"pmc":1057,"openalex":1058,"pm":1059,"doi":1060},"2990053215","6902357","W2990053215","31823916","10.4103\u002Fijmr.ijmr_1979_17",{"id":26,"text":1062,"url":1063,"identifiers":1064},"Sepanlou, 2020, The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet Gastroenterol Hepatol, 5, 245, 10.1016\u002FS2468-1253(19)30349-8","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fs2468-1253(19)30349-8",{"mag":1065,"openalex":1066,"pm":1067,"doi":1068},"3002179283","W3002179283","31981519","10.1016\u002Fs2468-1253(19)30349-8",{"id":26,"text":1070,"url":1071,"identifiers":1072},"Bajaj, 2021, The evolving challenge of infections in cirrhosis, N Engl J Med, 384, 2317, 10.1056\u002FNEJMra2021808","https:\u002F\u002Fdoi.org\u002F10.1056\u002Fnejmra2021808",{"mag":1073,"openalex":1074,"pm":1075,"doi":1076},"3167659775","W3167659775","34133861","10.1056\u002Fnejmra2021808",{"id":1078,"text":1079,"url":1080,"identifiers":1081},"a963e332-41a6-4d43-9ea5-bb26ffa43a67","Piano, 2019, Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide, Gastroenterology, 156, 1368, 10.1053\u002Fj.gastro.2018.12.005","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0016508518354027",{"doi":1082},"10.1053\u002Fj.gastro.2018.12.005",{"id":26,"text":1084,"url":1085,"identifiers":1086},"Gupta, 2020, Prediction of 28-day mortality in acute decompensation of cirrhosis through the presence of multidrug-resistant infections at admission, J Gastroenterol Hepatol, 35, 461, 10.1111\u002Fjgh.14788","https:\u002F\u002Fdoi.org\u002F10.1111\u002Fjgh.14788",{"mag":1087,"openalex":1088,"pm":1089,"doi":1090},"2963480658","W2963480658","31334860","10.1111\u002Fjgh.14788",{"id":26,"text":1092,"url":1093,"identifiers":1094},"Waidmann, 2015, Colonisation with multidrug-resistant bacteria is associated with increased mortality in patients with cirrhosis, Gut, 64, 1183, 10.1136\u002Fgutjnl-2014-309104","https:\u002F\u002Fdoi.org\u002F10.1136\u002Fgutjnl-2014-309104",{"mag":1095,"openalex":1096,"pm":1097,"doi":1098},"2026812245","W2026812245","25616276","10.1136\u002Fgutjnl-2014-309104",{"id":26,"text":1100,"url":1101,"identifiers":1102},"Bert, 2014, Risk factors associated with preoperative fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in liver transplant recipients, Transpl Infect Dis, 16, 84, 10.1111\u002Ftid.12169","http:\u002F\u002Fdx.doi.org\u002F10.1111\u002Ftid.12169",{"doi":1103},"10.1111\u002Ftid.12169",{"id":1105,"text":1106,"url":1107,"identifiers":1108},"cdc5443e-addc-458b-baad-5efa84d384cd","Pouriki, 2018, Intestinal colonization with resistant bacteria: a prognostic marker of mortality in decompensated cirrhosis, Eur J Clin Microbiol Infect Dis, 37, 127, 10.1007\u002Fs10096-017-3110-9","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs10096-017-3110-9",{"doi":1109},"10.1007\u002Fs10096-017-3110-9",{"id":26,"text":1111,"url":1112,"identifiers":1113},"Pettigrew, 2019, Gastrointestinal microbiota disruption and risk of colonization with carbapenem-resistant Pseudomonas aeruginosa in intensive care unit patients, Clin Infect Dis, 69, 604, 10.1093\u002Fcid\u002Fciy936","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fcid\u002Fciy936",{"mag":1114,"pmc":1115,"openalex":1116,"pm":1117,"doi":1118},"2899513950","6669284","W2899513950","30383203","10.1093\u002Fcid\u002Fciy936",{"id":26,"text":1120,"url":1121,"identifiers":1122},"Ferstl, 2018, Noninvasive screening identifies patients at risk for spontaneous bacterial peritonitis caused by multidrug-resistant organisms, Infect Drug Resist, 11, 2047, 10.2147\u002FIDR.S172587","https:\u002F\u002Fdoi.org\u002F10.2147\u002Fidr.s172587",{"mag":1123,"pmc":1124,"openalex":1125,"pm":1126,"doi":1127},"2899393117","6223386","W2899393117","30464547","10.2147\u002Fidr.s172587",{"id":1129,"text":1130,"url":1131,"identifiers":1132},"b60c7c14-7ae8-4297-acb9-9b429620fe6d","Prado, 2022, Rectal colonization by resistant bacteria increases the risk of infection by the colonizing strain in critically ill patients with cirrhosis, J Hepatol, 76, 1079, 10.1016\u002Fj.jhep.2021.12.042","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0168827822000137",{"doi":1133},"10.1016\u002Fj.jhep.2021.12.042",{"id":26,"text":1135,"url":1136,"identifiers":1137},"Wani, 2019, Socioeconomic status scales-modified Kuppuswamy and Udai Pareekh's scale updated for 2019, J Fam Med Prim Care, 8, 1846, 10.4103\u002Fjfmpc.jfmpc_288_19","http:\u002F\u002Fdx.doi.org\u002F10.4103\u002Fjfmpc.jfmpc_288_19",{"doi":1138},"10.4103\u002Fjfmpc.jfmpc_288_19",{"id":26,"text":1140,"url":1141,"identifiers":1142},"Moreau, 2013, Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis, Gastroenterology, 144, 1426, 10.1053\u002Fj.gastro.2013.02.042","https:\u002F\u002Fdoi.org\u002F10.1053\u002Fj.gastro.2013.02.042",{"mag":1143,"openalex":1144,"pm":1145,"doi":1146},"2007670274","W2007670274","23474284","10.1053\u002Fj.gastro.2013.02.042",{"id":1148,"text":1149,"url":1150,"identifiers":1151},"1ed76bed-c498-403b-a0c1-a421ac9ea91d","Verma, 2021, Comparative accuracy of prognostic models for short-term mortality in acute-on-chronic liver failure patients: CAP-ACLF, Hepatol Int, 15, 753, 10.1007\u002Fs12072-021-10175-w","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs12072-021-10175-w",{"doi":1152},"10.1007\u002Fs12072-021-10175-w",{"id":26,"text":1154,"url":1155,"identifiers":1156},"Haas, 2007, Measurement of compliance with hand hygiene, J Hosp Infect, 66, 6, 10.1016\u002Fj.jhin.2006.11.013","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jhin.2006.11.013",{"mag":1157,"openalex":1158,"pm":1159,"doi":1160},"2112685236","W2112685236","17276546","10.1016\u002Fj.jhin.2006.11.013",{"id":1162,"text":1163,"url":1164,"identifiers":1165},"7228b297-8981-4eab-bd26-f7b5d265251d","Magiorakos, 2012, Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance, Clin Microbiol Infect, 18, 268, 10.1111\u002Fj.1469-0691.2011.03570.x","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1198743X14616323",{"doi":1166},"10.1111\u002Fj.1469-0691.2011.03570.x",{"id":1038,"text":1168,"url":1040,"identifiers":1169},"Murray, 2022, Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis, Lancet, 399, 629, 10.1016\u002FS0140-6736(21)02724-0",{"doi":1042},{"id":26,"text":1171,"url":1172,"identifiers":1173},"2018, EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis, J Hepatol, 69, 406, 10.1016\u002Fj.jhep.2018.03.024","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jhep.2018.03.024",{"mag":1174,"openalex":1175,"pm":1176,"doi":1177},"2802906787","W2802906787","29653741","10.1016\u002Fj.jhep.2018.03.024",{"id":26,"text":1179,"url":1180,"identifiers":1181},"Pouriki, 2022, Rectal colonization by resistant bacteria is associated with infection by the colonizing strain and high mortality in decompensated cirrhosis, J Hepatol, 77, 1207, 10.1016\u002Fj.jhep.2022.05.013","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jhep.2022.05.013",{"openalex":1182,"pm":1183,"doi":1184},"W4281552313","35643207","10.1016\u002Fj.jhep.2022.05.013",false,{"id":1187,"createTime":1188,"updateTime":1189,"relativeEntities":1190,"slug":1191,"properties":1192,"entityType":791,"verifyStatus":25,"verifyTime":1189,"verifyNote":793,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":1199,"fullTextUrl":26,"authors":1200,"publicationType":994,"publisherRelationship":1321,"citationCount":26,"citationInfo":26,"publishDate":1355,"publishYear":1033,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":26,"isForceReanalyzing":1185},"bb1398ec-abe4-44bf-88d9-8e0b67815d60","2023-12-11T04:25:35.777+00:00","2024-12-15T02:07:28.178+00:00",[],"Spatial-molecular-and-cellular-determinants-of-STAT3-activation-in-liver-fibrosis-progression-in-non-alcoholic-fatty-liver-disease",{"references":1193,"title":1195,"doi":1197},{"VOID":1194},"Younossi, 2020, Epidemiology of chronic liver diseases in the USA in the past three decades, Gut, 69, 564, 10.1136\u002Fgutjnl-2019-318813\nYounossi, 2021, Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States, Clin Gastroenterol Hepatol, 19, 580, 10.1016\u002Fj.cgh.2020.05.064\nLee, 2022, Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies, J Intern Med, 291, 11, 10.1111\u002Fjoim.13380\nPowell, 2021, Non-alcoholic fatty liver disease, Lancet, 397, 2212, 10.1016\u002FS0140-6736(20)32511-3\nTaylor, 2020, Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis, Gastroenterology, 158, 1611, 10.1053\u002Fj.gastro.2020.01.043\nDulai, 2017, Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis, Hepatology, 65, 1557, 10.1002\u002Fhep.29085\nNoureddin, 2022, Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017-2018 transient elastography data and application of machine learning, Hepatol Commun, 6, 1537, 10.1002\u002Fhep4.1935\nJohnston, 2011, STAT3 signaling: anticancer strategies and challenges, Mol Interv, 11, 18, 10.1124\u002Fmi.11.1.4\nCarpenter, 2014, STAT3 target genes relevant to human cancers, Cancers, 6, 897, 10.3390\u002Fcancers6020897\nWang, 2011, Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target, Int J Biol Sci, 7, 536, 10.7150\u002Fijbs.7.536\nChoi, 2018, Expression patterns of STAT3, ERK and estrogen-receptor alpha are associated with development and histologic severity of hepatic steatosis: a retrospective study, Diagn Pathol, 13, 23, 10.1186\u002Fs13000-018-0698-8\nSu, 2015, Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition, Proc Natl Acad Sci United States America, 112, 7243, 10.1073\u002Fpnas.1507499112\nHoriguchi, 2007, Liver regeneration is suppressed in alcoholic cirrhosis: correlation with decreased STAT3 activation, Alcohol, 41, 271, 10.1016\u002Fj.alcohol.2007.04.008\nYang, 2007, Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma, J Clin Pathol, 60, 642, 10.1136\u002Fjcp.2006.036970\nLiang, 2018, Clinicopathological significance and prognostic role of p-STAT3 in patients with hepatocellular carcinoma, OncoTargets Ther, 11, 1203, 10.2147\u002FOTT.S156198\nGrohmann, 2018, Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC, Cell, 175, 1289, 10.1016\u002Fj.cell.2018.09.053\nJung, 2017, Multifunctional effects of a small-molecule STAT3 inhibitor on NASH and hepatocellular carcinoma in mice, Clin Cancer Res : official J Am Assoc Cancer Res, 23, 5537, 10.1158\u002F1078-0432.CCR-16-2253\nWang, 2018, The STAT3 inhibitor S3I-201 suppresses fibrogenesis and angiogenesis in liver fibrosis, Lab Invest, 98, 1600, 10.1038\u002Fs41374-018-0127-3\nKleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002\u002Fhep.20701\nPerkins, 2012, ReadqPCR and NormqPCR: R packages for the reading, quality checking and normalisation of RT-qPCR quantification cycle (Cq) data, BMC Genomics, 13, 296, 10.1186\u002F1471-2164-13-296\nMacParland, 2018, Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations, Nat Commun, 9, 4383, 10.1038\u002Fs41467-018-06318-7\nHan, 2018, Mapping the mouse cell atlas by microwell-seq, Cell, 172, 1091, 10.1016\u002Fj.cell.2018.02.001\nHu, 2020, CREBZF as a key regulator of STAT3 pathway in the control of liver regeneration in mice, Hepatology, 71, 1421, 10.1002\u002Fhep.30919\nHe, 2011, NF-kappaB and STAT3 - key players in liver inflammation and cancer, Cel Res, 21, 159, 10.1038\u002Fcr.2010.183\nMeng, 2012, Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice, Gastroenterology, 143, 765, 10.1053\u002Fj.gastro.2012.05.049\nXiang, 2018, The HLF\u002FIL-6\u002FSTAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis, Gut, 67, 1704, 10.1136\u002Fgutjnl-2016-313392\nFabregat, 2018, Transforming growth factor-beta-induced cell plasticity in liver fibrosis and hepatocarcinogenesis, Front Oncol, 8, 357, 10.3389\u002Ffonc.2018.00357\nXu, 2016, TGF-beta\u002FSMAD pathway and its regulation in hepatic fibrosis, J Histochem Cytochem : official J Histochem Soc, 64, 157, 10.1369\u002F0022155415627681\nHenderson, 2006, Galectin-3 regulates myofibroblast activation and hepatic fibrosis, Proc Natl Acad Sci United States America, 103, 5060, 10.1073\u002Fpnas.0511167103\nJeftic, 2015, Galectin-3 ablation enhances liver steatosis, but attenuates inflammation and IL-33-dependent fibrosis in obesogenic mouse model of nonalcoholic steatohepatitis, Mol Med, 21, 453, 10.2119\u002Fmolmed.2014.00178\nXu, 2014, Stat3 signaling activation crosslinking of TGF-beta1 in hepatic stellate cell exacerbates liver injury and fibrosis, Biochim Biophys Acta, 1842, 2237, 10.1016\u002Fj.bbadis.2014.07.025\nLiu, 2013, Transforming growth factor-beta (TGF-beta)-mediated connective tissue growth factor (CTGF) expression in hepatic stellate cells requires Stat3 signaling activation, J Biol Chem, 288, 30708, 10.1074\u002Fjbc.M113.478685\nTang, 2017, Transforming growth factor-beta (TGF-beta) directly activates the JAK1-STAT3 Axis to induce hepatic fibrosis in coordination with the SMAD pathway, J Biol Chem, 292, 4302, 10.1074\u002Fjbc.M116.773085\nCierpka, 2021, Perilipin 5 ameliorates hepatic stellate cell activation via SMAD2\u002F3 and SNAIL signaling pathways and suppresses STAT3 activation, Cells, 10, 2184, 10.3390\u002Fcells10092184\nGwag, 2022, Anti-CD47 antibody treatment attenuates liver inflammation and fibrosis in experimental non-alcoholic steatohepatitis models, Liver Int, 42, 829, 10.1111\u002Fliv.15182\nRamachandran, 2019, Resolving the fibrotic niche of human liver cirrhosis at single-cell level, Nature, 575, 512, 10.1038\u002Fs41586-019-1631-3\nChoi, 2019, IL-10-secreting human MSCs generated by TALEN gene editing ameliorate liver fibrosis through enhanced anti-fibrotic activity, Biomater Sci, 7, 1078, 10.1039\u002FC8BM01347K\nKarl, 2022, Dual roles of B lymphocytes in mouse models of diet-induced nonalcoholic fatty liver disease, Hepatology, 76, 1135, 10.1002\u002Fhep.32428\nTerkelsen, 2020, Transcriptional dynamics of hepatic sinusoid-associated cells after liver injury, Hepatology, 72, 2119, 10.1002\u002Fhep.31215\nRamirez-Pedraza, 2019, Interplay between macrophages and angiogenesis: a double-edged sword in liver disease, Front Immunol, 10, 2882, 10.3389\u002Ffimmu.2019.02882\nWan, 2014, Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells, Gastroenterology, 147, 1393, 10.1053\u002Fj.gastro.2014.08.039\nChen, 2016, LncSox4 promotes the self-renewal of liver tumour-initiating cells through Stat3-mediated Sox4 expression, Nat Commun, 7, 10.1038\u002Fncomms12598\nWang, 2016, Long non-coding RNA DILC regulates liver cancer stem cells via IL-6\u002FSTAT3 axis, J Hepatol, 64, 1283, 10.1016\u002Fj.jhep.2016.01.019\nWon, 2015, Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma, Hepatology, 62, 1160, 10.1002\u002Fhep.27968\nUthaya Kumar, 2016, TLR4 signaling via NANOG cooperates with STAT3 to activate Twist1 and promote formation of tumor-initiating stem-like cells in livers of mice, Gastroenterology, 150, 707, 10.1053\u002Fj.gastro.2015.11.002\nGreenbaum, 2011, The role of stem cells in liver repair and fibrosis, Int J Biochem Cel Biol, 43, 222, 10.1016\u002Fj.biocel.2009.11.006\nGrzelak, 2014, The intrahepatic signalling niche of hedgehog is defined by primary cilia positive cells during chronic liver injury, J Hepatol, 60, 143, 10.1016\u002Fj.jhep.2013.08.012\nZhang, 2015, miR-21 inhibition reduces liver fibrosis and prevents tumor development by inducing apoptosis of CD24+ progenitor cells, Cancer Res, 75, 1859, 10.1158\u002F0008-5472.CAN-14-1254\nCunningham, 2021, Liver zonation - revisiting old questions with new technologies, Front Physiol, 12, 10.3389\u002Ffphys.2021.732929",{"EN":1196},"Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease",{"VOID":1198},"10.1016\u002Fj.jhepr.2022.100628","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2589555922002002",[1201,1216,1233,1245,1260,1272,1284,1301],{"id":1202,"sortIndex":111,"researcher":26,"roles":1203,"affiliations":1204,"properties":1213},"b4330fe0-f195-4bf3-80b0-c412d8885469",[799],[1205],{"id":26,"sortIndex":36,"affiliation":1206,"properties":26},{"id":1207,"createTime":1208,"updateTime":1208,"relativeEntities":1209,"slug":26,"properties":1210,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"5edb8c31-164c-47b1-b223-942a493a90af","2023-12-13T07:25:10.011+00:00",[],{"title":1211},{"VI":1212},"Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center Houston, TX, USA",{"title":1214},{"VI":1215},"David J. Tweardy",{"id":1217,"sortIndex":158,"researcher":26,"roles":1218,"affiliations":1219,"properties":1230},"546dce6b-d5ca-422c-acfc-b21dbbe71e34",[799],[1220],{"id":26,"sortIndex":36,"affiliation":1221,"properties":26},{"id":1222,"createTime":1223,"updateTime":1224,"relativeEntities":1225,"slug":1226,"properties":1227,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"0a5e74f2-749e-4851-9899-050201519d52","2023-12-11T04:25:36.150+00:00","2025-06-11T23:16:55.888+00:00",[],"Department-of-Molecular-and-Cellular-Oncology-The-University-of-Texas-MD-Anderson-Cancer-Center-Houston-TX-USA",{"title":1228},{"VI":1229},"Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",{"title":1231},{"VI":1232},"Laura Beretta",{"id":1234,"sortIndex":115,"researcher":26,"roles":1235,"affiliations":1236,"properties":1242},"9c68839e-4380-4f02-8733-e7e0c76486a6",[799],[1237],{"id":26,"sortIndex":36,"affiliation":1238,"properties":26},{"id":1222,"createTime":1223,"updateTime":1224,"relativeEntities":1239,"slug":1226,"properties":1240,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1241},{"VI":1229},{"title":1243},{"VI":1244},"Jessica I. Sanchez",{"id":1246,"sortIndex":135,"researcher":26,"roles":1247,"affiliations":1248,"properties":1257},"cf22a4cf-212b-4b0c-991f-fe1ed5e079e1",[799],[1249],{"id":26,"sortIndex":36,"affiliation":1250,"properties":26},{"id":1251,"createTime":1252,"updateTime":1252,"relativeEntities":1253,"slug":26,"properties":1254,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"b52a70fd-25cb-42c1-b9c0-ae6e8e1766a5","2024-02-06T06:41:46.101+00:00",[],{"title":1255},{"VI":1256},"Department of Pathology, The University of Texas Medical Branch, Galveston, TX, USA",{"title":1258},{"VI":1259},"Heather L. Stevenson",{"id":1261,"sortIndex":36,"researcher":26,"roles":1262,"affiliations":1263,"properties":1269},"9f4ef17c-057b-4a73-8fd6-64eb05c12e8e",[799],[1264],{"id":26,"sortIndex":36,"affiliation":1265,"properties":26},{"id":1222,"createTime":1223,"updateTime":1224,"relativeEntities":1266,"slug":1226,"properties":1267,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1268},{"VI":1229},{"title":1270},{"VI":1271},"Jingjing Jiao",{"id":1273,"sortIndex":114,"researcher":26,"roles":1274,"affiliations":1275,"properties":1281},"826f9cf9-3527-4d2e-b03c-4797cae4f7a8",[799],[1276],{"id":26,"sortIndex":36,"affiliation":1277,"properties":26},{"id":1251,"createTime":1252,"updateTime":1252,"relativeEntities":1278,"slug":26,"properties":1279,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1280},{"VI":1256},{"title":1282},{"VI":1283},"Omar A. Saldarriaga",{"id":1285,"sortIndex":59,"researcher":26,"roles":1286,"affiliations":1287,"properties":1298},"17e01b2c-1c84-48ee-9f16-a3fe43901f97",[799],[1288],{"id":26,"sortIndex":36,"affiliation":1289,"properties":26},{"id":1290,"createTime":1291,"updateTime":1292,"relativeEntities":1293,"slug":1294,"properties":1295,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"bbd891c4-d9ac-4e71-9229-5027fdbc16ad","2023-12-29T00:27:44.934+00:00","2025-01-24T12:13:08.027+00:00",[],"Department-of-Translational-Molecular-Pathology-The-University-of-Texas-MD-Anderson-Cancer-Center-Houston-TX-USA",{"title":1296},{"VI":1297},"Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",{"title":1299},{"VI":1300},"Luisa M. Solis",{"id":1302,"sortIndex":162,"researcher":26,"roles":1303,"affiliations":1304,"properties":1318},"568638e7-3166-469e-b51c-7d24d02774a6",[799],[1305],{"id":1306,"sortIndex":36,"affiliation":1307,"properties":1316},"30a1d85f-e124-4987-8bf4-7a5da76fb970",{"id":1308,"createTime":1309,"updateTime":1310,"relativeEntities":1311,"slug":1312,"properties":1313,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"1a2cccb6-6d07-4c7c-b7f1-cfb9e9a3ff3d","2024-09-23T04:34:08.339+00:00","2025-02-05T21:21:22.959+00:00",[],"Department-of-Pathology-The-University-of-Texas-MD-Anderson-Cancer-Center-Houston-TX-USA",{"title":1314},{"EN":1315},"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",{"title":1317},{"VI":1315},{"title":1319},{"VI":1320},"Dipen M. Maru",{"url":1199,"publisher":1322,"properties":1351},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":1323,"slug":663,"properties":1324,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":114,"subjectFields":1329,"manageAffiliations":1330,"indexDatabases":1331,"url":768,"thumbnailPath":26,"statistic":1346,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"country":1325,"issn":1326,"introduce":1327,"title":1328},{"VOID":666},{"VOID":668},{"EN":670},{"EN":672},[],[],[1332,1339],{"id":747,"indexDatabase":1333,"url":760,"indexYears":761,"academicFieldIds":1338,"indexDatabaseRanking":767},{"id":749,"createTime":750,"updateTime":751,"relativeEntities":1334,"label":1335,"description":1336,"key":757,"publicationTags":1337,"standard":26},[],{"EN":754,"VI":754},{"EN":754,"VI":756},[759],[763,764,765,766],{"id":728,"indexDatabase":1340,"url":743,"indexYears":26,"academicFieldIds":1345,"indexDatabaseRanking":26},{"id":730,"createTime":731,"updateTime":732,"relativeEntities":1341,"label":1342,"description":1343,"key":739,"publicationTags":1344,"standard":26},[],{"EN":735,"VI":735},{"VI":737,"EN":738},[741,742],[745],{"impactFactor":36,"impactFactorByYear":1347,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":245,"totalPublicationByYear":1348,"totalCitation":36,"totalCitationByYear":1349,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":1350,"hindexLast5Year":36,"hindex":36},{},{"2019":158,"2020":111,"2021":124,"2022":298,"2023":287,"2024":59},{},{},{"volume":1352,"pages":1353},{"VOID":1027},{"VOID":1354},"100628","2023-02-01",{"id":1357,"createTime":1358,"updateTime":1359,"relativeEntities":1360,"slug":1361,"properties":1362,"entityType":791,"verifyStatus":25,"verifyTime":1359,"verifyNote":793,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":1369,"fullTextUrl":26,"authors":1370,"publicationType":994,"publisherRelationship":1386,"citationCount":26,"citationInfo":26,"publishDate":1420,"publishYear":1033,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":26,"isForceReanalyzing":1185},"20476cb1-6395-4c3d-8917-ee959abee7c9","2024-01-10T05:41:58.663+00:00","2024-12-15T07:33:53.092+00:00",[],"Innovative-approaches-to-the-management-of-ascites-in-cirrhosis",{"references":1363,"title":1365,"doi":1367},{"VOID":1364},"Bruno, 2013, Am J Gastroenterol, 108, 1112, 10.1038\u002Fajg.2013.110\nBalcar, 2022, Baveno Cooperation: an EASL consortium. Risk of further decompensation\u002Fmortality in patients with cirrhosis and ascites as the first single decompensation event, JHEP Rep, 4\nAdebayo, 2019, Refractory ascites in liver cirrhosis, Am J Gastroenterol, 114, 40, 10.1038\u002Fs41395-018-0185-6\nIwakiri, 2021, Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy, JHEP Rep, 3\nEngelmann, 2021, Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction, J Hepatol, 75, S49, 10.1016\u002Fj.jhep.2021.01.002\nJalan, 2021, New clinical and pathophysiological perspectives defining the trajectory of cirrhosis, J Hepatol, 75, S14, 10.1016\u002Fj.jhep.2021.01.018\nRipoll, 2007, Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis, Gastroenterology, 133, 481, 10.1053\u002Fj.gastro.2007.05.024\nVillanueva, 2019, β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, 393, 1597, 10.1016\u002FS0140-6736(18)31875-0\nLevy, 2019, Prevention of decompensation in cirrhosis: a new youth for β blockers, Lancet, 393, 1571, 10.1016\u002FS0140-6736(19)30736-6\nGroszmann, 2005, Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis, N Engl J Med, 353, 2254, 10.1056\u002FNEJMoa044456\nAbd Elrahim, 2018, Efficacy of carvedilol versus propranolol versus variceal band ligation for primary prevention of variceal bleeding, Hepatol Int, 12, 75, 10.1007\u002Fs12072-017-9835-9\nVillanueva, 2022, Carvedilol-IPD-MA-group and the Baveno Cooperation: an EASL Consortium. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis, J Hepatol, 77, 1014, 10.1016\u002Fj.jhep.2022.05.021\nSharma, 2022, Non-hemodynamic effects of beta-blockers in decompensated cirrhosis. In search of an ideal marker?, Clin Gastroenterol Hepatol, 20, E1511, 10.1016\u002Fj.cgh.2021.07.050\nde Franchis, 2022, Baveno VII - renewing consensus in portal hypertension, J Hepatol, 76, 959, 10.1016\u002Fj.jhep.2021.12.022\nDajti, 2022, A combined Baveno VII and spleen stiffness algorithm to improve the non-invasive diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease, Am J Gastroenterol, 117, 1825, 10.14309\u002Fajg.0000000000001887\nJachs, 2022, The sequential application of Baveno VII criteria and VITRO score improves diagnosis of clinically significant portal hypertension, Clin Gastroenterol Hepatol, 22, S1542\nFernández, 2019, Casulleras M.,et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis, Gastroenterology, 157, 149, 10.1053\u002Fj.gastro.2019.03.021\nCaraceni, 2018, Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial, Lancet, 391, 2417, 10.1016\u002FS0140-6736(18)30840-7\nCaraceni, 2021, On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites, J Hepatol, 74, 340, 10.1016\u002Fj.jhep.2020.08.021\nDi Pascoli, 2019, Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites, Liver Int, 39, 98, 10.1111\u002Fliv.13968\nSolà, 2018, Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial, J Hepatol, 69, 1250, 10.1016\u002Fj.jhep.2018.08.006\nCaraceni, 2022, Long-term albumin treatment in patients with cirrhosis and ascites, J Hepatol, 76, 1306, 10.1016\u002Fj.jhep.2022.03.005\nSaffo, 2018, SGLT2 inhibitors and cirrhosis: a unique perspective on the co-management of diabetes mellitus and ascites, Clin Liver Dis, 11, 141, 10.1002\u002Fcld.714\nMontalvo-Gordon, 2020, Sodium-glucose cotransporter 2 inhibitors ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes, Hepatology, 72, 1880, 10.1002\u002Fhep.31270\nKalambokis, 2021, Empagliflozin eliminates refractory ascites and hepatic hydrothorax in a patient with primary biliary cirrhosis, Am J Gastroenterol, 116, 618, 10.14309\u002Fajg.0000000000000995\nGao, 2021, SGLT2 Inhibitors: a new dawn for recurrent\u002Frefractory cirrhotic ascites, J Clin Transl Hepatol, 9, 795\nBiggins, 2021, Diagnosis, evaluation and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American association for the study of liver diseases, Hepatology, 74, 1014, 10.1002\u002Fhep.31884\nSalerno, 2007, Transjugular intra-hepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data, Gastroenterology, 133, 825, 10.1053\u002Fj.gastro.2007.06.020\nBusk, 2017, Effects of transjugular intrahepatic portosystemic shunt (TIPS) on blood volume distribution in patients with cirrhosis, Dig Liver Dis, 49, 1353, 10.1016\u002Fj.dld.2017.06.011\nLiu, 2021, Advances in cirrhotic cardiomyopathy, Curr Opin Gastroenterol, 37, 187, 10.1097\u002FMOG.0000000000000733\nBilley, 2019, A prospective study identifying predictive factors of cardiac decompensation after transjugular intrahepatic portosystemic shunt: the Toulouse Algorithm, Hepatology, 70, 1928, 10.1002\u002Fhep.30934\nModha, 2017, Symptomatic heart failure after transjugular intrahepatic portosystemic shunt placement: incidence, outcomes, and predictors, Cardiovasc Interv Radiol, 41, 564, 10.1007\u002Fs00270-017-1848-1\nTripathi, 2020, Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension, Gut, 69, 1173, 10.1136\u002Fgutjnl-2019-320221\nBoike, 2022, Advancing Liver Therapeutic Approaches (ALTA) Consortium. North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension, Clin Gastroenterol Hepatol, 20, 1636, 10.1016\u002Fj.cgh.2021.07.018\nFagiuoli, 2017, Consensus conference on TIPS management: techniques, indications, contraindications, Dig Liver Dis, 49, 121, 10.1016\u002Fj.dld.2016.10.011\nDeltenre, 2023, The role of transjugular intrahepatic portosystemic shunt in patients with cirrhosis and ascites: recent evolution and open questions, Hepatology, 77, 640, 10.1002\u002Fhep.32596\nSchepis, 2018, Under-dilated TIPS associate with efficacy and reduced encephalopathy in a prospective, non-randomized study of patients with cirrhosis, Clin Gastroenterol Hepatol, 16, 1153, 10.1016\u002Fj.cgh.2018.01.029\nPraktiknjo, 2021, Controlled under-dilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation, JHEP Rep, 3\nBureau, 2021, The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled trial, Ann Intern Med, 174, 633, 10.7326\u002FM20-0202\nSeifert, 2021, Recurrence of hepatic encephalopathy after TIPS: effective prophylaxis with combination of lactulose and rifaximin, J Clin Med, 10, 4763\nde Wit, 2020, BMJ Open Gastroenterol, 7, 10.1136\u002Fbmjgast-2020-000531\nLi, 2021, Long-term survival prediction for transjugular intrahepatic portosystemic shunt in severe cirrhotic ascites: assessment of ten prognostic models, Eur J Gastroenterol Hepatol, 33, 1547, 10.1097\u002FMEG.0000000000001890\nBettinger, 2021, Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival, J Hepatol, 74, 1362, 10.1016\u002Fj.jhep.2021.01.023\nBureau, 2011, Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS, J Hepatol, 54, 901, 10.1016\u002Fj.jhep.2010.08.025\nKraglund, 2021, External validation of the Freiburg index of post-TIPS survival, J Hepatol, 75, 746, 10.1016\u002Fj.jhep.2021.04.027\nWang, 2021, Freiburg index of post-TIPS survival: the first score for individual prediction and a complementary tool for risk stratification, J Hepatol, 75, 747, 10.1016\u002Fj.jhep.2021.05.042\nBureau, 2017, Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites, Gastroenterology, 152, 157, 10.1053\u002Fj.gastro.2016.09.016\nBureau, 2017, Alfapump® system vs. large volume paracentesis for refractory ascites: a multicenter randomized controlled study, J Hepatol, 67, 940, 10.1016\u002Fj.jhep.2017.06.010\nBellot, 2013, Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study, J Hepatol, 58, 922, 10.1016\u002Fj.jhep.2012.12.020\nThomas, 2015, Automated low flow pump system for the treatment of refractory ascites: a single-center experience, Langenbeck’s Arch Surg, 400, 979, 10.1007\u002Fs00423-015-1356-1\nStirnimann, 2017, Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis, Aliment Pharmacol Ther, 46, 981, 10.1111\u002Fapt.14331\nSolbach, 2018, Automated low-flow ascites pump in a real-world setting: complications and outcomes, Eur J Gastroenterol Hepatol, 30, 1082, 10.1097\u002FMEG.0000000000001149\nWong, 2020, Improvement in quality of life and decrease in large-volume paracentesis requirements with the automated low-flow ascites pump, Liver Transpl, 26, 651, 10.1002\u002Flt.25724\nWill, 2020, Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: outcomes and complications, United Eur Gastroenterol J, 8, 961, 10.1177\u002F2050640620938525\nLepida, 2019, Systematic review with meta-analysis: automated low-flow ascites pump therapy for refractory ascites, Aliment Pharmacol Ther, 50, 978, 10.1111\u002Fapt.15502\nSolà, 2017, Effects of alfapump™ system on kidney and circulatory function in patients with cirrhosis and refractory ascites, Liver Transpl, 23, 583, 10.1002\u002Flt.24763\nAagaard, 2022, Consensus care recommendations for alfapump®in cirrhotic patients with refractory or recurrent ascites, BMC Gastroenterol, 22, 111, 10.1186\u002Fs12876-022-02173-5\nStepanova, 2018, Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study, Qual Life Res, 27, 1513, 10.1007\u002Fs11136-018-1813-8\nNguyen-Khac, 2021, Combined treatment of refractory ascites with an alfapump® plus hernia repair in the same surgical session: a retrospective, multicentre, European pilot study in cirrhotic patients, J Visc Surg, 158, 27\nWill, 2022, Current treatment options of refractory ascites in liver cirrhosis - a systematic review and meta-analysis, Dig Liver Dis, 54, 1007, 10.1016\u002Fj.dld.2021.12.007\nStirnimann, 2022, Final safety and efficacy results from a 106 real-world patients registry with an ascites-mobilizing pump, Liver Int, 42, 2247, 10.1111\u002Fliv.15337\nWeil-Verhoeven, 2022, Alfapump® implantable device in the management of refractory ascites: an update, World J Hepatol, 14, 1344, 10.4254\u002Fwjh.v14.i7.1344\nReverter, 2019, Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis, Liver Int, 39, 705, 10.1111\u002Fliv.14042\nMandorfer, 2020, Noninvasive diagnostics for portal hypertension: a comprehensive review, Semin Liver Dis, 40, 240, 10.1055\u002Fs-0040-1708806\nBajaj, 2021, Admission urinary and serum metabolites predict renal outcomes in hospitalized patients with cirrhosis, Hepatology, 74, 2699, 10.1002\u002Fhep.31907\nPoyan Mehr, 2018, De novo NAD(+) biosynthetic impairment in acute kidney injury in humans, Nat Med, 24, 1351, 10.1038\u002Fs41591-018-0138-z\nPiano, 2021, Metabolomics to predict acute kidney injury in cirrhosis, Hepatology, 74, 2339, 10.1002\u002Fhep.32060",{"EN":1366},"Innovative approaches to the management of ascites in cirrhosis",{"VOID":1368},"10.1016\u002Fj.jhepr.2023.100749","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2589555923000800",[1371],{"id":1372,"sortIndex":36,"researcher":26,"roles":1373,"affiliations":1374,"properties":1383},"09c7c2d7-1a9e-44fc-b0fb-6aec3439d30e",[799],[1375],{"id":26,"sortIndex":36,"affiliation":1376,"properties":26},{"id":1377,"createTime":1378,"updateTime":1378,"relativeEntities":1379,"slug":26,"properties":1380,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"d98671b5-3c1d-440c-86fe-c22e36489e52","2024-01-10T05:41:58.681+00:00",[],{"title":1381},{"VI":1382},"Department of Medicine, Division of Gastroenterology & Hepatology, University Health Network, University of Toronto, Toronto, Ontario, Canada",{"title":1384},{"VI":1385},"Florence Wong",{"url":1369,"publisher":1387,"properties":1416},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":1388,"slug":663,"properties":1389,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":114,"subjectFields":1394,"manageAffiliations":1395,"indexDatabases":1396,"url":768,"thumbnailPath":26,"statistic":1411,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"country":1390,"issn":1391,"introduce":1392,"title":1393},{"VOID":666},{"VOID":668},{"EN":670},{"EN":672},[],[],[1397,1404],{"id":747,"indexDatabase":1398,"url":760,"indexYears":761,"academicFieldIds":1403,"indexDatabaseRanking":767},{"id":749,"createTime":750,"updateTime":751,"relativeEntities":1399,"label":1400,"description":1401,"key":757,"publicationTags":1402,"standard":26},[],{"EN":754,"VI":754},{"EN":754,"VI":756},[759],[763,764,765,766],{"id":728,"indexDatabase":1405,"url":743,"indexYears":26,"academicFieldIds":1410,"indexDatabaseRanking":26},{"id":730,"createTime":731,"updateTime":732,"relativeEntities":1406,"label":1407,"description":1408,"key":739,"publicationTags":1409,"standard":26},[],{"EN":735,"VI":735},{"VI":737,"EN":738},[741,742],[745],{"impactFactor":36,"impactFactorByYear":1412,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":245,"totalPublicationByYear":1413,"totalCitation":36,"totalCitationByYear":1414,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":1415,"hindexLast5Year":36,"hindex":36},{},{"2019":158,"2020":111,"2021":124,"2022":298,"2023":287,"2024":59},{},{},{"volume":1417,"pages":1418},{"VOID":1027},{"VOID":1419},"100749","2023-07-01",{"id":1422,"createTime":1423,"updateTime":1424,"relativeEntities":1425,"slug":1426,"properties":1427,"entityType":791,"verifyStatus":25,"verifyTime":1424,"verifyNote":793,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":1434,"fullTextUrl":26,"authors":1435,"publicationType":994,"publisherRelationship":1753,"citationCount":26,"citationInfo":26,"publishDate":1788,"publishYear":1789,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":26,"isForceReanalyzing":1185},"b01ebd9c-db4d-47b4-895f-5e75c072fd23","2024-01-01T15:37:37.720+00:00","2024-12-15T22:40:38.330+00:00",[],"Increased-serum-miR-193a-5p-during-non-alcoholic-fatty-liver-disease-progression-Diagnostic-and-mechanistic-relevance",{"references":1428,"title":1430,"doi":1432},{"VOID":1429},"Younossi, 2019, Non-alcoholic fatty liver disease – a global public health perspective, J Hepatol, 70, 531, 10.1016\u002Fj.jhep.2018.10.033\nAnstee, 2013, The genetics of NAFLD, Nat Rev Gastroenterol Hepatol, 10, 645, 10.1038\u002Fnrgastro.2013.182\nAnstee, 2019, From NASH to HCC: current concepts and future challenges, Nat Rev Gastroenterol Hepatol, 16, 411, 10.1038\u002Fs41575-019-0145-7\nAnstee, 2020, Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort, J Hepatol, 73, 505, 10.1016\u002Fj.jhep.2020.04.003\nAnstee, 2016, Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease, Gastroenterology, 150, 1728, 10.1053\u002Fj.gastro.2016.01.037\nKleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002\u002Fhep.20701\nBedossa, 2014, Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease, Hepatology, 60, 565, 10.1002\u002Fhep.27173\nRatziu, 2005, Sampling variability of liver biopsy in nonalcoholic fatty liver disease, Gastroenterology, 128, 1898, 10.1053\u002Fj.gastro.2005.03.084\nRinella, 2019, Report on the AASLD\u002FEASL joint workshop on clinical trial endpoints in NAFLD, J Hepatol, 71, 823, 10.1016\u002Fj.jhep.2019.04.019\nPillai, 2005, MicroRNA function: multiple mechanisms for a tiny RNA?, RNA, 11, 1753, 10.1261\u002Frna.2248605\nO'Brien, 2018, Overview of microRNA biogenesis, mechanisms of actions, and circulation, Front Endocrinol (Lausanne), 9, 402, 10.3389\u002Ffendo.2018.00402\nKozomara, 2019, miRBase: from microRNA sequences to function, Nucleic Acids Res, 47, D155, 10.1093\u002Fnar\u002Fgky1141\nZhou, 2018, miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges, Acta Pharmacol Sin, 39, 1073, 10.1038\u002Faps.2018.30\nWang, 2018, Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage, Clin Epigenetics, 10, 59, 10.1186\u002Fs13148-018-0492-1\nLópez-Riera, 2018, Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers, Sci Rep, 8, 10606, 10.1038\u002Fs41598-018-28854-4\nDongiovanni, 2018, miRNA signature in NAFLD: a turning point for a non-invasive diagnosis, Int J Mol Sci, 19, 10.3390\u002Fijms19123966\nPirola, 2015, Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis, Gut, 64, 800, 10.1136\u002Fgutjnl-2014-306996\nCheung, 2008, Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression, Hepatology, 48, 1810, 10.1002\u002Fhep.22569\nHarrison, 2020, A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study, Lancet Gastroenterol Hepatol, 5, 970, 10.1016\u002FS2468-1253(20)30252-1\nHardy, 2020, The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease, Contemp Clin Trials, 98, 106175, 10.1016\u002Fj.cct.2020.106175\nBedossa, 2012, Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients, Hepatology, 56, 1751, 10.1002\u002Fhep.25889\nSanyal, 2011, Endpoints and clinical trial design for nonalcoholic steatohepatitis, Hepatology, 54, 344, 10.1002\u002Fhep.24376\nLove, 2014, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol, 15, 550, 10.1186\u002Fs13059-014-0550-8\nRitchie, 2015, limma powers differential expression analyses for RNA-sequencing and microarray studies, Nucleic Acids Res, 43, e47, 10.1093\u002Fnar\u002Fgkv007\nDeLong, 1988, Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach, Biometrics, 44, 837, 10.2307\u002F2531595\nLivak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method, Methods, 25, 402, 10.1006\u002Fmeth.2001.1262\nAgarwal, 2015, Predicting effective microRNA target sites in mammalian mRNAs, Elife, 4, 10.7554\u002FeLife.05005\nChen, 2020, miRDB: an online database for prediction of functional microRNA targets, Nucleic Acids Res, 48, D127, 10.1093\u002Fnar\u002Fgkz757\nGovaere, 2020, Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis, Sci Transl Med, 12, 10.1126\u002Fscitranslmed.aba4448\nRamachandran, 2019, Resolving the fibrotic niche of human liver cirrhosis at single-cell level, Nature, 575, 512, 10.1038\u002Fs41586-019-1631-3\nMcPherson, 2010, Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease, Gut, 59, 1265, 10.1136\u002Fgut.2010.216077\nRicchi, 2009, Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes, J Gastroenterol Hepatol, 24, 830, 10.1111\u002Fj.1440-1746.2008.05733.x\nTan, 2014, A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease, PLoS One, 9, 10.1371\u002Fjournal.pone.0105192\nZhang, 2021, Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study, Aliment Pharmacol Ther, 53, 432, 10.1111\u002Fapt.16177\nJampoka, 2018, Serum miR-29a and miR-122 as potential biomarkers for non-alcoholic fatty liver disease (NAFLD), Microrna, 7, 215, 10.2174\u002F2211536607666180531093302\nArrese, 2015, Circulating microRNAs: emerging biomarkers of liver disease, Semin Liver Dis, 35, 43, 10.1055\u002Fs-0034-1397348\nRoy, 2015, miR-30c and miR-193 are a part of the TGF-beta-dependent regulatory network controlling extracellular matrix genes in liver fibrosis, J Dig Dis, 16, 513\nRoy, 2018, microRNA 193a-5p regulates levels of nucleolar- and spindle-associated protein 1 to suppress hepatocarcinogenesis, Gastroenterology, 155, 1951, 10.1053\u002Fj.gastro.2018.08.032\nButt, 2016, Parallel expression profiling of hepatic and serum microRNA-122 associated with clinical features and treatment responses in chronic hepatitis C patients, Sci Rep, 6, 21510, 10.1038\u002Fsrep21510\nHyun, 2016, MicroRNA-378 limits activation of hepatic stellate cells and liver fibrosis by suppressing Gli3 expression, Nat Commun, 7, 10993, 10.1038\u002Fncomms10993\nZheng, 2017, High expression of Rap2A is associated with poor prognosis of patients with hepatocellular carcinoma, Int J Clin Exp Pathol, 10, 9607\nLopez, 2018, Disruption of the Igf2 gene alters hepatic lipid homeostasis and gene expression in the newborn mouse, Am J Physiol Endocrinol Metab, 315, E735, 10.1152\u002Fajpendo.00048.2018\nHatzoglou, 2004, Regulation of cationic amino acid transport: the story of the CAT-1 transporter, Annu Rev Nutr, 24, 377, 10.1146\u002Fannurev.nutr.23.011702.073120\nLiu, 2013, Reversibility of liver fibrosis and inactivation of fibrogenic myofibroblasts, Curr Pathobiol Rep, 1, 209, 10.1007\u002Fs40139-013-0018-7\nSun, 2020, Hsa_circ_0001806 acts as a ceRNA to facilitate the stemness of colorectal cancer cells by increasing COL1A1, Onco Targets Ther, 13, 6315, 10.2147\u002FOTT.S255485\nPovero, 2014, Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease, PLoS One, 9, 10.1371\u002Fjournal.pone.0113651\nRamming, 2014, GPx8 peroxidase prevents leakage of H2O2 from the endoplasmic reticulum, Free Radic Biol Med, 70, 106, 10.1016\u002Fj.freeradbiomed.2014.01.018\nPagliassotti, 2012, Endoplasmic reticulum stress in nonalcoholic fatty liver disease, Annu Rev Nutr, 32, 17, 10.1146\u002Fannurev-nutr-071811-150644\nKhatib, 2020, The glutathione peroxidase 8 (GPX8)\u002FIL-6\u002FSTAT3 axis is essential in maintaining an aggressive breast cancer phenotype, Proc Natl Acad Sci U S A, 117, 21420, 10.1073\u002Fpnas.2010275117\nLiu, 2018, miRNAs in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis, J Hepatol, 69, 1335, 10.1016\u002Fj.jhep.2018.08.008",{"EN":1431},"Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance",{"VOID":1433},"10.1016\u002Fj.jhepr.2021.100409","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2589555921001853",[1436,1453,1468,1493,1505,1524,1539,1551,1568,1580,1595,1610,1629,1646,1658,1670,1692,1707,1719,1731],{"id":1437,"sortIndex":114,"researcher":26,"roles":1438,"affiliations":1439,"properties":1450},"5403a1c2-bc59-41d0-aec2-03ab7623a8f7",[799],[1440],{"id":26,"sortIndex":36,"affiliation":1441,"properties":26},{"id":1442,"createTime":1443,"updateTime":1444,"relativeEntities":1445,"slug":1446,"properties":1447,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"508d2851-e77c-46e8-abde-da502805b515","2023-12-11T13:33:06.127+00:00","2024-09-30T19:47:29.506+00:00",[],"Translational-and-Clinical-Research-Institute-Faculty-of-Medical-Sciences-Newcastle-University-Newcastle-Upon-Tyne-UK",{"title":1448},{"VI":1449},"Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK",{"title":1451},{"VI":1452},"Olivier Govaere",{"id":1454,"sortIndex":124,"researcher":26,"roles":1455,"affiliations":1456,"properties":1465},"a5ee2898-2e1a-432a-aeff-51b05e979900",[799],[1457],{"id":26,"sortIndex":36,"affiliation":1458,"properties":26},{"id":1459,"createTime":1460,"updateTime":1460,"relativeEntities":1461,"slug":26,"properties":1462,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"ccd46d5e-7861-4f04-97e0-2de933f19cfc","2024-01-01T15:37:37.841+00:00",[],{"title":1463},{"VI":1464},"Division of Gastroenterology, Department of Medical Sciences, University of Turin, Turin, Italy",{"title":1466},{"VI":1467},"Elisabetta Bugianesi",{"id":1469,"sortIndex":356,"researcher":26,"roles":1470,"affiliations":1471,"properties":1490},"fa28cbbf-b740-45b3-9d32-0ffa83e2698d",[799],[1472,1482],{"id":1473,"sortIndex":115,"affiliation":1474,"properties":1481},"67ecf9ed-a645-4d3a-bc06-71e7a7697fb6",{"id":1475,"createTime":1476,"updateTime":1476,"relativeEntities":1477,"slug":26,"properties":1478,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"2892da75-09e1-40fe-b396-d8b7175b3345","2023-12-26T02:50:31.003+00:00",[],{"title":1479},{"VI":1480},"Assistance Publique Hopitaux de Paris, Paris, France",{},{"id":26,"sortIndex":36,"affiliation":1483,"properties":26},{"id":1484,"createTime":1485,"updateTime":1485,"relativeEntities":1486,"slug":26,"properties":1487,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"c23225da-5bd6-4cd6-ba6c-700049fe76f6","2024-01-01T15:37:37.800+00:00",[],{"title":1488},{"VI":1489},"Institute of Cardiometabolism and Nutrition, Pitié Salpêtrière Hospital, Paris, France",{"title":1491},{"VI":1492},"Karine Clément",{"id":1494,"sortIndex":50,"researcher":26,"roles":1495,"affiliations":1496,"properties":1502},"8d508c82-1666-4315-8e3d-163d10bc15d0",[799],[1497],{"id":26,"sortIndex":36,"affiliation":1498,"properties":26},{"id":1442,"createTime":1443,"updateTime":1444,"relativeEntities":1499,"slug":1446,"properties":1500,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1501},{"VI":1449},{"title":1503},{"VI":1504},"Pierre Bedossa",{"id":1506,"sortIndex":336,"researcher":26,"roles":1507,"affiliations":1508,"properties":1521},"a3c1ec56-84f0-4be3-b24b-9c832252df1d",[799],[1509,1514],{"id":26,"sortIndex":36,"affiliation":1510,"properties":26},{"id":1484,"createTime":1485,"updateTime":1485,"relativeEntities":1511,"slug":26,"properties":1512,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1513},{"VI":1489},{"id":1515,"sortIndex":115,"affiliation":1516,"properties":1520},"cc23264e-c132-4315-9a19-f23e9b0f3921",{"id":1475,"createTime":1476,"updateTime":1476,"relativeEntities":1517,"slug":26,"properties":1518,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1519},{"VI":1480},{},{"title":1522},{"VI":1523},"Vlad Ratziu",{"id":1525,"sortIndex":116,"researcher":26,"roles":1526,"affiliations":1527,"properties":1536},"18abd9b1-250f-453e-9504-258c976acbff",[799],[1528],{"id":26,"sortIndex":36,"affiliation":1529,"properties":26},{"id":1530,"createTime":1531,"updateTime":1531,"relativeEntities":1532,"slug":26,"properties":1533,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"25bb91dd-3d92-4f4e-bd20-46afc316c21a","2024-01-01T15:37:37.966+00:00",[],{"title":1534},{"VI":1535},"Oxford Liver Unit, NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK",{"title":1537},{"VI":1538},"Jeremy F. Cobbold",{"id":1540,"sortIndex":36,"researcher":26,"roles":1541,"affiliations":1542,"properties":1548},"73a61214-b33d-4603-8de7-edb3d9423bc4",[799],[1543],{"id":26,"sortIndex":36,"affiliation":1544,"properties":26},{"id":1442,"createTime":1443,"updateTime":1444,"relativeEntities":1545,"slug":1446,"properties":1546,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1547},{"VI":1449},{"title":1549},{"VI":1550},"Katherine Johnson",{"id":1552,"sortIndex":111,"researcher":26,"roles":1553,"affiliations":1554,"properties":1565},"39241d50-a055-40a4-818a-46e84976e694",[799],[1555],{"id":26,"sortIndex":36,"affiliation":1556,"properties":26},{"id":1557,"createTime":1558,"updateTime":1559,"relativeEntities":1560,"slug":1561,"properties":1562,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"353c8862-bf45-4afd-bdf0-1bc651b439ac","2024-02-06T22:15:44.008+00:00","2024-09-30T19:47:29.419+00:00",[],"Biosciences-Institute-Faculty-of-Medical-Sciences-Newcastle-University-Newcastle-upon-Tyne-UK",{"title":1563},{"VI":1564},"Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK",{"title":1566},{"VI":1567},"Sarah H. Charlton",{"id":1569,"sortIndex":135,"researcher":26,"roles":1570,"affiliations":1571,"properties":1577},"ad49a129-2ddb-4ce3-b13e-ad4e877de7b6",[799],[1572],{"id":26,"sortIndex":36,"affiliation":1573,"properties":26},{"id":1442,"createTime":1443,"updateTime":1444,"relativeEntities":1574,"slug":1446,"properties":1575,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1576},{"VI":1449},{"title":1578},{"VI":1579},"Dina Tiniakos",{"id":1581,"sortIndex":298,"researcher":26,"roles":1582,"affiliations":1583,"properties":1592},"0cb6e0cb-cd83-4a70-ad62-c1bfade0a66e",[799],[1584],{"id":26,"sortIndex":36,"affiliation":1585,"properties":26},{"id":1586,"createTime":1587,"updateTime":1587,"relativeEntities":1588,"slug":26,"properties":1589,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"65d0bf01-0491-42a2-91e9-9e8e83c5bb18","2024-01-01T15:37:37.813+00:00",[],{"title":1590},{"VI":1591},"Metabolic Liver Research Program, I. Department of Medicine, University Medical Center of Johannes Gutenberg-University Mainz, Mainz, Germany",{"title":1593},{"VI":1594},"Jörn M. Schattenberg",{"id":1596,"sortIndex":53,"researcher":26,"roles":1597,"affiliations":1598,"properties":1607},"5996f160-5d4f-44c2-b81c-44ced103ecf0",[799],[1599],{"id":26,"sortIndex":36,"affiliation":1600,"properties":26},{"id":1601,"createTime":1602,"updateTime":1602,"relativeEntities":1603,"slug":26,"properties":1604,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"98163b00-8d9d-4031-9957-78ea63df618e","2024-02-10T17:00:48.980+00:00",[],{"title":1605},{"VI":1606},"Division of Diagnostics and Specialist Medicine, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden",{"title":1608},{"VI":1609},"Mattias Ekstedt",{"id":1611,"sortIndex":52,"researcher":26,"roles":1612,"affiliations":1613,"properties":1626},"202399d9-9458-4ff6-b0db-b2f6de23877f",[799],[1614],{"id":1615,"sortIndex":36,"affiliation":1616,"properties":1623},"1d3861d3-89be-422f-9e91-60126ed9e34a",{"id":1617,"createTime":1618,"updateTime":1618,"relativeEntities":1619,"slug":26,"properties":1620,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"ec430f2a-dbab-4e52-9b43-40c94c0c7614","2024-01-13T04:13:57.975+00:00",[],{"title":1621},{"VI":1622},"Internal Medicine Research Unit, Pfizer, Inc., Cambridge, MA, United States",{"title":1624},{"VI":1625},"Internal Medicine Research Unit, Pfizer Inc., Cambridge, MA, USA",{"title":1627},{"VI":1628},"M. Julia Brosnan",{"id":1630,"sortIndex":103,"researcher":26,"roles":1631,"affiliations":1632,"properties":1643},"136aea4b-94d8-4671-8f22-97bbc70ed0d8",[799],[1633],{"id":26,"sortIndex":36,"affiliation":1634,"properties":26},{"id":1635,"createTime":1636,"updateTime":1637,"relativeEntities":1638,"slug":1639,"properties":1640,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"5a4ed93e-f674-47ee-b908-acda66a22e10","2024-01-09T22:36:19.676+00:00","2024-10-01T16:46:08.851+00:00",[],"NIHR-Nottingham-Biomedical-Research-Centre-Nottingham-University-Hospitals-NHS-Trust-and-University-of-Nottingham-Nottingham-UK",{"title":1641},{"VI":1642},"NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK",{"title":1644},{"VI":1645},"Guruprasad P. Aithal",{"id":1647,"sortIndex":158,"researcher":26,"roles":1648,"affiliations":1649,"properties":1655},"b29124f9-bc07-42d3-9458-d4dfbff103a0",[799],[1650],{"id":26,"sortIndex":36,"affiliation":1651,"properties":26},{"id":1442,"createTime":1443,"updateTime":1444,"relativeEntities":1652,"slug":1446,"properties":1653,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1654},{"VI":1449},{"title":1656},{"VI":1657},"Michalina Zatorska",{"id":1659,"sortIndex":234,"researcher":26,"roles":1660,"affiliations":1661,"properties":1667},"64d11bd6-f751-4cc0-8c72-8f841bfa7464",[799],[1662],{"id":26,"sortIndex":36,"affiliation":1663,"properties":26},{"id":1442,"createTime":1443,"updateTime":1444,"relativeEntities":1664,"slug":1446,"properties":1665,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1666},{"VI":1449},{"title":1668},{"VI":1669},"Ann K. Daly",{"id":1671,"sortIndex":162,"researcher":26,"roles":1672,"affiliations":1673,"properties":1689},"7c86194c-2dd6-4339-878b-baf68e9d7f72",[799],[1674,1682],{"id":26,"sortIndex":36,"affiliation":1675,"properties":26},{"id":1676,"createTime":1677,"updateTime":1677,"relativeEntities":1678,"slug":26,"properties":1679,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"5c907352-cbf0-467b-b81f-32f5e43af50b","2024-01-01T15:37:37.746+00:00",[],{"title":1680},{"VI":1681},"Bioinformatics Support Unit, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK",{"id":1683,"sortIndex":115,"affiliation":1684,"properties":1688},"665b7ad8-9178-424b-a07c-b5715252338e",{"id":1557,"createTime":1558,"updateTime":1559,"relativeEntities":1685,"slug":1561,"properties":1686,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1687},{"VI":1564},{},{"title":1690},{"VI":1691},"Simon J. Cockell",{"id":1693,"sortIndex":51,"researcher":26,"roles":1694,"affiliations":1695,"properties":1704},"572597c1-91b4-4596-9452-c9c8e8af7d8e",[799],[1696],{"id":26,"sortIndex":36,"affiliation":1697,"properties":26},{"id":1698,"createTime":1699,"updateTime":1699,"relativeEntities":1700,"slug":26,"properties":1701,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"59df237f-7505-44bc-824e-24222d0f1abb","2024-01-29T08:28:08.329+00:00",[],{"title":1702},{"VI":1703},"Hepatology Department, Angers University Hospital, Angers, France",{"title":1705},{"VI":1706},"Jerome Boursier",{"id":1708,"sortIndex":115,"researcher":26,"roles":1709,"affiliations":1710,"properties":1716},"e8f76a6c-5c49-4d4b-840c-135c6ef9b570",[799],[1711],{"id":26,"sortIndex":36,"affiliation":1712,"properties":26},{"id":1676,"createTime":1677,"updateTime":1677,"relativeEntities":1713,"slug":26,"properties":1714,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1715},{"VI":1681},{"title":1717},{"VI":1718},"Peter J. Leary",{"id":1720,"sortIndex":59,"researcher":26,"roles":1721,"affiliations":1722,"properties":1728},"db02e893-7ded-431a-b855-5f98c6319ddd",[799],[1723],{"id":26,"sortIndex":36,"affiliation":1724,"properties":26},{"id":1557,"createTime":1558,"updateTime":1559,"relativeEntities":1725,"slug":1561,"properties":1726,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1727},{"VI":1564},{"title":1729},{"VI":1730},"Matthew J. Barter",{"id":1732,"sortIndex":173,"researcher":26,"roles":1733,"affiliations":1734,"properties":1750},"30976ab2-3be1-4789-8f4f-0c61ed2e061e",[799],[1735,1745],{"id":1736,"sortIndex":115,"affiliation":1737,"properties":1744},"df6892cc-4cc8-49ff-9cc2-8e95a3603ddd",{"id":1738,"createTime":1739,"updateTime":1739,"relativeEntities":1740,"slug":26,"properties":1741,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"5beb24c5-a9b8-4fba-8d8d-2507a6bab6ec","2024-01-10T04:14:18.727+00:00",[],{"title":1742},{"VI":1743},"Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK",{},{"id":26,"sortIndex":36,"affiliation":1746,"properties":26},{"id":1442,"createTime":1443,"updateTime":1444,"relativeEntities":1747,"slug":1446,"properties":1748,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1749},{"VI":1449},{"title":1751},{"VI":1752},"Quentin M. Anstee",{"url":1434,"publisher":1754,"properties":1783},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":1755,"slug":663,"properties":1756,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":114,"subjectFields":1761,"manageAffiliations":1762,"indexDatabases":1763,"url":768,"thumbnailPath":26,"statistic":1778,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"country":1757,"issn":1758,"introduce":1759,"title":1760},{"VOID":666},{"VOID":668},{"EN":670},{"EN":672},[],[],[1764,1771],{"id":747,"indexDatabase":1765,"url":760,"indexYears":761,"academicFieldIds":1770,"indexDatabaseRanking":767},{"id":749,"createTime":750,"updateTime":751,"relativeEntities":1766,"label":1767,"description":1768,"key":757,"publicationTags":1769,"standard":26},[],{"EN":754,"VI":754},{"EN":754,"VI":756},[759],[763,764,765,766],{"id":728,"indexDatabase":1772,"url":743,"indexYears":26,"academicFieldIds":1777,"indexDatabaseRanking":26},{"id":730,"createTime":731,"updateTime":732,"relativeEntities":1773,"label":1774,"description":1775,"key":739,"publicationTags":1776,"standard":26},[],{"EN":735,"VI":735},{"VI":737,"EN":738},[741,742],[745],{"impactFactor":36,"impactFactorByYear":1779,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":245,"totalPublicationByYear":1780,"totalCitation":36,"totalCitationByYear":1781,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":1782,"hindexLast5Year":36,"hindex":36},{},{"2019":158,"2020":111,"2021":124,"2022":298,"2023":287,"2024":59},{},{},{"volume":1784,"pages":1786},{"VOID":1785},"4",{"VOID":1787},"100409","2022-02-01",2022,{"id":1791,"createTime":1792,"updateTime":1793,"relativeEntities":1794,"slug":1795,"properties":1796,"entityType":791,"verifyStatus":25,"verifyTime":1793,"verifyNote":793,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":1803,"fullTextUrl":26,"authors":1804,"publicationType":994,"publisherRelationship":2155,"citationCount":26,"citationInfo":26,"publishDate":1355,"publishYear":1033,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":26,"isForceReanalyzing":1185},"235c5880-f5ce-4d2c-8372-e17ce38912d8","2024-01-13T10:11:16.609+00:00","2024-10-28T05:47:40.641+00:00",[],"Stellate-cell-expression-of-SPARC-related-modular-calcium-binding-protein-2-is-associated-with-human-non-alcoholic-fatty-liver-disease-severity",{"references":1797,"title":1799,"doi":1801},{"VOID":1798},"2022\nYounossi, 2019, The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis, J Hepatol, 71, 793, 10.1016\u002Fj.jhep.2019.06.021\nHagstrom, 2020, Health care costs of patients with biopsy-confirmed nonalcoholic fatty liver disease are nearly twice those of matched controls, Clin Gastroenterol Hepatol, 18, 1592, 10.1016\u002Fj.cgh.2019.10.023\nO'Hara, 2020, Cost of non-alcoholic steatohepatitis in Europe and the USA: the GAIN study, JHEP Rep, 2\nMatteoni, 1999, Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity, Gastroenterology, 116, 1413, 10.1016\u002FS0016-5085(99)70506-8\nCampos, 2008, A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients, Hepatology, 47, 1916, 10.1002\u002Fhep.22241\nKleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002\u002Fhep.20701\nMcGill, 1990, A 21-year experience with major hemorrhage after percutaneous liver biopsy, Gastroenterology, 99, 1396, 10.1016\u002F0016-5085(90)91167-5\nVuppalanchi, 2009, Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease, Clin Gastroenterol Hepatol, 7, 481, 10.1016\u002Fj.cgh.2008.12.015\nRatziu, 2005, Sampling variability of liver biopsy in nonalcoholic fatty liver disease, Gastroenterology, 128, 1898, 10.1053\u002Fj.gastro.2005.03.084\nDavison, 2020, Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials, J Hepatol, 73, 1322, 10.1016\u002Fj.jhep.2020.06.025\nWong, 2018, Noninvasive biomarkers in NAFLD and NASH - current progress and future promise, Nat Rev Gastroenterol Hepatol, 15, 461, 10.1038\u002Fs41575-018-0014-9\nTsuchida, 2017, Mechanisms of hepatic stellate cell activation, Nat Rev Gastroenterol Hepatol, 14, 397, 10.1038\u002Fnrgastro.2017.38\nAbdelaziz, 2015, Tissue inhibitors of metalloproteinase-1 and 2 and obesity related non-alcoholic fatty liver disease: is there a relationship, Digestion, 92, 130, 10.1159\u002F000439083\nBoyle, 2019, Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease, JHEP Rep, 1, 188, 10.1016\u002Fj.jhepr.2019.06.004\nLuo, 2018, An evaluation of the collagen fragments related to fibrogenesis and fibrolysis in nonalcoholic steatohepatitis, Sci Rep, 8, 10.1038\u002Fs41598-018-30457-y\nSaekmose, 2015, Microfibrillar-associated protein 4: a potential biomarker for screening for liver fibrosis in a mixed patient cohort, PLoS One, 10, 10.1371\u002Fjournal.pone.0140418\nNascimbeni, 2020, Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease, J Hepatol, 72, 828, 10.1016\u002Fj.jhep.2019.12.008\nDobin, 2013, STAR: ultrafast universal RNA-seq aligner, Bioinformatics, 29, 15, 10.1093\u002Fbioinformatics\u002Fbts635\nLiao, 2014, featureCounts: an efficient general purpose program for assigning sequence reads to genomic features, Bioinformatics, 30, 923, 10.1093\u002Fbioinformatics\u002Fbtt656\nAndrews, 2019\nEwels, 2016, MultiQC: summarize analysis results for multiple tools and samples in a single report, Bioinformatics, 32, 3047, 10.1093\u002Fbioinformatics\u002Fbtw354\nZiegenhain, 2021, BAMboozle removes genetic variation from human sequence data for open data sharing, Nat Commun, 12, 6216, 10.1038\u002Fs41467-021-26152-8\nRamachandran, 2019, Resolving the fibrotic niche of human liver cirrhosis at single-cell level, Nature, 575, 512, 10.1038\u002Fs41586-019-1631-3\nMacParland, 2018, Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations, Nat Commun, 9, 4383, 10.1038\u002Fs41467-018-06318-7\nPayen, 2021, Single-cell RNA sequencing of human liver reveals hepatic stellate cell heterogeneity, JHEP Rep, 3\nHao, 2021, Integrated analysis of multimodal single-cell data, Cell, 184, 3573, 10.1016\u002Fj.cell.2021.04.048\nMcGinnis, 2019, DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors, Cell Syst, 8, 329, 10.1016\u002Fj.cels.2019.03.003\nKorsunsky, 2019, Fast, sensitive and accurate integration of single-cell data with Harmony, Nat Methods, 16, 1289, 10.1038\u002Fs41592-019-0619-0\nDominguez Conde, 2022, Cross-tissue immune cell analysis reveals tissue-specific features in humans, Science, 376, 10.1126\u002Fscience.abl5197\nRobin, 2011, pROC: an open-source package for R and S+ to analyze and compare ROC curves, BMC Bioinformatics, 12, 77, 10.1186\u002F1471-2105-12-77\nGovaere, 2020, Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis, Sci Transl Med, 12, 10.1126\u002Fscitranslmed.aba4448\nTerkelsen, 2020, Transcriptional dynamics of hepatic sinusoid-associated cells after liver injury, Hepatology, 72, 2119, 10.1002\u002Fhep.31215\nGong, 2019, Gpnmb secreted from liver promotes lipogenesis in white adipose tissue and aggravates obesity and insulin resistance, Nat Metab, 1, 570, 10.1038\u002Fs42255-019-0065-4\nWang, 2021, Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis, Sci Rep, 11\nDobie, 2019, Single-cell transcriptomics uncovers zonation of function in the mesenchyme during liver fibrosis, Cell Rep, 29, 1832, 10.1016\u002Fj.celrep.2019.10.024\nBracht, 2015, Analysis of disease-associated protein expression using quantitative proteomics-fibulin-5 is expressed in association with hepatic fibrosis, J Proteome Res, 14, 2278, 10.1021\u002Facs.jproteome.5b00053\nChandran, 2022, Circulating TREM2 as a non-invasive diagnostic biomarker for NASH in patients with elevated liver stiffness, Hepatology, 00, 1\nHendrikx, 2022, Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH, J Hepatol, 77, 1373, 10.1016\u002Fj.jhep.2022.06.004\nVannahme, 2003, Characterization of SMOC-2, a modular extracellular calcium-binding protein, Biochem J, 373, 805, 10.1042\u002Fbj20030532\nBornstein, 2009, Matricellular proteins: an overview, J Cel Commun Signal, 3, 163, 10.1007\u002Fs12079-009-0069-z\nBornstein, 2002, Matricellular proteins: extracellular modulators of cell function, Curr Opin Cel Biol, 14, 608, 10.1016\u002FS0955-0674(02)00361-7\nLuo, 2018, Suppression of SMOC2 reduces bleomycin (BLM)-induced pulmonary fibrosis by inhibition of TGF-beta1\u002FSMADs pathway, Biomed Pharmacother, 105, 841, 10.1016\u002Fj.biopha.2018.03.058\nSu, 2016, Smoc2 potentiates proliferation of hepatocellular carcinoma cells via promotion of cell cycle progression, World J Gastroenterol, 22, 10053, 10.3748\u002Fwjg.v22.i45.10053\nLiu, 2008, The SPARC-related factor SMOC-2 promotes growth factor-induced cyclin D1 expression and DNA synthesis via integrin-linked kinase, Mol Biol Cel, 19, 248, 10.1091\u002Fmbc.e07-05-0510\nGerarduzzi, 2017, Silencing SMOC2 ameliorates kidney fibrosis by inhibiting fibroblast to myofibroblast transformation, JCI Insight, 2, 10.1172\u002Fjci.insight.90299\nSchmidt, 2021, Cadherin-11, Sparc-related modular calcium binding protein-2, and Pigment epithelium-derived factor are promising non-invasive biomarkers of kidney fibrosis, Kidney Int, 100, 672, 10.1016\u002Fj.kint.2021.04.037\nYuting, 2019, Secreted modular calcium-binding protein 2 promotes high fat diet (HFD)-induced hepatic steatosis through enhancing lipid deposition, fibrosis and inflammation via targeting TGF-beta1, Biochem Biophys Res Commun, 509, 48, 10.1016\u002Fj.bbrc.2018.12.006\nMederacke, 2013, Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology, Nat Commun, 4, 2823, 10.1038\u002Fncomms3823\nWang, 2021, TGF-beta1\u002FSMOC2\u002FAKT and ERK axis regulates proliferation, migration, and fibroblast to myofibroblast transformation in lung fibroblast, contributing with the asthma progression, Hereditas, 158, 47, 10.1186\u002Fs41065-021-00213-w\nMarcher, 2019, Transcriptional regulation of hepatic stellate cell activation in NASH, Sci Rep, 9, 2324, 10.1038\u002Fs41598-019-39112-6\nEkstedt, 2015, Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up, Hepatology, 61, 1547, 10.1002\u002Fhep.27368\nSamuel, 2018, Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases, Cell Metab, 27, 22, 10.1016\u002Fj.cmet.2017.08.002\nLan, 2013, Vascular fibrosis in atherosclerosis, Cardiovasc Pathol, 22, 401, 10.1016\u002Fj.carpath.2013.01.003\nHenderson, 2020, Fibrosis: from mechanisms to medicines, Nature, 587, 555, 10.1038\u002Fs41586-020-2938-9\nSchuler, 2021, Extensive remodeling of the extracellular matrix during aging contributes to age-dependent impairments of muscle stem cell functionality, Cel Rep, 35",{"EN":1800},"Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity",{"VOID":1802},"10.1016\u002Fj.jhepr.2022.100615","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2589555922001872",[1805,1832,1851,1870,1885,1904,1933,1952,1971,1993,2012,2031,2050,2069,2081,2100,2117,2136],{"id":1806,"sortIndex":116,"researcher":26,"roles":1807,"affiliations":1808,"properties":1829},"07b7fe62-be01-45a9-8197-90f1ad2b28c2",[799],[1809,1819],{"id":1810,"sortIndex":115,"affiliation":1811,"properties":1818},"7d54dcb4-b7cf-4c57-b0f4-ccf2edbdb87f",{"id":1812,"createTime":1813,"updateTime":1813,"relativeEntities":1814,"slug":26,"properties":1815,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"72b79a21-7e05-4c02-9df5-51bda99636a1","2024-01-13T10:11:16.763+00:00",[],{"title":1816},{"VI":1817},"Center for Functional Genomics and Tissue Plasticity (ATLAS), University of Southern Denmark, Odense, Denmark",{},{"id":26,"sortIndex":36,"affiliation":1820,"properties":26},{"id":1821,"createTime":1822,"updateTime":1823,"relativeEntities":1824,"slug":1825,"properties":1826,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"179de0f9-66b3-4696-8779-e0816b34485c","2023-12-25T11:09:31.278+00:00","2025-01-01T08:51:41.896+00:00",[],"Department-of-Biochemistry-and-Molecular-Biology-University-of-Southern-Denmark-Odense-Denmark",{"title":1827},{"VI":1828},"Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark",{"title":1830},{"VI":1831},"Susanne Mandrup",{"id":1833,"sortIndex":111,"researcher":26,"roles":1834,"affiliations":1835,"properties":1848},"22f059fc-7541-41ab-87a6-66cbb31190c0",[799],[1836,1843],{"id":1837,"sortIndex":115,"affiliation":1838,"properties":1842},"53d1332a-2f46-4c31-a15b-2e86bc03c8fc",{"id":1812,"createTime":1813,"updateTime":1813,"relativeEntities":1839,"slug":26,"properties":1840,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1841},{"VI":1817},{},{"id":26,"sortIndex":36,"affiliation":1844,"properties":26},{"id":1821,"createTime":1822,"updateTime":1823,"relativeEntities":1845,"slug":1825,"properties":1846,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1847},{"VI":1828},{"title":1849},{"VI":1850},"Fabio Avolio",{"id":1852,"sortIndex":115,"researcher":26,"roles":1853,"affiliations":1854,"properties":1867},"2670d25e-ce2b-4852-8cfd-ef90b7d0788e",[799],[1855,1862],{"id":1856,"sortIndex":115,"affiliation":1857,"properties":1861},"079aa944-ced2-4fbf-93fd-cc55eec14205",{"id":1812,"createTime":1813,"updateTime":1813,"relativeEntities":1858,"slug":26,"properties":1859,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1860},{"VI":1817},{},{"id":26,"sortIndex":36,"affiliation":1863,"properties":26},{"id":1821,"createTime":1822,"updateTime":1823,"relativeEntities":1864,"slug":1825,"properties":1865,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1866},{"VI":1828},{"title":1868},{"VI":1869},"Daniel Hansen",{"id":1871,"sortIndex":50,"researcher":26,"roles":1872,"affiliations":1873,"properties":1882},"dfb57757-0adb-464a-bec7-d400c4b28610",[799],[1874],{"id":26,"sortIndex":36,"affiliation":1875,"properties":26},{"id":1876,"createTime":1877,"updateTime":1877,"relativeEntities":1878,"slug":26,"properties":1879,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"effe1851-4fce-4e02-aed1-f71bef600dc9","2024-01-13T10:11:16.821+00:00",[],{"title":1880},{"VI":1881},"Department of Gastroenterology and Hepatology, University Hospital of Southern Denmark, Esbjerg, Denmark",{"title":1883},{"VI":1884},"Birgitte G. Jacobsen",{"id":1886,"sortIndex":36,"researcher":26,"roles":1887,"affiliations":1888,"properties":1901},"0d43ddda-08fe-4410-92da-69060c6d3652",[799],[1889,1896],{"id":1890,"sortIndex":115,"affiliation":1891,"properties":1895},"944d2b2e-14d4-4b4e-8981-63713e03a3cf",{"id":1812,"createTime":1813,"updateTime":1813,"relativeEntities":1892,"slug":26,"properties":1893,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1894},{"VI":1817},{},{"id":26,"sortIndex":36,"affiliation":1897,"properties":26},{"id":1821,"createTime":1822,"updateTime":1823,"relativeEntities":1898,"slug":1825,"properties":1899,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1900},{"VI":1828},{"title":1902},{"VI":1903},"Frederik T. Larsen",{"id":1905,"sortIndex":162,"researcher":26,"roles":1906,"affiliations":1907,"properties":1930},"9b807f05-b966-4627-9048-dce626e8183e",[799],[1908,1915,1920],{"id":1909,"sortIndex":115,"affiliation":1910,"properties":1914},"48993f84-db59-4772-a094-033503543485",{"id":1876,"createTime":1877,"updateTime":1877,"relativeEntities":1911,"slug":26,"properties":1912,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1913},{"VI":1881},{},{"id":26,"sortIndex":36,"affiliation":1916,"properties":26},{"id":1812,"createTime":1813,"updateTime":1813,"relativeEntities":1917,"slug":26,"properties":1918,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1919},{"VI":1817},{"id":1921,"sortIndex":114,"affiliation":1922,"properties":1929},"30b83de2-4f0d-4367-93a8-f811728116b5",{"id":1923,"createTime":1924,"updateTime":1924,"relativeEntities":1925,"slug":26,"properties":1926,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"3e05d37e-4c53-4d2b-89c2-469823df362f","2024-01-13T10:11:16.771+00:00",[],{"title":1927},{"VI":1928},"Center for Liver Research (FLASH), Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark",{},{"title":1931},{"VI":1932},"Charlotte W. Wernberg",{"id":1934,"sortIndex":51,"researcher":26,"roles":1935,"affiliations":1936,"properties":1949},"3d439639-8c85-4ba7-b6c2-24a053db2b01",[799],[1937,1944],{"id":1938,"sortIndex":115,"affiliation":1939,"properties":1943},"f4db8b52-f674-4069-8229-c91a49825b3a",{"id":1923,"createTime":1924,"updateTime":1924,"relativeEntities":1940,"slug":26,"properties":1941,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1942},{"VI":1928},{},{"id":26,"sortIndex":36,"affiliation":1945,"properties":26},{"id":1812,"createTime":1813,"updateTime":1813,"relativeEntities":1946,"slug":26,"properties":1947,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1948},{"VI":1817},{"title":1950},{"VI":1951},"Aleksander Krag",{"id":1953,"sortIndex":114,"researcher":26,"roles":1954,"affiliations":1955,"properties":1968},"b938fcfd-9494-445b-a349-6394a8e1f6e3",[799],[1956,1963],{"id":1957,"sortIndex":115,"affiliation":1958,"properties":1962},"7472832e-8026-40fc-be4b-3a7890b70bbd",{"id":1812,"createTime":1813,"updateTime":1813,"relativeEntities":1959,"slug":26,"properties":1960,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1961},{"VI":1817},{},{"id":26,"sortIndex":36,"affiliation":1964,"properties":26},{"id":1821,"createTime":1822,"updateTime":1823,"relativeEntities":1965,"slug":1825,"properties":1966,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1967},{"VI":1828},{"title":1969},{"VI":1970},"Mike K. Terkelsen",{"id":1972,"sortIndex":356,"researcher":26,"roles":1973,"affiliations":1974,"properties":1990},"e9ab9e71-f6cb-473b-957d-1b99ccaa70b5",[799],[1975,1980],{"id":26,"sortIndex":36,"affiliation":1976,"properties":26},{"id":1812,"createTime":1813,"updateTime":1813,"relativeEntities":1977,"slug":26,"properties":1978,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1979},{"VI":1817},{"id":1981,"sortIndex":115,"affiliation":1982,"properties":1989},"3800f0af-425a-48cc-8b47-e9314cff7bc6",{"id":1983,"createTime":1984,"updateTime":1984,"relativeEntities":1985,"slug":26,"properties":1986,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"cbaddb74-1d90-4a82-97a4-aeb11d3e69eb","2023-12-06T10:31:36.388+00:00",[],{"title":1987},{"VI":1988},"Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark",{},{"title":1991},{"VI":1992},"Vineesh Indira Chandran",{"id":1994,"sortIndex":336,"researcher":26,"roles":1995,"affiliations":1996,"properties":2009},"e967edfa-0d13-4498-a44d-9a751042a5d9",[799],[1997,2004],{"id":1998,"sortIndex":115,"affiliation":1999,"properties":2003},"98066773-04a0-4a7e-886e-d78c3c58c5d5",{"id":1812,"createTime":1813,"updateTime":1813,"relativeEntities":2000,"slug":26,"properties":2001,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2002},{"VI":1817},{},{"id":26,"sortIndex":36,"affiliation":2005,"properties":26},{"id":1821,"createTime":1822,"updateTime":1823,"relativeEntities":2006,"slug":1825,"properties":2007,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2008},{"VI":1828},{"title":2010},{"VI":2011},"Lars Grøntved",{"id":2013,"sortIndex":103,"researcher":26,"roles":2014,"affiliations":2015,"properties":2028},"94241f90-ac15-44be-9c53-c01aee825313",[799],[2016,2023],{"id":2017,"sortIndex":115,"affiliation":2018,"properties":2022},"3a888df8-7a05-41ee-83de-cfb8cafa2ba2",{"id":1812,"createTime":1813,"updateTime":1813,"relativeEntities":2019,"slug":26,"properties":2020,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2021},{"VI":1817},{},{"id":26,"sortIndex":36,"affiliation":2024,"properties":26},{"id":1821,"createTime":1822,"updateTime":1823,"relativeEntities":2025,"slug":1825,"properties":2026,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2027},{"VI":1828},{"title":2029},{"VI":2030},"Majken S. Siersbæk",{"id":2032,"sortIndex":52,"researcher":26,"roles":2033,"affiliations":2034,"properties":2047},"82432e21-4f69-401a-b628-4d78284c3c5b",[799],[2035,2042],{"id":2036,"sortIndex":115,"affiliation":2037,"properties":2041},"bf1fb581-27fb-4000-b0a1-2e5da869d0fa",{"id":1812,"createTime":1813,"updateTime":1813,"relativeEntities":2038,"slug":26,"properties":2039,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2040},{"VI":1817},{},{"id":26,"sortIndex":36,"affiliation":2043,"properties":26},{"id":1821,"createTime":1822,"updateTime":1823,"relativeEntities":2044,"slug":1825,"properties":2045,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2046},{"VI":1828},{"title":2048},{"VI":2049},"Ellen G. Klinggaard",{"id":2051,"sortIndex":135,"researcher":26,"roles":2052,"affiliations":2053,"properties":2066},"4c9c6383-985a-4752-9e5a-efcb82b33a01",[799],[2054,2061],{"id":2055,"sortIndex":115,"affiliation":2056,"properties":2060},"b37ef5da-7c36-4256-8e23-1cb781d93adb",{"id":1876,"createTime":1877,"updateTime":1877,"relativeEntities":2057,"slug":26,"properties":2058,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2059},{"VI":1881},{},{"id":26,"sortIndex":36,"affiliation":2062,"properties":26},{"id":1812,"createTime":1813,"updateTime":1813,"relativeEntities":2063,"slug":26,"properties":2064,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2065},{"VI":1817},{"title":2067},{"VI":2068},"Mette M. Lauridsen",{"id":2070,"sortIndex":158,"researcher":26,"roles":2071,"affiliations":2072,"properties":2078},"2cc70906-f9f3-4d43-b5d3-bc70223e12f7",[799],[2073],{"id":26,"sortIndex":36,"affiliation":2074,"properties":26},{"id":1876,"createTime":1877,"updateTime":1877,"relativeEntities":2075,"slug":26,"properties":2076,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2077},{"VI":1881},{"title":2079},{"VI":2080},"Lea L. Grønkjaer",{"id":2082,"sortIndex":124,"researcher":26,"roles":2083,"affiliations":2084,"properties":2097},"8567e21d-a5da-4e97-9aa0-756ec4dfab25",[799],[2085,2092],{"id":2086,"sortIndex":115,"affiliation":2087,"properties":2091},"66787aa7-4da1-446d-853d-4845239a22f3",{"id":1812,"createTime":1813,"updateTime":1813,"relativeEntities":2088,"slug":26,"properties":2089,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2090},{"VI":1817},{},{"id":26,"sortIndex":36,"affiliation":2093,"properties":26},{"id":1821,"createTime":1822,"updateTime":1823,"relativeEntities":2094,"slug":1825,"properties":2095,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2096},{"VI":1828},{"title":2098},{"VI":2099},"Kim Ravnskjaer",{"id":2101,"sortIndex":53,"researcher":26,"roles":2102,"affiliations":2103,"properties":2114},"ce6823b2-61f5-4457-a535-47dee4db0331",[799],[2104],{"id":26,"sortIndex":36,"affiliation":2105,"properties":26},{"id":2106,"createTime":2107,"updateTime":2108,"relativeEntities":2109,"slug":2110,"properties":2111,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"9ed73e0b-a837-40ea-8f13-cc12728a4ca8","2024-01-08T18:28:19.045+00:00","2024-10-12T03:59:20.252+00:00",[],"Department-of-Pathology-Odense-University-Hospital-Odense-Denmark",{"title":2112},{"VI":2113},"Department of Pathology, Odense University Hospital, Odense, Denmark",{"title":2115},{"VI":2116},"Tina Di Caterino",{"id":2118,"sortIndex":298,"researcher":26,"roles":2119,"affiliations":2120,"properties":2133},"3bab775c-4ff6-4d56-9579-ba9e488ffc5c",[799],[2121,2126],{"id":26,"sortIndex":36,"affiliation":2122,"properties":26},{"id":1812,"createTime":1813,"updateTime":1813,"relativeEntities":2123,"slug":26,"properties":2124,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2125},{"VI":1817},{"id":2127,"sortIndex":115,"affiliation":2128,"properties":2132},"6f4ddb22-42b6-4caa-8be0-1865c5fcfcc2",{"id":1983,"createTime":1984,"updateTime":1984,"relativeEntities":2129,"slug":26,"properties":2130,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2131},{"VI":1988},{},{"title":2134},{"VI":2135},"Jonas H. Graversen",{"id":2137,"sortIndex":59,"researcher":26,"roles":2138,"affiliations":2139,"properties":2152},"247fd96c-92ca-4eb6-946f-2e2cb85575a8",[799],[2140,2147],{"id":2141,"sortIndex":115,"affiliation":2142,"properties":2146},"255498ce-588d-4539-925e-9b10c8f40e7e",{"id":1812,"createTime":1813,"updateTime":1813,"relativeEntities":2143,"slug":26,"properties":2144,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2145},{"VI":1817},{},{"id":26,"sortIndex":36,"affiliation":2148,"properties":26},{"id":1821,"createTime":1822,"updateTime":1823,"relativeEntities":2149,"slug":1825,"properties":2150,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2151},{"VI":1828},{"title":2153},{"VI":2154},"Sofie M. Bendixen",{"url":1803,"publisher":2156,"properties":2185},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":2157,"slug":663,"properties":2158,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":114,"subjectFields":2163,"manageAffiliations":2164,"indexDatabases":2165,"url":768,"thumbnailPath":26,"statistic":2180,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"country":2159,"issn":2160,"introduce":2161,"title":2162},{"VOID":666},{"VOID":668},{"EN":670},{"EN":672},[],[],[2166,2173],{"id":747,"indexDatabase":2167,"url":760,"indexYears":761,"academicFieldIds":2172,"indexDatabaseRanking":767},{"id":749,"createTime":750,"updateTime":751,"relativeEntities":2168,"label":2169,"description":2170,"key":757,"publicationTags":2171,"standard":26},[],{"EN":754,"VI":754},{"EN":754,"VI":756},[759],[763,764,765,766],{"id":728,"indexDatabase":2174,"url":743,"indexYears":26,"academicFieldIds":2179,"indexDatabaseRanking":26},{"id":730,"createTime":731,"updateTime":732,"relativeEntities":2175,"label":2176,"description":2177,"key":739,"publicationTags":2178,"standard":26},[],{"EN":735,"VI":735},{"VI":737,"EN":738},[741,742],[745],{"impactFactor":36,"impactFactorByYear":2181,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":245,"totalPublicationByYear":2182,"totalCitation":36,"totalCitationByYear":2183,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":2184,"hindexLast5Year":36,"hindex":36},{},{"2019":158,"2020":111,"2021":124,"2022":298,"2023":287,"2024":59},{},{},{"volume":2186,"pages":2187},{"VOID":1027},{"VOID":2188},"100615",{"id":2190,"createTime":2191,"updateTime":2192,"relativeEntities":2193,"slug":2194,"properties":2195,"entityType":791,"verifyStatus":25,"verifyTime":2192,"verifyNote":793,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":2202,"fullTextUrl":26,"authors":2203,"publicationType":994,"publisherRelationship":2291,"citationCount":26,"citationInfo":26,"publishDate":1355,"publishYear":1033,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":26,"isForceReanalyzing":1185},"f87d47d6-d2ed-42a6-83ae-69d738fed013","2023-12-19T12:41:36.501+00:00","2024-12-06T09:41:16.822+00:00",[],"Health-inequalities-in-the-management-of-chronic-hepatitis-B-virus-infection-in-patients-from-sub-Saharan-Africa-in-high-income-countries",{"references":2196,"title":2198,"doi":2200},{"VOID":2197},"2022, Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019, Lancet Gastroenterol Hepatol, 7, 796, 10.1016\u002FS2468-1253(22)00124-8\n2017\nAlberts, 2022, Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review, Lancet Gastroenterol Hepatol, 7, 724, 10.1016\u002FS2468-1253(22)00050-4\nSpearman, 2017, Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets, Lancet Gastroenterol Hepatol, 2, 900, 10.1016\u002FS2468-1253(17)30295-9\nLemoine, 2015, Reducing the neglected burden of viral hepatitis in Africa: strategies for a global approach, J Hepatol, 62, 469, 10.1016\u002Fj.jhep.2014.10.008\nAhmad, 2018, Estimating the scale of chronic hepatitis B virus infection among migrants in EU\u002FEEA countries, BMC Infect Dis, 18, 34, 10.1186\u002Fs12879-017-2921-8\n2016\nConnor, 2018\nPublic Health, 2019\n2011\nEvlampidou, 2016, Low hepatitis B testing among migrants: a cross-sectional study in a UK city, Br J Gen Pract, 66, e382, 10.3399\u002Fbjgp16X684817\nWilliams, 2013, Screening immigrants for tuberculosis--why not for HBV infection?, Lancet, 381, 2164, 10.1016\u002FS0140-6736(13)61438-5\nAberra, 2019, The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia, J Hepatol, 70, 1065, 10.1016\u002Fj.jhep.2019.01.037\nHorton, 2020, Offline: COVID-19 is not a pandemic, Lancet, 396, 874, 10.1016\u002FS0140-6736(20)32000-6\nAldridge, 2018, Global patterns of mortality in international migrants: a systematic review and meta-analysis, Lancet, 392, 2553, 10.1016\u002FS0140-6736(18)32781-8\nOchieng, 2013, Black African migrants: the barriers with accessing and utilizing health promotion services in the UK, Eur J Public Health, 23, 265, 10.1093\u002Feurpub\u002Fcks063\n2017, EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection, J Hepatol, 67, 370, 10.1016\u002Fj.jhep.2017.03.021\nFattovich, 2008, Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors, J Hepatol, 48, 335, 10.1016\u002Fj.jhep.2007.11.011\nTerrault, 2018, Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance, Clin Liver Dis (Hoboken), 12, 33, 10.1002\u002Fcld.728\nSpearman, 2022, Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa, Lancet Gastroenterol Hepatol, 7, 1036, 10.1016\u002FS2468-1253(22)00041-3\nChu, 2017, Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers, Int J Cancer, 141, 711, 10.1002\u002Fijc.30782\nKimanya, 2021, Estimating the risk of aflatoxin-induced liver cancer in Tanzania based on biomarker data, PLoS One, 16, 10.1371\u002Fjournal.pone.0247281\nSarin, 2016, Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update, Hepatol Int, 10, 1, 10.1007\u002Fs12072-015-9675-4\nCargill, 2021, Risk stratification in chronic hepatitis B patients for hepatocellular carcinoma surveillance: management in migrant sub-Saharan African populations, Gut, 70, 629, 10.1136\u002Fgutjnl-2020-322181\nYuen, 2009, Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B, J Hepatol, 50, 80, 10.1016\u002Fj.jhep.2008.07.023\nWong, 2010, Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers, J Clin Oncol, 28, 1660, 10.1200\u002FJCO.2009.26.2675\nYang, 2011, Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score, Lancet Oncol, 12, 568, 10.1016\u002FS1470-2045(11)70077-8\nJung, 2015, Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy, Hepatology, 62, 1757, 10.1002\u002Fhep.28115\nWong, 2013, Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment, Gastroenterology, 144, 933, 10.1053\u002Fj.gastro.2013.02.002\nJohnson, 2014, The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers, Cancer Epidemiol Biomarkers Prev, 23, 144, 10.1158\u002F1055-9965.EPI-13-0870\nWong, 2015, Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?, J Hepatol, 63, 722, 10.1016\u002Fj.jhep.2015.05.019\nKramvis, 2016, The clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics, Rev Med Virol, 26, 285, 10.1002\u002Frmv.1885\nKramvis, 2007, Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes, Hepatol Res, 37, S9, 10.1111\u002Fj.1872-034X.2007.00098.x\nSpearman, 2021, Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa, Lancet Gastroenterol Hepatol, 6, 1036, 10.1016\u002FS2468-1253(21)00275-2\nChang, 2010, Long-term entecavir therapy results in the reversal of fibrosis\u002Fcirrhosis and continued histological improvement in patients with chronic hepatitis B, Hepatology, 52, 886, 10.1002\u002Fhep.23785\nNguyen, 2019, Reduced incidence of hepatocellular carcinoma in cirrhotic and noncirrhotic patients with chronic hepatitis B treated with Tenofovir-A propensity Score-Matched study, J Infect Dis, 219, 10, 10.1093\u002Finfdis\u002Fjiy391\nWang, 2020, Nucleos(t)ide analogues for reducing hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis, Gut Liver, 14, 232, 10.5009\u002Fgnl18546\nArends, 2015, Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians, Gut, 64, 1289, 10.1136\u002Fgutjnl-2014-307023\nPapatheodoridis, 2015, Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort, J Viral Hepat, 22, 120, 10.1111\u002Fjvh.12283\nPapatheodoridis, 2017, The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B, Hepatology, 66, 1444, 10.1002\u002Fhep.29320\nChoi, 2021, Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis, Clin Gastroenterol Hepatol, 19, 246, 10.1016\u002Fj.cgh.2020.05.008\nHsu, 2020, Tenofovir versus entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B, Am J Gastroenterol, 115, 271, 10.14309\u002Fajg.0000000000000428\nIloeje, 2006, Predicting cirrhosis risk based on the level of circulating hepatitis B viral load, Gastroenterology, 130, 678, 10.1053\u002Fj.gastro.2005.11.016\nDusheiko, 2019, An appraisal of the WHO hepatitis B treatment guidelines applicability to Africans, J Hepatol, 70, 1046, 10.1016\u002Fj.jhep.2019.03.009\n2015\nYoshida, 2019, Clinical utility of TREAT-B score in African and non-African HBV-infected patients living in Europe, J Hepatol, 70, 1295, 10.1016\u002Fj.jhep.2019.03.008\nDesalegn, 2018, Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia, BMC Med, 16, 234, 10.1186\u002Fs12916-018-1229-x\nCuenca-Gomez, 2018, Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice, BMC Infect Dis, 18, 568, 10.1186\u002Fs12879-018-3469-y\nPeralta, 2011, Racial and ethnic differences in kidney function decline among persons without chronic kidney disease, J Am Soc Nephrol, 22, 1327, 10.1681\u002FASN.2010090960\nCappuccio, 1997, Prevalence, detection, and management of cardiovascular risk factors in different ethnic groups in south London, Heart, 78, 555, 10.1136\u002Fhrt.78.6.555\nVilla, 2018, Renal health after long-term exposure to tenofovir disoproxil fumarate (TDF) in HIV\u002FHBV positive adults in Ghana, J Infect, 76, 515\nSurial, 2020, Brief report: switching from TDF to TAF in HIV\u002FHBV-coinfected individuals with renal dysfunction-A prospective cohort study, J Acquir Immune Defic Syndr, 85, 227, 10.1097\u002FQAI.0000000000002429\nMallon, 2021, Weight gain before and after switch from TDF to TAF in a U.S. cohort study, J Int AIDS Soc, 24\nByrne, 2014, Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection, J Hepatol, 61, 210, 10.1016\u002Fj.jhep.2014.04.001\nEggemoen, 2013, Vitamin D status in recently arrived immigrants from Africa and Asia: a cross-sectional study from Norway of children, adolescents and adults, BMJ Open, 3, 10.1136\u002Fbmjopen-2013-003293\nMokaya, 2020, Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: an observational case series of South African adults, J Clin Virol, 129, 10.1016\u002Fj.jcv.2020.104548\nBuster, 2009, Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa, Gastroenterology, 137, 2002, 10.1053\u002Fj.gastro.2009.08.061\nAgarwal, 2022, A case of HBV-induced liver failure in the REEF-2 phase II trial: implications for finite treatment strategies in HBV ‘cure’, J Hepatol, 77, 245, 10.1016\u002Fj.jhep.2022.03.006\nvan Bommel, 2021, Risks and benefits of discontinuation of nucleos(t)ide analogue treatment: a treatment concept for patients with HBeAg-negative chronic hepatitis B, Hepatol Commun, 5, 1632, 10.1002\u002Fhep4.1708\nHadziyannis, 2012, Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir, Gastroenterology, 143, 629, 10.1053\u002Fj.gastro.2012.05.039\nBerg, 2017, Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study, J Hepatol, 67, 918, 10.1016\u002Fj.jhep.2017.07.012\nPapatheodoridis, 2016, Discontinuation of oral antivirals in chronic hepatitis B: a systematic review, Hepatology, 63, 1481, 10.1002\u002Fhep.28438\nHall, 2022, Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis, Gut, 71, 1629\nLiu, 2019, The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among asian patients with chronic hepatitis B: a systematic review, Hepatology, 70, 1045, 10.1002\u002Fhep.30474\nSonneveld, 2022, Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels, J Hepatol, 76, 1042, 10.1016\u002Fj.jhep.2022.01.007\nJeng, 2013, Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients, Hepatology, 58, 1888, 10.1002\u002Fhep.26549\nYeo, 2019, Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis, Gastroenterology, 156, 635, 10.1053\u002Fj.gastro.2018.10.027\nShimakawa, 2016, Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from the Gambia, Gut, 65, 2007, 10.1136\u002Fgutjnl-2015-309892\nHwenda, 2022, The African Medicines Agency: the key to unlocking clinical research in Africa, Lancet Glob Health, 10, e1088, 10.1016\u002FS2214-109X(22)00243-1\nToto, 2020, Conducting clinical trials in sub-Saharan Africa: challenges and lessons learned from the Malawi Cryptosporidium study, Trials, 21, 680, 10.1186\u002Fs13063-020-04620-8\nHanass-Hancock, 2021, Participants' characteristics and motivations to screen for HIV vaccine and monoclonal antibody trials in KwaZulu-Natal, South Africa, Trials, 22, 897, 10.1186\u002Fs13063-021-05792-7\nKarita, 2009, CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa, PLoS One, 4, 10.1371\u002Fjournal.pone.0004401\nNeuschwander-Tetri, 2008, Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels, Arch Intern Med, 168, 663, 10.1001\u002Farchinternmed.2007.131\nHaddy, 1999, Benign ethnic neutropenia: what is a normal absolute neutrophil count?, J Lab Clin Med, 133, 15, 10.1053\u002Flc.1999.v133.a94931\nLakhotia, 2019, Natural history of benign ethnic neutropenia in individuals of African ancestry, Blood Cells Mol Dis, 77, 12, 10.1016\u002Fj.bcmd.2019.01.009\nVastola, 2018, Laboratory eligibility criteria as potential barriers to participation by Black men in prostate cancer clinical trials, JAMA Oncol, 4, 413, 10.1001\u002Fjamaoncol.2017.4658\nTian, 2022, Feasibility of hepatitis B elimination in high-income countries with ongoing immigration, J Hepatol, 77, 947, 10.1016\u002Fj.jhep.2022.04.014\nKim, 2021, Improving care of migrants is key for viral hepatitis elimination in Europe, Bull World Health Organ, 99, 280, 10.2471\u002FBLT.20.260919\nMartin, 2019, Chronic hepatitis B virus case-finding in UK populations born abroad in intermediate or high endemicity countries: an economic evaluation, BMJ Open, 9, 10.1136\u002Fbmjopen-2019-030183\nHargreaves, 2020, Delivering multi-disease screening to migrants for latent TB and blood-borne viruses in an emergency department setting: a feasibility study, Trav Med Infect Dis, 36, 10.1016\u002Fj.tmaid.2020.101611\nShimakawa, 2022, Rapid point-of-care test for hepatitis B core-related antigen to diagnose high viral load in resource-limited settings, Clin Gastroenterol Hepatol, 10.1016\u002Fj.cgh.2022.05.026\nFreeland, 2020, Barriers to hepatitis B screening and prevention for African immigrant populations in the United States: a qualitative study, Viruses, 12, 10.3390\u002Fv12030305\nAdjei, 2020, “To die is better than to tell”: reasons for and against disclosure of chronic hepatitis B status in Ghana, BMC Public Health, 20, 663, 10.1186\u002Fs12889-020-08811-5\nMude, 2019, A qualitative investigation of barriers, support-seeking and coping among South Sudanese people with chronic hepatitis B in Australia, Aust J Prim Health, 10.1071\u002FPY19015\nSaunders, 2021, Healthcare utilization among migrants to the UK: cross-sectional analysis of two national surveys, J Health Serv Res Pol, 26, 54, 10.1177\u002F1355819620911392\nLai, 1998, A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group, N Engl J Med, 339, 61, 10.1056\u002FNEJM199807093390201\nHadziyannis, 2003, Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B, N Engl J Med, 348, 800, 10.1056\u002FNEJMoa021812\nChang, 2006, A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B, N Engl J Med, 354, 1001, 10.1056\u002FNEJMoa051285\nMarcellin, 2008, Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B, N Engl J Med, 359, 2442, 10.1056\u002FNEJMoa0802878\nButi, 2016, Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial, Lancet Gastroenterol Hepatol, 1, 196, 10.1016\u002FS2468-1253(16)30107-8\nChan, 2016, Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial, Lancet Gastroenterol Hepatol, 1, 185, 10.1016\u002FS2468-1253(16)30024-3\nBazinet, 2020, Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy, Gastroenterology, 158, 2180, 10.1053\u002Fj.gastro.2020.02.058",{"EN":2199},"Health inequalities in the management of chronic hepatitis B virus infection in patients from sub-Saharan Africa in high-income countries",{"VOID":2201},"10.1016\u002Fj.jhepr.2022.100623","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2589555922001951",[2204,2233,2245,2267],{"id":2205,"sortIndex":114,"researcher":26,"roles":2206,"affiliations":2207,"properties":2230},"1223c7a5-af56-4086-a62d-e01cdd06dc0b",[799],[2208,2218],{"id":26,"sortIndex":36,"affiliation":2209,"properties":26},{"id":2210,"createTime":2211,"updateTime":2212,"relativeEntities":2213,"slug":2214,"properties":2215,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"af530f5a-da06-4948-975c-dec06b9c0a09","2024-01-25T14:20:36.192+00:00","2024-09-24T23:04:34.800+00:00",[],"Institute-of-Liver-Studies-King-s-College-Hospital-London-United-Kingdom",{"title":2216},{"VI":2217},"Institute of Liver Studies, King's College Hospital, London, United Kingdom",{"id":2219,"sortIndex":115,"affiliation":2220,"properties":2229},"d0f0ad07-6bff-4efe-8568-fa15d3e61b18",{"id":2221,"createTime":2222,"updateTime":2223,"relativeEntities":2224,"slug":2225,"properties":2226,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"a9253ab5-8024-4b66-ab98-9a2131c7b5e5","2023-12-21T20:35:55.357+00:00","2024-12-03T03:17:53.785+00:00",[],"University-College-London-Medical-School-London-UK",{"title":2227},{"VI":2228},"University College London Medical School, London, UK",{},{"title":2231},{"VI":2232},"Geoffrey Dusheiko",{"id":2234,"sortIndex":59,"researcher":26,"roles":2235,"affiliations":2236,"properties":2242},"5523401d-d570-4f17-a608-123ec029b01a",[799],[2237],{"id":26,"sortIndex":36,"affiliation":2238,"properties":26},{"id":2210,"createTime":2211,"updateTime":2212,"relativeEntities":2239,"slug":2214,"properties":2240,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2241},{"VI":2217},{"title":2243},{"VI":2244},"Kosh Agarwal",{"id":2246,"sortIndex":36,"researcher":26,"roles":2247,"affiliations":2248,"properties":2264},"825090c2-5e10-49dd-a53a-7dfdc97f2753",[799],[2249,2259],{"id":2250,"sortIndex":115,"affiliation":2251,"properties":2258},"474baf49-4ec3-463b-b173-f991f4a693cb",{"id":2252,"createTime":2253,"updateTime":2253,"relativeEntities":2254,"slug":26,"properties":2255,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"cf33aabf-f8e7-4362-b752-61476bbad2ef","2023-12-19T12:41:30.298+00:00",[],{"title":2256},{"VI":2257},"Gastroenterology and Hepatology Department, Royal Perth Hospital, Perth, Australia",{},{"id":26,"sortIndex":36,"affiliation":2260,"properties":26},{"id":2210,"createTime":2211,"updateTime":2212,"relativeEntities":2261,"slug":2214,"properties":2262,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2263},{"VI":2217},{"title":2265},{"VI":2266},"Tim Mitchell",{"id":2268,"sortIndex":115,"researcher":26,"roles":2269,"affiliations":2270,"properties":2288},"f8bcda55-9b5e-4147-ab07-59c295fd5226",[799],[2271,2283],{"id":2272,"sortIndex":115,"affiliation":2273,"properties":2282},"128d8993-b88e-40bf-8498-a3270e96c5df",{"id":2274,"createTime":2275,"updateTime":2276,"relativeEntities":2277,"slug":2278,"properties":2279,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"36ebc585-0867-47bc-a948-cd853300b3f7","2023-11-26T18:25:51.101+00:00","2024-09-12T10:31:00.062+00:00",[],"Department-of-Inflammation-Biology-King-s-College-London-London-UK",{"title":2280},{"VI":2281},"Department of Inflammation Biology, King's College London, London, UK",{},{"id":26,"sortIndex":36,"affiliation":2284,"properties":26},{"id":2210,"createTime":2211,"updateTime":2212,"relativeEntities":2285,"slug":2214,"properties":2286,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2287},{"VI":2217},{"title":2289},{"VI":2290},"Jeremy S. Nayagam",{"url":2202,"publisher":2292,"properties":2321},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":2293,"slug":663,"properties":2294,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":114,"subjectFields":2299,"manageAffiliations":2300,"indexDatabases":2301,"url":768,"thumbnailPath":26,"statistic":2316,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"country":2295,"issn":2296,"introduce":2297,"title":2298},{"VOID":666},{"VOID":668},{"EN":670},{"EN":672},[],[],[2302,2309],{"id":747,"indexDatabase":2303,"url":760,"indexYears":761,"academicFieldIds":2308,"indexDatabaseRanking":767},{"id":749,"createTime":750,"updateTime":751,"relativeEntities":2304,"label":2305,"description":2306,"key":757,"publicationTags":2307,"standard":26},[],{"EN":754,"VI":754},{"EN":754,"VI":756},[759],[763,764,765,766],{"id":728,"indexDatabase":2310,"url":743,"indexYears":26,"academicFieldIds":2315,"indexDatabaseRanking":26},{"id":730,"createTime":731,"updateTime":732,"relativeEntities":2311,"label":2312,"description":2313,"key":739,"publicationTags":2314,"standard":26},[],{"EN":735,"VI":735},{"VI":737,"EN":738},[741,742],[745],{"impactFactor":36,"impactFactorByYear":2317,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":245,"totalPublicationByYear":2318,"totalCitation":36,"totalCitationByYear":2319,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":2320,"hindexLast5Year":36,"hindex":36},{},{"2019":158,"2020":111,"2021":124,"2022":298,"2023":287,"2024":59},{},{},{"volume":2322,"pages":2323},{"VOID":1027},{"VOID":2324},"100623",{"id":2326,"createTime":2327,"updateTime":2328,"relativeEntities":2329,"slug":2330,"properties":2331,"entityType":791,"verifyStatus":25,"verifyTime":2328,"verifyNote":793,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":2338,"fullTextUrl":26,"authors":2339,"publicationType":994,"publisherRelationship":2485,"citationCount":26,"citationInfo":26,"publishDate":2518,"publishYear":1033,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":26,"isForceReanalyzing":1185},"5649be2a-07f4-43be-abd8-b55a5efe4df0","2023-12-25T00:36:33.505+00:00","2025-02-11T11:06:40.847+00:00",[],"Biliary-disease-progression-in-childhood-onset-autoimmune-liver-disease-a-30-year-follow-up-into-adulthood",{"references":2332,"title":2334,"doi":2336},{"VOID":2333},"Mack, 2020, Diagnosis and management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases, Hepatology, 72, 671, 10.1002\u002Fhep.31065\nMieli-Vergani, 2018, Diagnosis and management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement, J Pediatr Gastroenterol Nutr, 66, 345, 10.1097\u002FMPG.0000000000001801\nHarrington, 2022, Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis, Hepatology, 76, 1862, 10.1002\u002Fhep.32591\nBoberg, 2011, Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue, J Hepatol, 54, 374, 10.1016\u002Fj.jhep.2010.09.002\nDi Giorgio, 2020, Seamless management of Juvenile Autoimmune Liver Disease: Long-Term medical and Social Outcome, J Pediatr, 218, 121, 10.1016\u002Fj.jpeds.2019.11.028\nMontano-Loza, 2021, Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver, Can Liver J, 4, 401, 10.3138\u002Fcanlivj-2021-0006\nRicciuto, 2023, Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: A coming of age or an age-ist problem?, J Hepatol, 79, 567, 10.1016\u002Fj.jhep.2023.02.030\nKerkar, 2018, Autoimmune Hepatitis, Sclerosing Cholangitis, and Autoimmune Sclerosing Cholangitis or Overlap Syndrome, Clin Liver Dis, 22, 689, 10.1016\u002Fj.cld.2018.06.005\nMataya, 2018, Autoimmune Liver Diseases in Children, Pediatr Ann, 47, e452, 10.3928\u002F19382359-20181022-02\nBeretta-Piccoli, 2018, Autoimmune sclerosing cholangitis: Evidence and open questions, J Autoimmun, 95, 15, 10.1016\u002Fj.jaut.2018.10.008\nKumar, 2021, Autoimmune Sclerosing Cholangitis in Children: A Prospective Case-Control Study, Pediatr Gastroenterol Hepatol Nutr, 24, 154, 10.5223\u002Fpghn.2021.24.2.154\nDi Giorgio, 2022, Cutting edge issues in juvenile sclerosing cholangitis, Dig Liver Dis, 54, 417, 10.1016\u002Fj.dld.2021.06.028\nRamonet, 2022, Autoimmune hepatitis in pediatrics, a review by the Working Group of the Latin American Society for Pediatric Gastroenterology, Hepatology, and Nutrition, Arch Argent Pediatr, 120, 281\nSebode, 2018, Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda, Liver Int, 38, 15, 10.1111\u002Fliv.13458\nSokollik, 2018, Juvenile autoimmune hepatitis: A comprehensive review, J Autoimmun, 95, 69, 10.1016\u002Fj.jaut.2018.10.007\nChapman, 2019, British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis, Gut, 68, 1356, 10.1136\u002Fgutjnl-2018-317993\nTrivedi, 2021, Recent advances in clinical practice: epidemiology of autoimmune liver diseases, Gut, 70, 1989, 10.1136\u002Fgutjnl-2020-322362\n2015, EASL Clinical Practice Guidelines: Autoimmune hepatitis, J Hepatol, 63, 971, 10.1016\u002Fj.jhep.2015.06.030\nMilkiewicz, 2020, Primary Sclerosing Cholangitis With Features of Autoimmune Hepatitis: Exploring the Global Variation in management, Hepatol Commun, 4, 399, 10.1002\u002Fhep4.1467\nMaggiore, 2023, Long-term outcomes of patients with type 1 or 2 autoimmune hepatitis presenting in childhood, J Hepatol, 78, 979, 10.1016\u002Fj.jhep.2023.01.013\nWiecek, 2021, Analysis of the Clinical Course of Primary Sclerosing Cholangitis in Paediatric Population-Single Center Study, Medicina (Kaunas), 57, 663, 10.3390\u002Fmedicina57070663\nGregorio, 2001, Autoimmune hepatitis\u002Fsclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study, Hepatology, 33, 544, 10.1053\u002Fjhep.2001.22131\nDi Giorgio, 2019, Biliary features in liver histology of children with autoimmune liver disease, Hepatol Int, 13, 510, 10.1007\u002Fs12072-019-09948-1\nDeneau, 2013, Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history, Hepatology, 58, 1392, 10.1002\u002Fhep.26454\nNayagam, 2022, Clinical course of inflammatory bowel disease and impact on liver disease outcomes in patients with autoimmune sclerosing cholangitis, Clin Res Hepatol Gastroenterol, 46, 10.1016\u002Fj.clinre.2022.101980\nRoepe, 2021, Presentation and Outcomes of Autoimmune Hepatitis Type 1 and Type 2 in Children: A Single-center Study, J Pediatr Gastroenterol Nutr, 72, 101, 10.1097\u002FMPG.0000000000002892\nCarbone, 2014, Autoimmune liver disease, autoimmunity and liver transplantation, J Hepatol, 60, 210, 10.1016\u002Fj.jhep.2013.09.020\nCouchonnal, 2021, Long-term results of pediatric liver transplantation for autoimmune liver disease, Clin Res Hepatol Gastroenterol, 45, 10.1016\u002Fj.clinre.2020.08.013\nRocha, 2022, Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases, Gastroenterol Hepatol, 45, 83, 10.1016\u002Fj.gastrohep.2021.03.011\nÇavuş, 2022, Is there any predictor for relapse after treatment withdrawal in autoimmune hepatitis patients in the real life?, Int J Immunopathol Pharmacol, 36, 10.1177\u002F03946320221077860\nVolk, 2021, Diagnosis and management of Autoimmune Hepatitis in Adults and Children: A Patient-Friendly Summary of the 2019 AASLD Guidelines, Clin Liver Dis (Hoboken), 17, 85, 10.1002\u002Fcld.1080\nDeneau, 2014, Outcome after discontinuation of immunosuppression in children with autoimmune hepatitis: a population-based study, J Pediatr, 164, 714, 10.1016\u002Fj.jpeds.2013.12.008",{"EN":2335},"Biliary disease progression in childhood onset autoimmune liver disease – a 30-year follow-up into adulthood",{"VOID":2337},"10.1016\u002Fj.jhepr.2023.100901","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS258955592300232X",[2340,2365,2397,2409,2435,2447,2466],{"id":2341,"sortIndex":135,"researcher":26,"roles":2342,"affiliations":2343,"properties":2362},"46f28020-4655-4049-ac91-0b5ae0781159",[799],[2344,2354],{"id":2345,"sortIndex":115,"affiliation":2346,"properties":2353},"f0439566-1c40-4064-b014-7d0e2c3848d6",{"id":2347,"createTime":2348,"updateTime":2348,"relativeEntities":2349,"slug":26,"properties":2350,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"30075fb0-a7ea-4fa5-be5a-380b0341f59a","2023-12-25T00:36:33.606+00:00",[],{"title":2351},{"VI":2352},"Toronto Centre for Liver Disease, Department of Medicine, University of Toronto, Toronto, Canada",{},{"id":26,"sortIndex":36,"affiliation":2355,"properties":26},{"id":2356,"createTime":2357,"updateTime":2357,"relativeEntities":2358,"slug":26,"properties":2359,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"30bf8149-b8fe-4ac2-b4e1-d12a3f7c3ddf","2023-12-25T00:36:33.602+00:00",[],{"title":2360},{"VI":2361},"NIHR Biomedical Research Centre, University Hospitals Birmingham, Birmingham, UK",{"title":2363},{"VI":2364},"Hirschfield GM",{"id":2366,"sortIndex":115,"researcher":26,"roles":2367,"affiliations":2368,"properties":2394},"0bf30b06-0b7c-421a-8d21-63dae6ef3ad2",[799],[2369,2376,2386],{"id":2370,"sortIndex":114,"affiliation":2371,"properties":2375},"ed38b642-c2db-4890-9e83-b65e92c01a9e",{"id":2356,"createTime":2357,"updateTime":2357,"relativeEntities":2372,"slug":26,"properties":2373,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2374},{"VI":2361},{},{"id":2377,"sortIndex":115,"affiliation":2378,"properties":2385},"a76fb8e6-5987-43f4-8df6-f616387aa082",{"id":2379,"createTime":2380,"updateTime":2380,"relativeEntities":2381,"slug":26,"properties":2382,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"41e039c3-f1fd-450b-977f-4dad2809e94f","2023-12-25T00:36:33.592+00:00",[],{"title":2383},{"VI":2384},"Liver Unit, Birmingham Women’s & Children’s Hospital, Birmingham, UK",{},{"id":26,"sortIndex":36,"affiliation":2387,"properties":26},{"id":2388,"createTime":2389,"updateTime":2389,"relativeEntities":2390,"slug":26,"properties":2391,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"32b8e48d-8115-4c43-806f-63759b0f6ca8","2023-12-25T00:36:33.576+00:00",[],{"title":2392},{"VI":2393},"Centre for Liver and Gastrointestinal Research, University of Birmingham, Birmingham, UK",{"title":2395},{"VI":2396},"Rajanayagam J",{"id":2398,"sortIndex":114,"researcher":26,"roles":2399,"affiliations":2400,"properties":2406},"62a7aeb7-6352-4785-a918-d469c3c594a5",[799],[2401],{"id":26,"sortIndex":36,"affiliation":2402,"properties":26},{"id":2388,"createTime":2389,"updateTime":2389,"relativeEntities":2403,"slug":26,"properties":2404,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2405},{"VI":2393},{"title":2407},{"VI":2408},"Russell E",{"id":2410,"sortIndex":36,"researcher":26,"roles":2411,"affiliations":2412,"properties":2432},"9fffb350-5ffb-4107-a550-b5d6381f4611",[799],[2413,2420,2427],{"id":2414,"sortIndex":114,"affiliation":2415,"properties":2419},"9a40d650-f764-43f5-9c78-dd997abb0c4c",{"id":2356,"createTime":2357,"updateTime":2357,"relativeEntities":2416,"slug":26,"properties":2417,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2418},{"VI":2361},{},{"id":2421,"sortIndex":115,"affiliation":2422,"properties":2426},"b6954b8c-ac15-411b-82ce-b78925ff950f",{"id":2379,"createTime":2380,"updateTime":2380,"relativeEntities":2423,"slug":26,"properties":2424,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2425},{"VI":2384},{},{"id":26,"sortIndex":36,"affiliation":2428,"properties":26},{"id":2388,"createTime":2389,"updateTime":2389,"relativeEntities":2429,"slug":26,"properties":2430,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2431},{"VI":2393},{"title":2433},{"VI":2434},"Warner S",{"id":2436,"sortIndex":59,"researcher":26,"roles":2437,"affiliations":2438,"properties":2444},"aa17d0b2-a2eb-4771-807b-781759d79c25",[799],[2439],{"id":26,"sortIndex":36,"affiliation":2440,"properties":26},{"id":2379,"createTime":2380,"updateTime":2380,"relativeEntities":2441,"slug":26,"properties":2442,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2443},{"VI":2384},{"title":2445},{"VI":2446},"Lloyd C",{"id":2448,"sortIndex":111,"researcher":26,"roles":2449,"affiliations":2450,"properties":2463},"75544b02-2ca6-4794-8b34-101efe2b5c2f",[799],[2451,2458],{"id":2452,"sortIndex":115,"affiliation":2453,"properties":2457},"b255f586-2b4b-4251-bf47-efd1fec5742c",{"id":2356,"createTime":2357,"updateTime":2357,"relativeEntities":2454,"slug":26,"properties":2455,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2456},{"VI":2361},{},{"id":26,"sortIndex":36,"affiliation":2459,"properties":26},{"id":2388,"createTime":2389,"updateTime":2389,"relativeEntities":2460,"slug":26,"properties":2461,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2462},{"VI":2393},{"title":2464},{"VI":2465},"Ferguson J",{"id":2467,"sortIndex":162,"researcher":26,"roles":2468,"affiliations":2469,"properties":2482},"3e7e129c-63a8-465e-b82a-b9fc0702f221",[799],[2470,2475],{"id":26,"sortIndex":36,"affiliation":2471,"properties":26},{"id":2388,"createTime":2389,"updateTime":2389,"relativeEntities":2472,"slug":26,"properties":2473,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2474},{"VI":2393},{"id":2476,"sortIndex":115,"affiliation":2477,"properties":2481},"d3a217d1-e43f-4a4a-aff0-5bdb9d6708e5",{"id":2379,"createTime":2380,"updateTime":2380,"relativeEntities":2478,"slug":26,"properties":2479,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2480},{"VI":2384},{},{"title":2483},{"VI":2484},"Kelly D. A",{"url":2338,"publisher":2486,"properties":2515},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":2487,"slug":663,"properties":2488,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":114,"subjectFields":2493,"manageAffiliations":2494,"indexDatabases":2495,"url":768,"thumbnailPath":26,"statistic":2510,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"country":2489,"issn":2490,"introduce":2491,"title":2492},{"VOID":666},{"VOID":668},{"EN":670},{"EN":672},[],[],[2496,2503],{"id":747,"indexDatabase":2497,"url":760,"indexYears":761,"academicFieldIds":2502,"indexDatabaseRanking":767},{"id":749,"createTime":750,"updateTime":751,"relativeEntities":2498,"label":2499,"description":2500,"key":757,"publicationTags":2501,"standard":26},[],{"EN":754,"VI":754},{"EN":754,"VI":756},[759],[763,764,765,766],{"id":728,"indexDatabase":2504,"url":743,"indexYears":26,"academicFieldIds":2509,"indexDatabaseRanking":26},{"id":730,"createTime":731,"updateTime":732,"relativeEntities":2505,"label":2506,"description":2507,"key":739,"publicationTags":2508,"standard":26},[],{"EN":735,"VI":735},{"VI":737,"EN":738},[741,742],[745],{"impactFactor":36,"impactFactorByYear":2511,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":245,"totalPublicationByYear":2512,"totalCitation":36,"totalCitationByYear":2513,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":2514,"hindexLast5Year":36,"hindex":36},{},{"2019":158,"2020":111,"2021":124,"2022":298,"2023":287,"2024":59},{},{},{"pages":2516},{"VOID":2517},"100901","2023-09-01",{"id":2520,"createTime":2521,"updateTime":2522,"relativeEntities":2523,"slug":2524,"properties":2525,"entityType":791,"verifyStatus":25,"verifyTime":2522,"verifyNote":793,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":2532,"fullTextUrl":26,"authors":2533,"publicationType":994,"publisherRelationship":2688,"citationCount":26,"citationInfo":26,"publishDate":2722,"publishYear":1033,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":26,"isForceReanalyzing":1185},"70edbafc-b060-49be-8423-fb2373ea2ccf","2024-01-15T07:41:38.684+00:00","2024-12-07T05:40:43.938+00:00",[],"Management-of-splanchnic-vein-thrombosis",{"references":2526,"title":2528,"doi":2530},{"VOID":2527},"Jones, 2018, Access to care in rare liver diseases: new challenges and new opportunities, J Hepatol, 68, 577, 10.1016\u002Fj.jhep.2017.11.004\nDe Gottardi, 2022, Porto-sinusoidal vascular disorder, J Hepatol, 77, 1124, 10.1016\u002Fj.jhep.2022.05.033\nDenninger, 2000, Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors, Hepatology, 31, 587, 10.1002\u002Fhep.510310307\nDarwish Murad, 2009, Etiology, management, and outcome of the Budd-Chiari syndrome, Ann Intern Med, 151, 167, 10.7326\u002F0003-4819-151-3-200908040-00004\nPlessier, 2010, Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study, Hepatology, 51, 210, 10.1002\u002Fhep.23259\nPoisson, 2017, Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: a prospective cohort study, J Hepatol, 67, 501, 10.1016\u002Fj.jhep.2017.04.021\nBureau, 2016, Central obesity is associated with non-cirrhotic portal vein thrombosis, J Hepatol, 64, 427, 10.1016\u002Fj.jhep.2015.08.024\nChagneau-Derrode, 2013, Impact of cytoreductive therapy on the outcome of patients with myeloproliferative neoplasms and hepato-splanchnic vein thrombosis, Hepatology, 58, 847A\nDesbois, 2014, Behcet’s disease in Budd-Chiari syndrome, Orphanet J Rare Dis, 9, 104, 10.1186\u002Fs13023-014-0153-1\nMagaz, 2021, Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis, J Hepatol, 74, 89, 10.1016\u002Fj.jhep.2020.06.045\nPlessier, 2022, Paroxysmal nocturnal hemoglobinuria and vascular liver disease: eculizumab therapy decreases mortality and thrombotic complications, Am J Hematol, 10.1002\u002Fajh.26474\nSmalberg, 2012, Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis, Blood, 120, 4921, 10.1182\u002Fblood-2011-09-376517\nTuron, 2015, Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis, J Hepatol, 62, 72, 10.1016\u002Fj.jhep.2014.08.032\nPlompen, 2015, Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis, Haematologica, 10.3324\u002Fhaematol.2014.120857\nQi, 2016, Review article: the aetiology of primary Budd-Chiari syndrome - differences between the West and China, Aliment Pharmacol Ther, 44, 1152, 10.1111\u002Fapt.13815\nFan, 2020, Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: a hospital-based observational study, J Gastroenterol Hepatol, 35, 1215, 10.1111\u002Fjgh.14925\nDebureaux, 2020, Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses, Blood Adv, 4, 3708\nKiladjian, 2021, Benefits of molecular profiling with next-generation sequencing for the diagnosis and prognosis of myeloproliferative neoplasms in splanchnic vein thrombosis, J Hepatol, 74, 251, 10.1016\u002Fj.jhep.2020.07.043\nChait, 2005, Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis, Br J Haematol, 129, 553, 10.1111\u002Fj.1365-2141.2005.05490.x\nLevine, 2002, The antiphospholipid syndrome, New Engl J Med, 346, 752, 10.1056\u002FNEJMra002974\nQi, 2015, Associations of antiphospholipid antibodies with splanchnic vein thrombosis: a systematic review with meta-analysis, Medicine (Baltimore), 94, e496, 10.1097\u002FMD.0000000000000496\nSakr, 2020, Characteristics and outcome of primary Budd-Chiari syndrome due to Behçet’s syndrome, Clin Res Hepatol Gastroenterol, 44, 503, 10.1016\u002Fj.clinre.2019.10.006\nHoekstra, 2009, Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study, J Hepatol, 51, 696, 10.1016\u002Fj.jhep.2009.06.019\nAfredj, 2015, Aetiological factors of Budd-Chiari syndrome in Algeria, World J Hepatol, 7, 903, 10.4254\u002Fwjh.v7.i6.903\nDe Broucker, 2022, Multicenter study on recent portal venous system thrombosis associated with cytomegalovirus disease, J Hepatol, 76, 115, 10.1016\u002Fj.jhep.2021.09.011\nBuso, 2021, Acute splanchnic vein thrombosis in patients with COVID-19: a systematic review, Dig Liver Dis, 53, 937, 10.1016\u002Fj.dld.2021.05.021\nHippisley-Cox, 2021, Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study, BMJ, 374, n1931, 10.1136\u002Fbmj.n1931\nBaiges, 2022, Impact of SARS-CoV-2 pandemic on vascular liver diseases, Clin Gastroenterol Hepatol, 20, 1525, 10.1016\u002Fj.cgh.2021.12.032\nQi, 2014, Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis, Clin Gastroenterol Hepatol, 12, 1801, 10.1016\u002Fj.cgh.2014.04.026\nFisher, 2000, Deficiency of natural anticoagulant proteins C, S, and antithrombin in portal vein thrombosis: a secondary phenomenon?, Gut, 46, 534, 10.1136\u002Fgut.46.4.534\nBaiges, 2020, Congenital antithrombin deficiency in patients with splanchnic vein thrombosis, Liver Int, 40, 1168, 10.1111\u002Fliv.14342\nQi, 2014, Methylenetetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia in Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis of observational studies, Hepatol Res, 44, E480, 10.1111\u002Fhepr.12348\nBissonnette, 2015, Pregnancy and vascular liver disease, J Clin Exp Hepatol, 5, 41, 10.1016\u002Fj.jceh.2014.12.007\nJanssen, 2000, Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study, Blood, 96, 2364\nRajani, 2010, The epidemiology and clinical features of portal vein thrombosis: a multicentre study, Aliment Pharmacol Ther, 32, 1154, 10.1111\u002Fj.1365-2036.2010.04454.x\nSoret, 2020, Risk factors for vascular liver diseases: vascular liver diseases: position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver, Clin Res Hepatol Gastroenterol, 44, 410, 10.1016\u002Fj.clinre.2020.03.010\nRebours, 2012, Extrahepatic portal venous system thrombosis in recurrent acute and chronic alcoholic pancreatitis is caused by local inflammation and not thrombophilia, Am J Gastroenterol, 107, 1579, 10.1038\u002Fajg.2012.231\nVan Wettere, 2018, Diagnosis of Budd-Chiari syndrome, Abdom Radiol (NY), 43, 1896, 10.1007\u002Fs00261-017-1447-2\nValla, 2018, Budd-Chiari syndrome\u002Fhepatic venous outflow tract obstruction, Hepatol Int, 12, 168, 10.1007\u002Fs12072-017-9810-5\nOllivier-Hourmand, 2018, The epidemiology of Budd-Chiari syndrome in France, Dig Liver Dis, 50, 931, 10.1016\u002Fj.dld.2018.04.004\nPlessier, 2006, Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome, Hepatology, 44, 1308, 10.1002\u002Fhep.21354\nNorthup, 2021, Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American association for the study of liver diseases, Hepatology, 73, 366, 10.1002\u002Fhep.31646\nde Franchis, 2021, Baveno VII - renewing consensus in portal hypertension, J Hepatol\nEapen, 2006, Favourable medium term outcome following hepatic vein recanalisation and\u002For transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome, Gut, 55, 878, 10.1136\u002Fgut.2005.071423\nSeijo, 2013, Good long-term outcome of Budd-Chiari syndrome with a step-wise management, Hepatology, 57, 1962, 10.1002\u002Fhep.26306\nTripathi, 2014, Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in Budd-Chiari syndrome, Aliment Pharmacol Ther, 39, 864, 10.1111\u002Fapt.12668\nRautou, 2009, Prognostic indices for Budd-Chiari syndrome: valid for clinical studies but insufficient for individual management, Am J Gastroenterol, 104, 1140, 10.1038\u002Fajg.2009.63\nGarcia-Pagán, 2008, TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients, Gastroenterology, 135, 808, 10.1053\u002Fj.gastro.2008.05.051\n2016, Vascular diseases of the liver, J Hepatol, 64, 179, 10.1016\u002Fj.jhep.2015.07.040\nZeitoun, 1999, Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting, Hepatology, 30, 84, 10.1002\u002Fhep.510300125\nAl-Jafar, 2015, Long standing eculizumab treatment without anticoagulant therapy in high-risk thrombogenic paroxysmal nocturnal hemoglobinuria, Hematol Rep, 7, 5927, 10.4081\u002Fhr.2015.5927\nRandi, 2010, Heparin-induced thrombocytopenia in patients with Philadelphia-negative myeloproliferative disorders and unusual splanchnic or cerebral vein thrombosis, Acta Haematol, 123, 140, 10.1159\u002F000280466\nZaman, 2016, Increased prevalence of heparin-induced thrombocytopenia in patients with Budd-Chiari syndrome: a retrospective analysis, Eur J Gastroenterol Hepatol, 28, 967, 10.1097\u002FMEG.0000000000000632\nDe Gottardi, 2016, Antithrombotic treatment with direct-acting oral anticoagulants (DOACs) in patients with splanchnic vein thrombosis and cirrhosis, Liver Int\nSemmler, 2022, Outcome of Budd-Chiari syndrome (BCS) patients treated with direct oral anticoagulants (DOACs) - an Austrian multicenter study, Clin Gastroenterol Hepatol, S1542–3565, 449\nSharma, 2020, Dabigatran as an oral anticoagulant in patients with Budd-Chiari syndrome post-percutaneous endovascular intervention, J Gastroenterol Hepatol, 35, 654, 10.1111\u002Fjgh.14843\nDufrost, 2021, Direct oral anticoagulants in antiphospholipid syndrome: meta-analysis of randomized controlled trials, Autoimmun Rev, 20, 10.1016\u002Fj.autrev.2020.102711\nRautou, 2011, Bleeding in patients with Budd–Chiari syndrome, J Hepatol, 54, 56, 10.1016\u002Fj.jhep.2010.06.019\nMukund, 2018, Budd–Chiari syndrome: a focussed and collaborative approach, Hepatol Int, 12, 483, 10.1007\u002Fs12072-018-9900-z\nWang, 2019, Angioplasty with versus without routine stent placement for Budd-Chiari syndrome: a randomised controlled trial, Lancet Gastroenterol Hepatol, 4, 686, 10.1016\u002FS2468-1253(19)30177-3\nHayek, 2017, Long-term outcome and analysis of dysfunction of transjugular intrahepatic portosystemic shunt placement in chronic primary Budd-Chiari syndrome, Radiology, 283, 280, 10.1148\u002Fradiol.2016152641\nLanglet, 2002, Is surgical portosystemic shunt the treatment of choice in Budd-Chiari syndrome?, Acta Gastroenterol Belg, 65, 155\nBachet, 2007, Long-term portosystemic shunt patency as a determinant of outcome in Budd-Chiari syndrome, J Hepatol, 46, 60, 10.1016\u002Fj.jhep.2006.08.016\nSegev, 2007, Twenty years of liver transplantation for Budd-Chiari syndrome: a national registry analysis, Liver Transplant, 13, 1285, 10.1002\u002Flt.21220\nRautou, 2009, Pregnancy in women with known and treated Budd-Chiari syndrome: maternal and fetal outcomes, J Hepatol, 51, 47, 10.1016\u002Fj.jhep.2009.02.028\nKhan, 2017, Outcomes of pregnancy in patients with known Budd-Chiari syndrome, World J Hepatol, 9, 945, 10.4254\u002Fwjh.v9.i21.945\nShukla, 2018, Pregnancy outcomes in women with Budd Chiari Syndrome before onset of symptoms and after treatment, Liver Int, 38, 754, 10.1111\u002Fliv.13552\nBates, 2012, VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines, Chest, 141, e691S, 10.1378\u002Fchest.11-2300\nMoucari, 2008, Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors, Gut, 57, 828, 10.1136\u002Fgut.2007.139477\nGwon, 2010, Hepatocellular carcinoma associated with membranous obstruction of the inferior vena cava: incidence, characteristics, and risk factors and clinical efficacy of TACE, Radiology, 254, 617, 10.1148\u002Fradiol.09090738\nSempoux, 2018, Hepatocellular nodules in vascular liver diseases, Virchows Arch, 473, 33, 10.1007\u002Fs00428-018-2373-6\nVilgrain, 2018, Benign and malignant hepatocellular lesions in patients with vascular liver diseases, Abdom Radiol (NY), 43, 1968, 10.1007\u002Fs00261-018-1502-7\nVan Wettere, 2019, Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with Budd-Chiari syndrome, J Hepatol, 70, 1123, 10.1016\u002Fj.jhep.2019.01.009\nPaul, 2015, Incidence and risk factors of hepatocellular carcinoma in patients with hepatic venous outflow tract obstruction, Aliment Pharmacol Ther, 41, 961, 10.1111\u002Fapt.13173\nVan Wettere, 2020, Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome, JHEP Rep, 2\nNuzzo, 2017, Predictive factors of intestinal necrosis in acute mesenteric ischemia: prospective study from an intestinal stroke center, Am J Gastroenterol, 112, 597, 10.1038\u002Fajg.2017.38\nBerzigotti, 2014, Imaging in clinical decision-making for portal vein thrombosis, Nat Rev Gastroenterol Hepatol, 11, 308, 10.1038\u002Fnrgastro.2013.258\nElkrief, 2013, Type 2 diabetes mellitus as a risk factor for intestinal resection in patients with superior mesenteric vein thrombosis, Liver Int Off J Int Assoc Study Liver\nNoronha Ferreira, 2016, Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis, Hepatology, 63, 1640, 10.1002\u002Fhep.28466\nDe Gaetano, 1995, Cavernous transformation of the portal vein: patterns of intrahepatic and splanchnic collateral circulation detected with Doppler sonography, AJR Am J Roentgenol, 165, 1151, 10.2214\u002Fajr.165.5.7572494\nSharma, 2012, Liver and spleen stiffness in patients with extrahepatic portal vein obstruction, Radiology, 263, 893, 10.1148\u002Fradiol.12111046\nAcosta, 2008, Epidemiology, risk and prognostic factors in mesenteric venous thrombosis, Br J Surg, 95, 1245, 10.1002\u002Fbjs.6319\nNuzzo, 2019, Oral antibiotics reduce intestinal necrosis in acute mesenteric ischemia: a prospective cohort study, Am J Gastroenterol, 114, 348, 10.1038\u002Fs41395-018-0389-9\nCondat, 2000, Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy, Hepatology, 32, 466, 10.1053\u002Fjhep.2000.16597\nTurnes, 2008, Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation, Clin Gastroenterol Hepatol, 6, 1412, 10.1016\u002Fj.cgh.2008.07.031\nAmitrano, 2007, Prognostic factors in noncirrhotic patients with splanchnic vein thromboses, Am J Gastroenterol, 102, 2464, 10.1111\u002Fj.1572-0241.2007.01477.x\nValeriani, 2020, Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis, Blood\nPlessier, 2022, Rivaroxaban prophylaxis in noncirrhotic portal vein thrombosis, NEJM Evid, 1, 10.1056\u002FEVIDoa2200104\nGuillaume, 2018, Bleeding risk of variceal band ligation in extrahepatic portal vein obstruction is not increased by oral anticoagulation, Eur J Gastroenterol Hepatol, 30, 563, 10.1097\u002FMEG.0000000000001061\nHernández-Gea, 2019, Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis, J Hepatol, 71, 175, 10.1016\u002Fj.jhep.2019.02.015\nBenmassaoud, 2019, A stepwise thrombolysis regimen in the management of acute portal vein thrombosis in patients with evidence of intestinal ischaemia, Aliment Pharmacol Ther, 50, 1049, 10.1111\u002Fapt.15479\nMarot, 2018, Percutaneous portal vein recanalization using self-expandable nitinol stents in patients with non-cirrhotic non-tumoral portal vein occlusion, Diagn Interv Imaging\nFanelli, 2011, Transjugular intrahepatic portosystemic shunt with expanded-polytetrafuoroethylene-covered stents in non-cirrhotic patients with portal cavernoma, Dig Liver Dis, 43, 78, 10.1016\u002Fj.dld.2010.06.001\nKnight, 2021, TIPS for adults without cirrhosis with chronic mesenteric venous thrombosis and EHPVO refractory to standard-of-care therapy, Hepatology, 74, 2735, 10.1002\u002Fhep.31915\nArtru, 2022, Portal vein recanalisation alone to treat severe portal hypertension in non-cirrhotic patients with chronic extrahepatic portal vein obstruction, JHEP Rep, 4\nAggarwal, 2011, Extra hepatic portal vein obstruction and pregnancy outcome: largest reported experience, J Obstet Gynaecol Res, 37, 575, 10.1111\u002Fj.1447-0756.2010.01407.x\nMandal, 2012, Is pregnancy safe with extrahepatic portal vein obstruction? An analysis, Singapore Med J, 53, 676\nHoekstra, 2012, Pregnancy in women with portal vein thrombosis: results of a multicentric European study on maternal and fetal management and outcome, J Hepatol, 57, 1214, 10.1016\u002Fj.jhep.2012.07.034\nDhiman, 2014, Portal cavernoma cholangiopathy: consensus statement of a working party of the Indian national association for study of the liver, J Clin Exp Hepatol, 4, S2, 10.1016\u002Fj.jceh.2014.02.003\nDhiman, 2007, Portal hypertensive biliopathy, Gut, 56, 1001, 10.1136\u002Fgut.2006.103606\nPuri, 2014, Pathogenesis of portal cavernoma cholangiopathy: is it compression by collaterals or ischemic injury to bile ducts during portal vein thrombosis?, J Clin Exp Hepatol, 4, S27, 10.1016\u002Fj.jceh.2013.05.015\nCondat, 2003, Portal cavernoma-associated cholangiopathy: a clinical and MR cholangiography coupled with MR portography imaging study, Hepatology, 37, 1302, 10.1053\u002Fjhep.2003.50232\nMalkan, 1999, Cholangiopathy associated with portal hypertension: diagnostic evaluation and clinical implications, Gastrointest Endosc, 49, 344, 10.1016\u002FS0016-5107(99)70011-8\nLlop, 2011, Portal cholangiopathy: radiological classification and natural history, Gut, 60, 853, 10.1136\u002Fgut.2010.230201\nSenzolo, 2021, Current knowledge and management of portal vein thrombosis in cirrhosis, J Hepatol, 75, 442, 10.1016\u002Fj.jhep.2021.04.029\nNery, 2015, Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study, Hepatology, 61, 660, 10.1002\u002Fhep.27546\nFrancoz, 2012, Portal vein thrombosis, cirrhosis, and liver transplantation, J Hepatol, 57, 203, 10.1016\u002Fj.jhep.2011.12.034\nTuron, 2021, Predicting portal thrombosis in cirrhosis: a prospective study of clinical, ultrasonographic and hemostatic factors, J Hepatol, 75, 1367, 10.1016\u002Fj.jhep.2021.07.020\nFortea, 2020, Portal thrombosis in cirrhosis: role of thrombophilic disorders, J Clin Med, 9, E2822\nAyala, 2012, Obesity is an independent risk factor for pre-transplant portal vein thrombosis in liver recipients, BMC Gastroenterol, 12, 114, 10.1186\u002F1471-230X-12-114\nAbdel-Razik, 2015, De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the Model for End-stage Liver Disease scoring system, Eur J Gastroenterol Hepatol, 27, 585, 10.1097\u002FMEG.0000000000000325\nMangia, 2005, Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors, Eur J Gastroenterol Hepatol, 17, 745, 10.1097\u002F00042737-200507000-00009\nZocco, 2009, Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development, J Hepatol, 51, 682, 10.1016\u002Fj.jhep.2009.03.013\nNery, 2019, Nonselective beta-blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study, Aliment Pharmacol Ther, 49, 582, 10.1111\u002Fapt.15137\nXu, 2019, Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis, Hepatol Int, 13, 468, 10.1007\u002Fs12072-019-09951-6\nZanetto, 2022, Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications, Liver Int, 42, 1229, 10.1111\u002Fliv.15183\nSherman, 2019, Distinguishing tumor from bland portal vein thrombus in liver transplant candidates with hepatocellular carcinoma: the A-VENA criteria, Liver Transpl, 25, 207, 10.1002\u002Flt.25345\nDodd, 1993, Percutaneous biopsy of portal vein thrombus: a new staging technique for hepatocellular carcinoma, AJR Am J Roentgenol, 161, 229, 10.2214\u002Fajr.161.2.8392785\nLoffredo, 2017, Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis, Gastroenterology, 10.1053\u002Fj.gastro.2017.04.042\nQi, 2018, Transient portal vein thrombosis in liver cirrhosis, BMC Med, 16, 83, 10.1186\u002Fs12916-018-1069-8\nFrancoz, 2005, Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation, Gut, 54, 691, 10.1136\u002Fgut.2004.042796\nAmitrano, 2004, Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis, J Hepatol, 40, 736, 10.1016\u002Fj.jhep.2004.01.001\nMaruyama, 2013, De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes, Am J Gastroenterol, 108, 568, 10.1038\u002Fajg.2012.452\nLuca, 2012, Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis, Radiology, 265, 124, 10.1148\u002Fradiol.12112236\nZhang, 2020, Prevalence and clinical significance of portal vein thrombosis in patients with cirrhosis and acute decompensation, Clin Gastroenterol Hepatol, 18, 2564, 10.1016\u002Fj.cgh.2020.02.037\nEnglesbe, 2010, Portal vein thrombosis and liver transplant survival benefit, Liver Transpl, 16, 999, 10.1002\u002Flt.22105\nHibi, 2014, When and why portal vein thrombosis matters in liver transplantation: a critical audit of 174 cases, Ann Surg, 259, 760, 10.1097\u002FSLA.0000000000000252\nDriever, 2022, Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus, Hepatology, 75, 898, 10.1002\u002Fhep.32169\nRodriguez-Castro, 2019, A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis, Eur J Gastroenterol Hepatol, 31, 34, 10.1097\u002FMEG.0000000000001237\nVilla, 2012, Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis, Gastroenterology, 143, 1253, 10.1053\u002Fj.gastro.2012.07.018\nGuerrero, 2021, OS-1544 Anticoagulation improves overall survival through portal vein recanalization in patients with cirrhosis and portal vein thrombosis: individual patient data meta-analysis (IMPORTAL study), J Hepatol, 75, S191\nDelgado, 2012, Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis, Clin Gastroenterol Hepatol, 10, 776, 10.1016\u002Fj.cgh.2012.01.012\nIntagliata, 2021, AGA technical review on coagulation in cirrhosis, Gastroenterology, 161, 1630, 10.1053\u002Fj.gastro.2021.09.004\nLa Mura, 2018, Harmful and beneficial effects of anticoagulants in patients with cirrhosis and portal vein thrombosis, Clin Gastroenterol Hepatol, 16, 1146, 10.1016\u002Fj.cgh.2017.10.016\nSenzolo, 2021, Comparison of fondaparinux and low-molecular-weight heparin in the treatment of portal vein thrombosis in cirrhosis, Am J Med, 134, 1278, 10.1016\u002Fj.amjmed.2021.05.013\nTurco, 2019, Anticoagulation in the cirrhotic patient, JHEP Rep, 1, 227, 10.1016\u002Fj.jhepr.2019.02.006\nMort, 2020, Rates of bleeding and discontinuation of direct oral anticoagulants in patients with decompensated cirrhosis, Clin Gastroenterol Hepatol\nSemmler, 2021, Safety of direct oral anticoagulants in patients with advanced liver disease, Liver Int, 41, 2159, 10.1111\u002Fliv.14992\n2022, Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis, J Hepatol, S0168–8278, 02033\nIntagliata, 2016, Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation, Dig Dis Sci, 61, 1721, 10.1007\u002Fs10620-015-4012-2\nNagaoki, 2018, Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis, Hepatol Res, 48, 51, 10.1111\u002Fhepr.12895\nHanafy, 2019, Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis, Vascul Pharmacol, 113, 86, 10.1016\u002Fj.vph.2018.05.002\nPerarnau, 2010, Feasibility and long-term evolution of TIPS in cirrhotic patients with portal thrombosis, Eur J Gastroenterol Hepatol, 22, 1093, 10.1097\u002FMEG.0b013e328338d995\nHarding, 2015, Portal vein thrombosis in cirrhosis: controversies and latest developments, World J Gastroenterol, 21, 6769, 10.3748\u002Fwjg.v21.i22.6769\nRodrigues, 2019, Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis, Aliment Pharmacol Ther, 49, 20, 10.1111\u002Fapt.15044\nThornburg, 2017, Pretransplantation portal vein recanalization and transjugular intrahepatic portosystemic shunt creation for chronic portal vein thrombosis: final analysis of a 61-patient cohort, J Vasc Interv Radiol, 28, 1714, 10.1016\u002Fj.jvir.2017.08.005\nWang, 2016, Is post-TIPS anticoagulation therapy necessary in patients with cirrhosis and portal vein thrombosis? A randomized controlled trial, Radiology, 279, 943, 10.1148\u002Fradiol.2015150369\nAzoulay, 2021, Renoportal anastomosis during liver transplantation in patients with portal vein thrombosis: first long-term results from a multicenter study, Ann Surg\nSteffel, 2021, 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation, EP Europace, 23, 1612, 10.1093\u002Feuropace\u002Feuab065",{"EN":2529},"Management of splanchnic vein thrombosis",{"VOID":2531},"10.1016\u002Fj.jhepr.2022.100667","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2589555922002397",[2534,2559,2574,2597,2609,2628,2650,2669],{"id":2535,"sortIndex":158,"researcher":26,"roles":2536,"affiliations":2537,"properties":2556},"6607d3cc-8748-4d39-a650-b8ebbc6ed92e",[799],[2538,2548],{"id":2539,"sortIndex":115,"affiliation":2540,"properties":2547},"e8399e0d-4830-4229-b176-4e46a39b8d8b",{"id":2541,"createTime":2542,"updateTime":2542,"relativeEntities":2543,"slug":26,"properties":2544,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"4d9da5e9-d868-444a-8d0e-5cabffac8f37","2024-01-15T07:41:38.715+00:00",[],{"title":2545},{"VI":2546},"Service d'Hépatologie, AP-HP, Hôpital Beaujon, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Clichy, France",{},{"id":26,"sortIndex":36,"affiliation":2549,"properties":26},{"id":2550,"createTime":2551,"updateTime":2551,"relativeEntities":2552,"slug":26,"properties":2553,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"3e45c754-5ef9-4a72-bca2-f68ec73bdaa7","2024-01-15T07:41:38.744+00:00",[],{"title":2554},{"VI":2555},"Université Paris-Cité, Inserm, Centre de recherche sur l'inflammation, UMR 1149, Paris, France",{"title":2557},{"VI":2558},"Pierre-Emmanuel Rautou",{"id":2560,"sortIndex":59,"researcher":26,"roles":2561,"affiliations":2562,"properties":2571},"8fb22319-2589-4b36-92f4-1ab243340c80",[799],[2563],{"id":26,"sortIndex":36,"affiliation":2564,"properties":26},{"id":2565,"createTime":2566,"updateTime":2566,"relativeEntities":2567,"slug":26,"properties":2568,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"fcba6bb3-5c8f-428a-be97-c66851cf6bf2","2024-01-15T07:41:38.700+00:00",[],{"title":2569},{"VI":2570},"Service d’Hépato-Gastroentérologie CHU de Tours, France",{"title":2572},{"VI":2573},"Louis d’Alteroche",{"id":2575,"sortIndex":111,"researcher":26,"roles":2576,"affiliations":2577,"properties":2594},"667790f1-22fc-4b25-b312-b3c2d646eeba",[799],[2578,2589],{"id":2579,"sortIndex":115,"affiliation":2580,"properties":2588},"39a07930-2c7f-4777-ba4c-f0bed179fe0a",{"id":2581,"createTime":2582,"updateTime":2582,"relativeEntities":2583,"slug":2584,"properties":2585,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"a000537e-d650-4abb-9633-030dad0e466a","2024-04-15T11:50:12.003+00:00",[],"Service-de-radiologie-H%C3%B4pital-Beaujon-APHP-Nord-Clichy-France",{"title":2586},{"EN":2587},"Service de radiologie, Hôpital Beaujon, APHP.Nord, Clichy, France",{},{"id":26,"sortIndex":36,"affiliation":2590,"properties":26},{"id":2550,"createTime":2551,"updateTime":2551,"relativeEntities":2591,"slug":26,"properties":2592,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2593},{"VI":2555},{"title":2595},{"VI":2596},"Maxime Ronot",{"id":2598,"sortIndex":36,"researcher":26,"roles":2599,"affiliations":2600,"properties":2606},"c1012f17-e32b-440d-8576-785da68a6713",[799],[2601],{"id":26,"sortIndex":36,"affiliation":2602,"properties":26},{"id":2565,"createTime":2566,"updateTime":2566,"relativeEntities":2603,"slug":26,"properties":2604,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2605},{"VI":2570},{"title":2607},{"VI":2608},"Laure Elkrief",{"id":2610,"sortIndex":115,"researcher":26,"roles":2611,"affiliations":2612,"properties":2625},"025282f1-5b5c-49e6-8069-5579c3d408d7",[799],[2613,2618],{"id":26,"sortIndex":36,"affiliation":2614,"properties":26},{"id":2550,"createTime":2551,"updateTime":2551,"relativeEntities":2615,"slug":26,"properties":2616,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2617},{"VI":2555},{"id":2619,"sortIndex":115,"affiliation":2620,"properties":2624},"2671c204-3d4a-4bfd-95a5-a100b86968e9",{"id":2541,"createTime":2542,"updateTime":2542,"relativeEntities":2621,"slug":26,"properties":2622,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2623},{"VI":2546},{},{"title":2626},{"VI":2627},"Audrey Payancé",{"id":2629,"sortIndex":162,"researcher":26,"roles":2630,"affiliations":2631,"properties":2647},"3b0300b9-80b1-4bf7-bcda-f2d8568ec63b",[799],[2632,2637],{"id":26,"sortIndex":36,"affiliation":2633,"properties":26},{"id":2550,"createTime":2551,"updateTime":2551,"relativeEntities":2634,"slug":26,"properties":2635,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2636},{"VI":2555},{"id":2638,"sortIndex":115,"affiliation":2639,"properties":2646},"66dd7884-d88c-4693-8c6b-af149022ba0e",{"id":2640,"createTime":2641,"updateTime":2641,"relativeEntities":2642,"slug":26,"properties":2643,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"46c5a86b-085c-45a8-a45a-93dd536f5bd3","2024-01-15T07:41:38.760+00:00",[],{"title":2644},{"VI":2645},"Service d’anatomie et cytologie pathologique, Hôpital Beaujon APHP.Nord, Clichy, France",{},{"title":2648},{"VI":2649},"Valérie Paradis",{"id":2651,"sortIndex":114,"researcher":26,"roles":2652,"affiliations":2653,"properties":2666},"37b9cd02-c441-4462-afd7-2c9ab48f7fb3",[799],[2654,2661],{"id":2655,"sortIndex":115,"affiliation":2656,"properties":2660},"a5061cd2-c90c-48e6-a904-ead5c52fe5f7",{"id":2541,"createTime":2542,"updateTime":2542,"relativeEntities":2657,"slug":26,"properties":2658,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2659},{"VI":2546},{},{"id":26,"sortIndex":36,"affiliation":2662,"properties":26},{"id":2550,"createTime":2551,"updateTime":2551,"relativeEntities":2663,"slug":26,"properties":2664,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2665},{"VI":2555},{"title":2667},{"VI":2668},"Aurélie Plessier",{"id":2670,"sortIndex":135,"researcher":26,"roles":2671,"affiliations":2672,"properties":2685},"58f41db3-5e22-44cf-9c77-1ac5f7ae2844",[799],[2673,2680],{"id":2674,"sortIndex":115,"affiliation":2675,"properties":2679},"2744f4b3-f6b5-4f91-ba49-7975cf479c1b",{"id":2541,"createTime":2542,"updateTime":2542,"relativeEntities":2676,"slug":26,"properties":2677,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2678},{"VI":2546},{},{"id":26,"sortIndex":36,"affiliation":2681,"properties":26},{"id":2550,"createTime":2551,"updateTime":2551,"relativeEntities":2682,"slug":26,"properties":2683,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2684},{"VI":2555},{"title":2686},{"VI":2687},"Dominique Valla",{"url":2532,"publisher":2689,"properties":2718},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":2690,"slug":663,"properties":2691,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":114,"subjectFields":2696,"manageAffiliations":2697,"indexDatabases":2698,"url":768,"thumbnailPath":26,"statistic":2713,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"country":2692,"issn":2693,"introduce":2694,"title":2695},{"VOID":666},{"VOID":668},{"EN":670},{"EN":672},[],[],[2699,2706],{"id":747,"indexDatabase":2700,"url":760,"indexYears":761,"academicFieldIds":2705,"indexDatabaseRanking":767},{"id":749,"createTime":750,"updateTime":751,"relativeEntities":2701,"label":2702,"description":2703,"key":757,"publicationTags":2704,"standard":26},[],{"EN":754,"VI":754},{"EN":754,"VI":756},[759],[763,764,765,766],{"id":728,"indexDatabase":2707,"url":743,"indexYears":26,"academicFieldIds":2712,"indexDatabaseRanking":26},{"id":730,"createTime":731,"updateTime":732,"relativeEntities":2708,"label":2709,"description":2710,"key":739,"publicationTags":2711,"standard":26},[],{"EN":735,"VI":735},{"VI":737,"EN":738},[741,742],[745],{"impactFactor":36,"impactFactorByYear":2714,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":245,"totalPublicationByYear":2715,"totalCitation":36,"totalCitationByYear":2716,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":2717,"hindexLast5Year":36,"hindex":36},{},{"2019":158,"2020":111,"2021":124,"2022":298,"2023":287,"2024":59},{},{},{"volume":2719,"pages":2720},{"VOID":1027},{"VOID":2721},"100667","2023-04-01",{"id":2724,"createTime":2725,"updateTime":2726,"relativeEntities":2727,"slug":2728,"properties":2729,"entityType":791,"verifyStatus":25,"verifyTime":2726,"verifyNote":793,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":2736,"fullTextUrl":26,"authors":2737,"publicationType":994,"publisherRelationship":2974,"citationCount":26,"citationInfo":26,"publishDate":1355,"publishYear":1033,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":26,"isForceReanalyzing":1185},"46458d4f-4e84-438f-8457-609ce30a085f","2023-12-27T11:24:06.788+00:00","2024-12-07T15:36:39.140+00:00",[],"Factors-impacting-survival-after-transarterial-radioembolization-in-patients-with-hepatocellular-carcinoma-Results-from-the-prospective-CIRT-study",{"references":2730,"title":2732,"doi":2734},{"VOID":2731},"Rumgay, 2022, Global, regional and national burden of primary liver cancer by subtype, Eur J Cancer, 161, 108, 10.1016\u002Fj.ejca.2021.11.023\nSung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 71, 209, 10.3322\u002Fcaac.21660\nGiannini, 2015, Prognosis of untreated hepatocellular carcinoma, Hepatology, 61, 184, 10.1002\u002Fhep.27443\nBenson, 2021, Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology, J Natl Compr Canc Netw, 19, 541, 10.6004\u002Fjnccn.2021.0022\n2012, EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol, 56, 908, 10.1016\u002Fj.jhep.2011.12.001\n2018, EASL clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol, 69, 182, 10.1016\u002Fj.jhep.2018.03.019\nMarrero, 2018, Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases, Hepatology, 68, 723, 10.1002\u002Fhep.29913\nVogel, 2019, Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 30, 871, 10.1093\u002Fannonc\u002Fmdy510\nVogel, 2021, Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines, Ann Oncol, 32, 801, 10.1016\u002Fj.annonc.2021.02.014\nCheng, 2009, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, 25, 10.1016\u002FS1470-2045(08)70285-7\nFinn, 2020, Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma, N Engl J Med, 382, 1894, 10.1056\u002FNEJMoa1915745\nKudo, 2018, Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial, Lancet, 391, 1163, 10.1016\u002FS0140-6736(18)30207-1\nLlovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056\u002FNEJMoa0708857\nAaronson, 1993, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 85, 365, 10.1093\u002Fjnci\u002F85.5.365\nHilgard, 2010, Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival, Hepatology, 52, 1741, 10.1002\u002Fhep.23944\nSalem, 2013, Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization, Clin Gastroenterol Hepatol, 11, 1358, 10.1016\u002Fj.cgh.2013.04.028\nSalem, 2010, Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes, Gastroenterology, 138, 52, 10.1053\u002Fj.gastro.2009.09.006\nSangro, 2011, Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation, Hepatology, 54, 868, 10.1002\u002Fhep.24451\nChow, 2018, SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma, J Clin Oncol, 36, 1913, 10.1200\u002FJCO.2017.76.0892\nVilgrain, 2017, Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial, Lancet Oncol, 18, 1624, 10.1016\u002FS1470-2045(17)30683-6\nSposito, 2018, The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future, Hepatobiliary Surg Nutr, 7, 487, 10.21037\u002Fhbsn.2018.10.06\nVan Der Gucht, 2017, Resin versus glass microspheres for (90)Y transarterial radioembolization: comparing survival in unresectable hepatocellular carcinoma using pretreatment partition model dosimetry, J Nucl Med, 58, 1334, 10.2967\u002Fjnumed.116.184713\nGarin, 2021, Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial, Lancet Gastroenterol Hepatol, 6, 17, 10.1016\u002FS2468-1253(20)30290-9\nGarin, 2020, Major impact of personalized dosimetry using 90Y loaded glass microspheres SIRT in HCC: final overall survival analysis of a multicenter randomized phase II study (DOSISPHERE-01), J Clin Oncol, 38, 516, 10.1200\u002FJCO.2020.38.4_suppl.516\nHelmberger, 2021, Clinical application of trans-arterial radioembolization in hepatic malignancies in Europe: first results from the prospective multicentre observational study CIRSE Registry for SIR-spheres therapy (CIRT), Cardiovasc Intervent Radiol, 44, 21, 10.1007\u002Fs00270-020-02642-y\nHelmberger, 2020, Clinical application of radioembolization in hepatic malignancies: protocol for a prospective multicenter observational study, JMIR Res Protoc, 9, 10.2196\u002F16296\nJohnson, 2015, Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade, J Clin Oncol, 33, 550, 10.1200\u002FJCO.2014.57.9151\nReig, 2021, BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update, J Hepatol, 76, 681, 10.1016\u002Fj.jhep.2021.11.018\nOp den Winkel, 2022, A simple prognostic scoring system for hepatocellular carcinoma treated with selective internal radiation therapy, Dig Dis, 40, 322, 10.1159\u002F000517458\nAbdallah, 2020, The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study, Expert Rev Gastroenterol Hepatol, 14, 619, 10.1080\u002F17474124.2020.1777856\nAbouchaleh, 2018, (90)Y radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: long-term outcomes in a 185-patient cohort, J Nucl Med, 59, 1042, 10.2967\u002Fjnumed.117.199752\nTohme, 2018, Radioembolization for hepatocellular carcinoma: a nationwide 10-year experience, J Vasc Interv Radiol, 29, 912, 10.1016\u002Fj.jvir.2018.03.018\nGarin, 2015, Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis, J Nucl Med, 56, 339, 10.2967\u002Fjnumed.114.145177\nKulik, 2008, Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis, Hepatology, 47, 71, 10.1002\u002Fhep.21980\nSpreafico, 2018, Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion, J Hepatol, 68, 724, 10.1016\u002Fj.jhep.2017.12.026\nPeng, 2020, ALBI versus child-pugh in predicting outcome of patients with HCC: a systematic review, Expert Rev Gastroenterol Hepatol, 14, 383, 10.1080\u002F17474124.2020.1748010\nGao, 2020, Toxicity and survival of hepatocellular carcinoma patients with hepatitis B infection treated with yttrium-90 radioembolization: an updated 15-year study, J Vasc Interv Radiol, 31, 401, 10.1016\u002Fj.jvir.2019.08.033\nSalem, 2018, Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience, Hepatology, 68, 1429, 10.1002\u002Fhep.29691\nSangro, 2018, Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies, Eur J Nucl Med Mol Imaging, 45, 1721, 10.1007\u002Fs00259-018-3968-5\nChoi, 2021, Anatomic variations of the hepatic artery in 5625 patients, Radiol Cardiothorac Imaging, 3, 10.1148\u002Fryct.2021210007\nAramburu, 2016, Numerical investigation of liver radioembolization via computational particle-hemodynamics: the role of the microcatheter distal direction and microsphere injection point and velocity, J Biomech, 49, 3714, 10.1016\u002Fj.jbiomech.2016.09.034\nBorg, 2019, Vascular redistribution for SIRT—a quantitative assessment of treatment success and long-term analysis of recurrence and survival outcomes, J Clin Interv Radiol ISVIR, 3, 89, 10.1055\u002Fs-0039-1694091\nSpina, 2019, Expected and unexpected imaging findings after (90)Y transarterial radioembolization for liver tumors, Radiographics, 39, 578, 10.1148\u002Frg.2019180095\nRicke, 2021, Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma, J Hepatol, 75, 1387, 10.1016\u002Fj.jhep.2021.07.037\nLoffroy, 2021, Short-term safety and quality of life outcomes following radioembolization in primary and secondary liver tumours: a multi-centre analysis of 200 patients in France, Cardiovasc Intervent Radiol, 44, 36, 10.1007\u002Fs00270-020-02643-x\nBraat, 2017, Radioembolization-induced liver disease: a systematic review, Eur J Gastroenterol Hepatol, 29, 144, 10.1097\u002FMEG.0000000000000772\nKao, 2011, Clinical implications of the body surface area method versus partition model dosimetry for yttrium-90 radioembolization using resin microspheres: a technical review, Ann Nucl Med, 25, 455, 10.1007\u002Fs12149-011-0499-6\nGil-Alzugaray, 2013, Prognostic factors and prevention of radioembolization-induced liver disease, Hepatology, 57, 1078, 10.1002\u002Fhep.26191\nSangro, 2008, Liver disease induced by radioembolization of liver tumors: description and possible risk factors, Cancer, 112, 1538, 10.1002\u002Fcncr.23339\nHermann, 2020, Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with (90)Y in the SARAH study, Radiology, 296, 673, 10.1148\u002Fradiol.2020191606",{"EN":2733},"Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study",{"VOID":2735},"10.1016\u002Fj.jhepr.2022.100633","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2589555922002051",[2738,2753,2768,2783,2798,2814,2829,2845,2860,2875,2887,2902,2919,2944,2959],{"id":2739,"sortIndex":36,"researcher":26,"roles":2740,"affiliations":2741,"properties":2750},"098e1dec-b3ab-4c7b-bac2-43fd09ffc9d3",[799],[2742],{"id":26,"sortIndex":36,"affiliation":2743,"properties":26},{"id":2744,"createTime":2745,"updateTime":2745,"relativeEntities":2746,"slug":26,"properties":2747,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"aa3e5e77-fdce-4d0e-8da3-33974338b832","2023-12-12T22:32:38.273+00:00",[],{"title":2748},{"VI":2749},"Department of Internal Medicine and Gastroenterology, HELIOS Klinikum Berlin-Buch, Berlin, Germany",{"title":2751},{"VI":2752},"Frank Kolligs",{"id":2754,"sortIndex":116,"researcher":26,"roles":2755,"affiliations":2756,"properties":2765},"6fa7bc5b-57c7-4c13-8521-7c316e5e1757",[799],[2757],{"id":26,"sortIndex":36,"affiliation":2758,"properties":26},{"id":2759,"createTime":2760,"updateTime":2760,"relativeEntities":2761,"slug":26,"properties":2762,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"70e75521-d06f-475d-8fc7-e338c432598b","2023-12-27T11:24:07.040+00:00",[],{"title":2763},{"VI":2764},"Interventional Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom",{"title":2766},{"VI":2767},"Graham Munneke",{"id":2769,"sortIndex":356,"researcher":26,"roles":2770,"affiliations":2771,"properties":2780},"ea8fd024-660d-4f4d-8d54-9133edb68bba",[799],[2772],{"id":26,"sortIndex":36,"affiliation":2773,"properties":26},{"id":2774,"createTime":2775,"updateTime":2775,"relativeEntities":2776,"slug":26,"properties":2777,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"4b79e1f9-bfcd-4e18-a3e9-3add5d8f1198","2024-01-09T00:35:57.615+00:00",[],{"title":2778},{"VI":2779},"Clinical Research Department, Cardiovascular and Interventional Radiological Society of Europe, Vienna, Austria",{"title":2781},{"VI":2782},"Niels de Jong",{"id":2784,"sortIndex":158,"researcher":26,"roles":2785,"affiliations":2786,"properties":2795},"cf372e6f-c5a9-4846-be8c-4d3140cc66e6",[799],[2787],{"id":26,"sortIndex":36,"affiliation":2788,"properties":26},{"id":2789,"createTime":2790,"updateTime":2790,"relativeEntities":2791,"slug":26,"properties":2792,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"18dc1345-d80b-421f-a112-3bead86731a7","2024-02-11T08:46:48.232+00:00",[],{"title":2793},{"VI":2794},"Liver Unit and HPB Oncology Area, Clínica Universidad de Navarra and CIBEREHD, Pamplona, Spain",{"title":2796},{"VI":2797},"Bruno Sangro",{"id":2799,"sortIndex":59,"researcher":26,"roles":2800,"affiliations":2801,"properties":2811},"822b03ea-980e-470d-b46a-af9d457ae92c",[799],[2802],{"id":26,"sortIndex":36,"affiliation":2803,"properties":26},{"id":2804,"createTime":2805,"updateTime":2805,"relativeEntities":2806,"slug":2807,"properties":2808,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"614730eb-1c3d-49c0-bbd8-a27d98bb7770","2024-04-20T01:28:50.758+00:00",[],"Department-of-Radiology-and-Nuclear-Medicine-University-of-Magdeburg-Magdeburg-Germany",{"title":2809},{"EN":2810},"Department of Radiology and Nuclear Medicine, University of Magdeburg, Magdeburg, Germany",{"title":2812},{"VI":2813},"Maciej Pech",{"id":2815,"sortIndex":52,"researcher":26,"roles":2816,"affiliations":2817,"properties":2826},"94908213-7e3e-466c-996a-f6d83f209ec0",[799],[2818],{"id":26,"sortIndex":36,"affiliation":2819,"properties":26},{"id":2820,"createTime":2821,"updateTime":2821,"relativeEntities":2822,"slug":26,"properties":2823,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"46d1978b-3a7d-44a1-8c6f-b5a21fcbf632","2024-02-11T08:46:48.254+00:00",[],{"title":2824},{"VI":2825},"Radiology, Universitair Ziekenhuis Leuven, Leuven, Belgium",{"title":2827},{"VI":2828},"Geert Maleux",{"id":2830,"sortIndex":135,"researcher":26,"roles":2831,"affiliations":2832,"properties":2843},"063e3b22-4a8e-4656-9aca-90b084736d8a",[799],[2833],{"id":26,"sortIndex":36,"affiliation":2834,"properties":26},{"id":2835,"createTime":2836,"updateTime":2837,"relativeEntities":2838,"slug":2839,"properties":2840,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"00057614-2b0b-4e18-9915-9dccd3592279","2023-12-27T11:24:06.946+00:00","2025-06-11T13:31:59.466+00:00",[],"Universit%C3%A9-Paris-Cit%C3%A9-Paris-Service-de-Radiologie-APHP-Nord-H%C3%B4pital-Beaujon-Clichy-France",{"title":2841},{"VI":2842},"Université Paris Cité, Paris & Service de Radiologie, APHP Nord, Hôpital Beaujon, Clichy, France",{"title":2844},{"VI":2596},{"id":2846,"sortIndex":111,"researcher":26,"roles":2847,"affiliations":2848,"properties":2857},"be850251-2968-45cf-938f-d7ca2ab74ae4",[799],[2849],{"id":26,"sortIndex":36,"affiliation":2850,"properties":26},{"id":2851,"createTime":2852,"updateTime":2852,"relativeEntities":2853,"slug":26,"properties":2854,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"8e78c1f9-8d86-4f94-acc4-ac450af307ee","2023-12-27T11:24:06.810+00:00",[],{"title":2855},{"VI":2856},"Department of Radiology, School of Medicine, Hacettepe University, Sihhiye Campus, Ankara, Turkey",{"title":2858},{"VI":2859},"Bora Peynircioglu",{"id":2861,"sortIndex":50,"researcher":26,"roles":2862,"affiliations":2863,"properties":2872},"54c8e899-8007-4e25-aa53-558fade79d09",[799],[2864],{"id":26,"sortIndex":36,"affiliation":2865,"properties":26},{"id":2866,"createTime":2867,"updateTime":2867,"relativeEntities":2868,"slug":26,"properties":2869,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"f1fa083e-a184-4321-826b-815d4e9a32b1","2024-02-11T08:46:48.195+00:00",[],{"title":2870},{"VI":2871},"Service de Médecine Nucléaire Et Imagerie Moléculaire, CHUV, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland",{"title":2873},{"VI":2874},"Niklaus Schaefer",{"id":2876,"sortIndex":103,"researcher":26,"roles":2877,"affiliations":2878,"properties":2884},"b1c202bb-a123-4adf-809c-e8d60dd1878a",[799],[2879],{"id":26,"sortIndex":36,"affiliation":2880,"properties":26},{"id":2774,"createTime":2775,"updateTime":2775,"relativeEntities":2881,"slug":26,"properties":2882,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2883},{"VI":2779},{"title":2885},{"VI":2886},"Bleranda Zeka",{"id":2888,"sortIndex":115,"researcher":26,"roles":2889,"affiliations":2890,"properties":2899},"5aec1884-25be-4379-bc62-239314622bad",[799],[2891],{"id":26,"sortIndex":36,"affiliation":2892,"properties":26},{"id":2893,"createTime":2894,"updateTime":2894,"relativeEntities":2895,"slug":26,"properties":2896,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"29922e1f-9430-4401-9e5a-f6bea3f40d98","2023-12-27T11:24:06.855+00:00",[],{"title":2897},{"VI":2898},"Oncology and Hematology, Asklepios Tumorzentrum Hamburg, AK Altona, Hamburg, Germany",{"title":2900},{"VI":2901},"Dirk Arnold",{"id":2903,"sortIndex":114,"researcher":26,"roles":2904,"affiliations":2905,"properties":2916},"49a56bf5-9e78-4a40-819d-994a5ae2ab48",[799],[2906],{"id":26,"sortIndex":36,"affiliation":2907,"properties":26},{"id":2908,"createTime":2909,"updateTime":2910,"relativeEntities":2911,"slug":2912,"properties":2913,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"04ed501f-defb-484e-a623-eeb068fb78f5","2023-12-26T14:11:20.369+00:00","2025-06-11T18:08:48.129+00:00",[],"Department-of-Radiology-IRCCS-Azienda-Ospedaliero-Universitaria-Di-Bologna-Bologna-Italy",{"title":2914},{"VI":2915},"Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy",{"title":2917},{"VI":2918},"Rita Golfieri",{"id":2920,"sortIndex":53,"researcher":26,"roles":2921,"affiliations":2922,"properties":2941},"658de59a-19d3-42c6-b043-c57fb6e592da",[799],[2923,2931],{"id":26,"sortIndex":36,"affiliation":2924,"properties":26},{"id":2925,"createTime":2926,"updateTime":2926,"relativeEntities":2927,"slug":26,"properties":2928,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"11690aad-5791-464a-80a4-8ca3b222d460","2024-01-27T17:47:53.567+00:00",[],{"title":2929},{"VI":2930},"Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Unité de Recherche Clinique, Paris, France",{"id":2932,"sortIndex":115,"affiliation":2933,"properties":2940},"2f3ecb75-b1e1-4974-9307-c27700de917c",{"id":2934,"createTime":2935,"updateTime":2935,"relativeEntities":2936,"slug":26,"properties":2937,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"43b8929f-066c-4f94-ac0b-203704a09244","2023-12-27T11:24:06.891+00:00",[],{"title":2938},{"VI":2939},"INSERM, Centre d'Investigation Clinique 1418 (CIC1418), Paris, France",{},{"title":2942},{"VI":2943},"Helena Pereira",{"id":2945,"sortIndex":298,"researcher":26,"roles":2946,"affiliations":2947,"properties":2956},"4ce29763-8767-44c0-a501-967d0f80dbec",[799],[2948],{"id":26,"sortIndex":36,"affiliation":2949,"properties":26},{"id":2950,"createTime":2951,"updateTime":2951,"relativeEntities":2952,"slug":26,"properties":2953,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"a2908ce9-8bae-43bd-b7ea-5fffaf7e50a9","2024-02-11T08:46:48.113+00:00",[],{"title":2954},{"VI":2955},"Department of Radiology, Neuroradiology and Minimal-Invasive Therapy, Klinikum Bogenhausen, Munich, Germany",{"title":2957},{"VI":2958},"Thomas Helmberger",{"id":2960,"sortIndex":162,"researcher":26,"roles":2961,"affiliations":2962,"properties":2971},"3fca141e-6a9b-4577-8d55-7b7af2673f44",[799],[2963],{"id":26,"sortIndex":36,"affiliation":2964,"properties":26},{"id":2965,"createTime":2966,"updateTime":2966,"relativeEntities":2967,"slug":26,"properties":2968,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"f26d55f4-7ccb-4330-84eb-e6da86dae04f","2023-12-27T11:24:06.927+00:00",[],{"title":2969},{"VI":2970},"Institute of Diagnostic and Interventional Radiology, Universitätsspital Zürich, Zürich, Switzerland",{"title":2972},{"VI":2973},"Thomas Pfammatter",{"url":2736,"publisher":2975,"properties":3004},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":2976,"slug":663,"properties":2977,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":114,"subjectFields":2982,"manageAffiliations":2983,"indexDatabases":2984,"url":768,"thumbnailPath":26,"statistic":2999,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"country":2978,"issn":2979,"introduce":2980,"title":2981},{"VOID":666},{"VOID":668},{"EN":670},{"EN":672},[],[],[2985,2992],{"id":747,"indexDatabase":2986,"url":760,"indexYears":761,"academicFieldIds":2991,"indexDatabaseRanking":767},{"id":749,"createTime":750,"updateTime":751,"relativeEntities":2987,"label":2988,"description":2989,"key":757,"publicationTags":2990,"standard":26},[],{"EN":754,"VI":754},{"EN":754,"VI":756},[759],[763,764,765,766],{"id":728,"indexDatabase":2993,"url":743,"indexYears":26,"academicFieldIds":2998,"indexDatabaseRanking":26},{"id":730,"createTime":731,"updateTime":732,"relativeEntities":2994,"label":2995,"description":2996,"key":739,"publicationTags":2997,"standard":26},[],{"EN":735,"VI":735},{"VI":737,"EN":738},[741,742],[745],{"impactFactor":36,"impactFactorByYear":3000,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":245,"totalPublicationByYear":3001,"totalCitation":36,"totalCitationByYear":3002,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":3003,"hindexLast5Year":36,"hindex":36},{},{"2019":158,"2020":111,"2021":124,"2022":298,"2023":287,"2024":59},{},{},{"volume":3005,"pages":3006},{"VOID":1027},{"VOID":3007},"100633",{"id":3009,"createTime":3010,"updateTime":3011,"relativeEntities":3012,"slug":3013,"properties":3014,"entityType":791,"verifyStatus":25,"verifyTime":3011,"verifyNote":793,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":3021,"fullTextUrl":26,"authors":3022,"publicationType":994,"publisherRelationship":3140,"citationCount":26,"citationInfo":26,"publishDate":3175,"publishYear":3176,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":26,"isForceReanalyzing":1185},"a0c2d5fa-cf04-4f04-ac19-a72fbec3458e","2023-12-22T18:20:34.921+00:00","2025-02-11T20:56:45.241+00:00",[],"Geo-epidemiology-and-environmental-co-variate-mapping-of-primary-biliary-cholangitis-and-primary-sclerosing-cholangitis",{"references":3015,"title":3017,"doi":3019},{"VOID":3016},"Zenewicz, 2010, Unraveling the genetics of autoimmunity, Cell, 140, 791, 10.1016\u002Fj.cell.2010.03.003\nMcNally, 2009, Are transient environmental agents involved in the cause of primary biliary cirrhosis? Evidence from space–time clustering, Hepatology, 50, 1169, 10.1002\u002Fhep.23139\nMcNally, 2011, Seasonal variation in the patient diagnosis of primary biliary cirrhosis: further evidence for an environmental component to etiology, Hepatology, 54, 2099, 10.1002\u002Fhep.24597\nMcNally, 2014, No rise in incidence but geographical heterogeneity in the occurrence of primary biliary cirrhosis in North East England, Am J Epidemiol, 179, 492, 10.1093\u002Faje\u002Fkwt308\nAla, 2006, Increased prevalence of primary biliary cirrhosis near superfund toxic waste sites, Hepatology, 43, 525, 10.1002\u002Fhep.21076\nStanca, 2008, Pathogenic role of environmental toxins in immune-mediated liver diseases, J Immunotoxicol, 5, 59, 10.1080\u002F15476910802019086\nHirschfield, 2010, Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis, Nat Genet, 42, 655, 10.1038\u002Fng.631\nJi, 2016, Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease, Nat Genet, 49, 269, 10.1038\u002Fng.3745\nLiu, 2013, Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis, Nat Genet, 45, 670, 10.1038\u002Fng.2616\nMells, 2011, Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis, Nat Genet, 43, 329, 10.1038\u002Fng.789\nHirschfield, 2018, The British Society of Gastroenterology\u002FUK-PBC primary biliary cholangitis treatment and management guidelines, Gut, 67, 1568, 10.1136\u002Fgutjnl-2017-315259\nLindor, 2009, Primary biliary cirrhosis, Hepatology, 50, 291, 10.1002\u002Fhep.22906\nChapman, 2019, British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis, Gut, 68, 1356, 10.1136\u002Fgutjnl-2018-317993\nHennes, 2008, Simplified criteria for the diagnosis of autoimmune hepatitis, Hepatology, 48, 169, 10.1002\u002Fhep.22322\nBailey, 1995\nSpiegelhalter, 2002, Bayesian measures of model complexity and fit (with discussion), J R Stat Soc, 64, 583, 10.1111\u002F1467-9868.00353\nSpiegelhalter, 2014, The deviance information criterion: 12 years on (with discussion), J R Stat Soc, 76, 485, 10.1111\u002Frssb.12062\nMetcalf, 1996, Natural history of early primary biliary cirrhosis, Lancet, 348, 1399, 10.1016\u002FS0140-6736(96)04410-8\nPrince, 2002, Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years, Gastroenterology, 123, 1044, 10.1053\u002Fgast.2002.36027\nPrince, 2010, Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations, Gut, 59, 508, 10.1136\u002Fgut.2009.184218\nPrince, 2001, The geographical distribution of primary biliary cirrhosis in a well-defined cohort, Hepatology, 34, 1083, 10.1053\u002Fjhep.2001.29760\nAndersen, 2014, Effects of coffee consumption, smoking, and hormones on risk for primary sclerosing cholangitis, Clin Gastroenterol Hepatol, 12, 1019, 10.1016\u002Fj.cgh.2013.09.024\nCorpechot, 2010, Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis, J Hepatol, 53, 162, 10.1016\u002Fj.jhep.2010.02.019\nEaton, 2015, A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease, Aliment Pharmacol Ther, 41, 980, 10.1111\u002Fapt.13154\nGershwin, 2005, Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients, Hepatology, 42, 1194, 10.1002\u002Fhep.20907\nCrinnion, 2011, Polychlorinated biphenyls: persistent pollutants with immunological, neurological, and endocrinological consequences, Altern Med Rev, 16, 5\nMilnerowicz, 2015, Pro-inflammatory effects of metals in persons and animals exposed to tobacco smoke, J Trace Elem Med Biol, 29, 1, 10.1016\u002Fj.jtemb.2014.04.008\nBergquist, 2005, Increased prevalence of primary sclerosing cholangitis among first-degree relatives, J Hepatol, 42, 252, 10.1016\u002Fj.jhep.2004.10.011\nBergquist, 2008, Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis, Clin Gastroenterol Hepatol, 6, 939, 10.1016\u002Fj.cgh.2008.03.016\nJones, 1999, Familial primary biliary cirrhosis reassessed: a geographically-based population study, J Hepatol, 30, 402, 10.1016\u002FS0168-8278(99)80097-X\nSalama, 2019, Cadmium-induced hepatocellular injury: modulatory effects of gamma-glutamyl cysteine on the biomarkers of inflammation, DNA damage, and apoptotic cell death, J Trace Elem Med Biol, 52, 74, 10.1016\u002Fj.jtemb.2018.12.003\nGalunin, 2014, Cadmium mobility in sediments and soils from a coal mining area on Tibagi River watershed: environmental risk assessment, J Hazard Mater, 265, 280, 10.1016\u002Fj.jhazmat.2013.11.010\nMishra, 2008, Heavy metal pollution induced due to coal mining effluent on surrounding aquatic ecosystem and its management through naturally occurring aquatic macrophytes, Bioresour Technol, 99, 930, 10.1016\u002Fj.biortech.2007.03.010\nDe Chowdhuri\nvan Niekerk, 2018, Role of bile acids and the biliary HCO3- umbrella in the pathogenesis of primary biliary cholangitis, Clin Liver Dis, 22, 457, 10.1016\u002Fj.cld.2018.03.013\nOspondpant, 2019, Cadmium induces apoptotic program imbalance and cell cycle inhibitor expression in cultured human astrocytes, Environ Toxicol Pharmacol, 65, 53, 10.1016\u002Fj.etap.2018.12.001\nJarup, 2009, Current status of cadmium as an environmental health problem, Toxicol Appl Pharmacol, 238, 201, 10.1016\u002Fj.taap.2009.04.020\nPares, 1981, Renal tubular acidosis in primary biliary cirrhosis, Gastroenterology, 80, 681, 10.1016\u002F0016-5085(81)90125-6\nThomas, 2009, Early kidney damage in a population exposed to cadmium and other heavy metals, Environ Health Perspect, 117, 181, 10.1289\u002Fehp.11641\nKeane, 2014, Sociodemographic trends in the incidence of pancreatic and biliary tract cancer in UK primary care, PLoS One, 9, e108498, 10.1371\u002Fjournal.pone.0108498\nPollock, 1997, Breast, lung and colorectal cancer incidence and survival in South Thames Region, 1987–1992: the effect of social deprivation, J Public Health Med, 19, 288, 10.1093\u002Foxfordjournals.pubmed.a024632\nSmith, 1998, Individual social class, area-based deprivation, cardiovascular disease risk factors, and mortality: the Renfrew and Paisley Study, J Epidemiol Community Health, 52, 399, 10.1136\u002Fjech.52.6.399\nCorsini, 2008, Effects of pesticide exposure on the human immune system, Hum Exp Toxicol, 27, 671, 10.1177\u002F0960327108094509\nTabrez, 2014, Gene-environment interactions in heavy metal and pesticide carcinogenesis, Mutat Res Genet Toxicol Environ Mutagen, 760, 1, 10.1016\u002Fj.mrgentox.2013.11.002\nDwivedi, 2011, Concomitant exposure to arsenic and organophosphates on tissue oxidative stress in rats, Food Chem Toxicol, 49, 1152, 10.1016\u002Fj.fct.2011.02.007",{"EN":3018},"Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis",{"VOID":3020},"10.1016\u002Fj.jhepr.2020.100202","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2589555920301361",[3023,3038,3065,3080,3104,3121],{"id":3024,"sortIndex":111,"researcher":26,"roles":3025,"affiliations":3026,"properties":3035},"483152fe-f367-4519-bc4f-76919c4c3c7a",[799],[3027],{"id":26,"sortIndex":36,"affiliation":3028,"properties":26},{"id":3029,"createTime":3030,"updateTime":3030,"relativeEntities":3031,"slug":26,"properties":3032,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"9766b8cd-c0e5-4e91-91ff-8fe0c566327f","2024-01-04T14:19:27.754+00:00",[],{"title":3033},{"VI":3034},"School of Natural and Environmental Sciences, Newcastle University, Newcastle Upon Tyne, UK",{"title":3036},{"VI":3037},"Steven Rushton",{"id":3039,"sortIndex":162,"researcher":26,"roles":3040,"affiliations":3041,"properties":3062},"c3630659-d9a7-493a-a355-935f13b2bfa0",[799],[3042,3052],{"id":3043,"sortIndex":115,"affiliation":3044,"properties":3051},"bc445a65-e38f-46e3-ac79-20a209227ce3",{"id":3045,"createTime":3046,"updateTime":3046,"relativeEntities":3047,"slug":26,"properties":3048,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"37eb1b79-a524-4949-90c3-df9f8ba0206f","2023-12-22T18:20:34.982+00:00",[],{"title":3049},{"VI":3050},"Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, UK",{},{"id":26,"sortIndex":36,"affiliation":3053,"properties":26},{"id":3054,"createTime":3055,"updateTime":3056,"relativeEntities":3057,"slug":3058,"properties":3059,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"06d317e2-628f-4fbe-828d-e27dc4768cab","2023-12-12T08:02:20.560+00:00","2025-06-11T19:52:58.679+00:00",[],"Translational-and-Clinical-Research-Institute-Newcastle-University-Newcastle-Upon-Tyne-UK",{"title":3060},{"VI":3061},"Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK",{"title":3063},{"VI":3064},"David Emrys Jeffreys Jones",{"id":3066,"sortIndex":114,"researcher":26,"roles":3067,"affiliations":3068,"properties":3077},"053e9f43-cf22-4c65-a29d-ea4f6ddee2f5",[799],[3069],{"id":26,"sortIndex":36,"affiliation":3070,"properties":26},{"id":3071,"createTime":3072,"updateTime":3072,"relativeEntities":3073,"slug":26,"properties":3074,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"65676e18-3f45-4ea3-bdaa-028ae31f656d","2024-01-16T06:38:02.840+00:00",[],{"title":3075},{"VI":3076},"School of Natural and Environmental Sciences, Newcastle University, Newcastle-upon-Tyne, UK",{"title":3078},{"VI":3079},"Mark David Foster Shirley",{"id":3081,"sortIndex":36,"researcher":26,"roles":3082,"affiliations":3083,"properties":3101},"3f8dbccd-27cc-4fd8-8770-b72d2de32f4d",[799],[3084,3096],{"id":3085,"sortIndex":115,"affiliation":3086,"properties":3095},"e332e26d-f85e-45e0-8c7c-38bb46ac6f3f",{"id":3087,"createTime":3088,"updateTime":3089,"relativeEntities":3090,"slug":3091,"properties":3092,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"c80bedc2-8aaa-4878-8638-f93046e04488","2023-12-13T15:50:06.338+00:00","2024-09-21T04:08:06.168+00:00",[],"Newcastle-upon-Tyne-Hospitals-NHS-Foundation-Trust-Newcastle-upon-Tyne-UK",{"title":3093},{"VI":3094},"Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK",{},{"id":26,"sortIndex":36,"affiliation":3097,"properties":26},{"id":3054,"createTime":3055,"updateTime":3056,"relativeEntities":3098,"slug":3058,"properties":3099,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3100},{"VI":3061},{"title":3102},{"VI":3103},"Jessica Katharine Dyson",{"id":3105,"sortIndex":115,"researcher":26,"roles":3106,"affiliations":3107,"properties":3118},"d882136c-997c-4d94-ae3d-2d58bfde7176",[799],[3108],{"id":26,"sortIndex":36,"affiliation":3109,"properties":26},{"id":3110,"createTime":3111,"updateTime":3112,"relativeEntities":3113,"slug":3114,"properties":3115,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"09a2b8cf-7249-40a2-8d33-2c2da2c53133","2023-12-23T08:58:33.819+00:00","2025-06-11T22:34:20.422+00:00",[],"Wellcome-Centre-for-Mitochondrial-Research-Newcastle-University-Newcastle-Upon-Tyne-UK",{"title":3116},{"VI":3117},"Wellcome Centre for Mitochondrial Research, Newcastle University, Newcastle-Upon-Tyne, UK",{"title":3119},{"VI":3120},"Alasdair Blain",{"id":3122,"sortIndex":59,"researcher":26,"roles":3123,"affiliations":3124,"properties":3137},"4d774f8c-3884-4a6b-92c9-cbea0d3b08ae",[799],[3125,3130],{"id":26,"sortIndex":36,"affiliation":3126,"properties":26},{"id":3054,"createTime":3055,"updateTime":3056,"relativeEntities":3127,"slug":3058,"properties":3128,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3129},{"VI":3061},{"id":3131,"sortIndex":115,"affiliation":3132,"properties":3136},"5e443d6c-890b-4db6-ae7a-7bdaf8450eaf",{"id":3045,"createTime":3046,"updateTime":3046,"relativeEntities":3133,"slug":26,"properties":3134,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3135},{"VI":3050},{},{"title":3138},{"VI":3139},"Mark Hudson",{"url":3021,"publisher":3141,"properties":3170},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":3142,"slug":663,"properties":3143,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":114,"subjectFields":3148,"manageAffiliations":3149,"indexDatabases":3150,"url":768,"thumbnailPath":26,"statistic":3165,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"country":3144,"issn":3145,"introduce":3146,"title":3147},{"VOID":666},{"VOID":668},{"EN":670},{"EN":672},[],[],[3151,3158],{"id":747,"indexDatabase":3152,"url":760,"indexYears":761,"academicFieldIds":3157,"indexDatabaseRanking":767},{"id":749,"createTime":750,"updateTime":751,"relativeEntities":3153,"label":3154,"description":3155,"key":757,"publicationTags":3156,"standard":26},[],{"EN":754,"VI":754},{"EN":754,"VI":756},[759],[763,764,765,766],{"id":728,"indexDatabase":3159,"url":743,"indexYears":26,"academicFieldIds":3164,"indexDatabaseRanking":26},{"id":730,"createTime":731,"updateTime":732,"relativeEntities":3160,"label":3161,"description":3162,"key":739,"publicationTags":3163,"standard":26},[],{"EN":735,"VI":735},{"VI":737,"EN":738},[741,742],[745],{"impactFactor":36,"impactFactorByYear":3166,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":245,"totalPublicationByYear":3167,"totalCitation":36,"totalCitationByYear":3168,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":3169,"hindexLast5Year":36,"hindex":36},{},{"2019":158,"2020":111,"2021":124,"2022":298,"2023":287,"2024":59},{},{},{"volume":3171,"pages":3173},{"VOID":3172},"3",{"VOID":3174},"100202","2021-02-01",2021]